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Abstract	  
	  
Hookworms	   are	   parasitic	   nematodes	   that	   reside	   in	   the	   intestines	   of	   their	   host,	  where	  
they	  feed	  on	  host	  blood.	  The	  large	  number	  of	  infected	  individuals	  and	  the	  long	  survival	  
time	   inside	   the	  host	  makes	   it	   interesting	   to	   study	   the	   immunomodulatory	  activities	  of	  
the	  hookworms.	  The	  excretory/secretory	  (ES)	  products	  are	  suspected	  to	  be	  responsible	  
for	   these	   effects.	   One	   aim	   of	   this	   project	  was	   to	   fractionate	   the	   low	  molecular	  weight	  
part	  (<	  10	  kDa)	  of	  ES	  products	  from	  the	  dog	  hookworm	  Ancylostoma	  caninum	  and	  test	  
their	  activity	  in	  a	  mouse	  colitis	  model	  that	  resembles	  human	  Crohn’s	  disease.	  The	  results	  
were	  inconclusive,	  but	  trends	  could	  be	  seen	  and	  it	  seems	  that	  two	  fractions	  might	  show	  
activity	  in	  the	  future	  if	  the	  tests	  are	  scaled	  up.	  The	  second	  aim	  was	  to	  use	  Fmoc-­‐SPPS	  to	  
synthesise	   two	   disulfide-­‐rich	   peptides	   that	   were	   identified	   in	   the	   transcriptome	   of	  
hookworms.	  These	  peptides	  possess	  the	  cysteine	   framework	  of	   the	  sea	  anemone	  toxin	  
ShK,	  which	  is	  able	  to	  block	  voltage-­‐gated	  potassium	  channels.	  One	  peptide,	  Name2,	  was	  
synthesised	  successfully	  and	  as	  predicted	  folded	  into	  a	  ShK-­‐like	  domain	  as	  confirmed	  by	  
NMR	  spectroscopy.	  The	  three	  dimensional	  structure	  of	  the	  peptide	  was	  determined	  and	  
it	  was	  revealed	  to	  contain	  two	  helical	  segments	  that	  were	  braced	  by	  the	  three	  disulfide	  
bonds.	  Difficulties	  were	  encountered	  in	  the	  synthesis	  of	  Acan1	  and	  the	  correct	  peptide	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  effect	  
NOESY	   	   	   	   	   Nuclear	  Overhauser	  effect	  spectroscopy	  
PBS	   	   	   	   	   	   Phosphate	  buffered	  saline	  
RP-­‐HPLC	   	  Reverse-­‐phase	  high-­‐pressure	  liquid	  
chromatography	   	   	  
SPPS	   	   	   	   	   	   Solid	  phase	  peptide	  synthesis	  
TCEP	  ⋅	  HCl	  	   	   	   	   	   Tris(2-­‐carboxyethyl)phosphine	  hydrochloride	  
TFA	   	   	   	   	   	   Trifluoroacetic	  acid	  
TIPS	   	   	   	   	   	   Triisopropylsilane	  
TNBS	   	   	   	   	   	   2,4,6-­‐Trinitrobenzenesulfonic	  acid	  
TNF-­‐α	  	   	   	   	   	   Tumour	  necrosis	  factor	  α	  
TOCSY	  	   	   	   	   	   Total	  correlation	  spectroscopy	  
Xan	   	   	   	   	   	   Xanthenyl	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1.	  Introduction	  
1.1	  Peptides	  and	  their	  potential	  use	  as	  drugs	  
Peptides	  are	  made	  of	  amino	  acids,	   covalently	   joined	   together	  by	  amide	  bonds	   [1].	  The	  
size	  of	  biologically	  occurring	  peptides	  shows	  a	  great	  variability,	  ranging	  from	  dipeptides	  
to	  proteins	  with	  masses	  above	  10,000	  Da	  [1].	  In	  general,	  all	  organisms	  use	  the	  same	  set	  
of	   20	   proteinogenic	   amino	   acids	   encoded	   in	   the	   genetic	   code	   for	   their	   synthesis	   of	  
peptides	  and	  proteins	  [1].	  Exceptions	  are	  peptides	  where	  uncommon	  amino	  acids	  have	  
been	   incorporated	   during	   the	   synthesis	   or	   certain	   residues	   that	   underwent	  
postsynthetic	   modifications,	   like	   hydroxylation	   or	   carboxylation	   [1].	   Peptides	   and	  
proteins	  are	   involved	   in	  many	  different	  biological	  processes,	   such	  as	   the	   regulation	  of	  
blood	   glucose	   after	   a	   meal	   by	   the	   hormone	   insulin,	   or	   the	   conversion	   of	   glucose	   to	  
glucose	   6-­‐phosphate	   by	   the	   enzyme	   hexokinase	   in	   the	   first	   step	   of	   the	   metabolic	  
pathways	   to	   utilize	   the	   carbohydrate	   as	   fuel.	   Peptides	   also	   transduce	   signals	   as	  
neurotransmitters	  and	  receptors,	  are	  part	  of	  the	  immune	  defence	  (as	  antibodies)	  or	  do	  
harm	  (toxins)	  [2].	  This	  variety	  of	  biological	  functions	  makes	  peptides	  and	  proteins	  very	  
attractive	   for	   scientists	   to	   test	   their	   effect	   in	   different	   diseases,	   and	   peptides	   are	  
undergoing	   phase	   1	   trials	   for	   indications	   including	   cancer,	   metabolic	   diseases,	  
inflammation	  and	  virology	  [3].	  Compared	  to	  traditional	  small	  molecule	  drugs,	  peptides	  
are	  said	  to	  be	  more	  selective	  with	  lower	  affinity	  for	  non-­‐target	  structures,	  and	  less	  toxic	  
[3,	   4].	   However,	   their	   susceptibility	   to	   degradation	   in	   the	   gastrointestinal	   tract	   and	  
limited	   permeation	   of	   the	   intestinal	   epithelium	   present	   huge	   difficulties	   to	   the	  
development	   of	   peptides	   as	   drugs,	   and	   they	  usually	   show	   low	  oral	   bioavailability	   and	  
must	  be	  given	  parenterally	  [5].	  Other	  disadvantages	  are	  revealed	  once	  the	  peptide	  has	  
made	   it	   to	   the	  systemic	  circulation:	  a	  short	  half-­‐life	  because	  of	   fast	  elimination	  via	   the	  
kidneys	   and	   exposure	   to	   proteases;	   and	   potential	   immunogenicity	   [4].	   Fortunately,	  
much	   progress	   has	   been	  made	   in	   developing	   techniques	   that	   improve	   the	   stability	   of	  
peptides,	  and	  renal	  excretion	  and	  degradation	  by	  enzymes	  can	  be	  reduced	  by	  pegylation	  
[3].	  In	  this	  process,	  polymers	  of	  ethylene	  glycol	  are	  attached	  to	  the	  peptide	  and	  several	  
pegylated	   peptide	   drugs	   are	  marketed	   [3].	   Another	  way	   to	   enhance	   the	   stability	   is	   to	  
make	  a	  peptidomimetic,	  where	   the	  parts	  of	   the	  peptide	  susceptible	   to	  degradation	  are	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replaced	  by	  other	  chemical	  groups	  [6].	  Nowadays,	  desired	  peptides	  can	  be	  isolated	  from	  
tissues,	  produced	  by	  biotechnological	  methods	  or	  by	  direct	  chemical	  synthesis	  [1].	  	  	  
	  
1.2	  Solid-­‐Phase	  Peptide	  Synthesis	  (SPPS)	  
Using	  traditional	  methods,	  the	  direct	  chemical	  synthesis	  of	  short	  peptides	  took	  place	  in	  
solution,	  which	  posed	  significant	  problems	  in	  terms	  of	  solubility	  and	  purification	  as	  the	  
peptide	  chain	  increased	  in	  length	  [7,	  8].	  The	  purification	  involved	  the	  extraction	  of	  the	  
desired	   reaction	   product	   and	   had	   to	   be	   conducted	   after	   each	   attachment	   of	   a	   new	  
residue,	   a	   quite	   laborious	   procedure	   [7,	   8].	   In	   contrast,	   the	   technique	   of	   solid-­‐phase	  
peptide	   synthesis	   (SPPS),	   developed	   by	   Robert	   Bruce	   Merrifield,	   takes	   advantage	   of	  
using	  a	  solid	  support	  for	  the	  peptide	  synthesis	  [7].	  This	  solid	  support	  is	  made	  of	  polymer	  
beads,	  also	  called	  resin,	  and	  the	  synthesis	  takes	  place	  directly	  on	  the	  resin	  because	  the	  
first	  amino	  acid	  is	  covalently	  attached	  to	  it	  [7].	  The	  subsequent	  residues	  are	  coupled	  to	  
the	  chain	  individually	  by	  repeating	  the	  coupling	  reaction	  and	  deprotection	  reaction	  for	  
each	  added	  residue	  until	  the	  peptide	  is	  complete	  (figure	  1)	  [7].	  The	  order	  of	  the	  amino	  
acids	  is	  determined	  by	  the	  peptide	  sequence	  and	  one	  starts	  with	  the	  amino	  acid	  at	  the	  C-­‐
terminus	  of	  the	  peptide,	  which	  means	  that	  the	  carboxylic	  acid	  group	  of	  the	  first	  amino	  
acid	  reacts	  with	   the	  resin	  and	   the,	   still	  protected,	  amino	  group	  will	   condense	  with	   the	  
carboxylic	  acid	  group	  of	  the	  next	  amino	  acid	  to	  form	  a	  peptide	  bond.	  The	  amino	  group	  
on	  the	  α-­‐carbon,	  as	  well	  as	  the	  side	  chains	  with	  functional	  groups,	  need	  to	  be	  protected	  
so	  that	  only	  the	  carboxylic	  acid	  group	  of	  the	  introduced	  amino	  acid	  is	  able	  to	  take	  part	  in	  
the	  formation	  of	  a	  new	  peptide	  bond	  with	  the	  amino	  group	  of	  the	  residue	  attached	  to	  the	  
resin	   [8].	   Thereafter,	   the	   protecting	   group	   on	   the	   amino	   group	   of	   the	   residue	   just	  
coupled	  to	  the	  peptide	  chain	  is	  removed,	  so	  that	  a	  new	  peptide	  bond	  can	  be	  made	  with	  
the	  next	  residue	  introduced,	  but	  it	  is	  important	  not	  to	  deprotect	  the	  side	  chains	  during	  
this	  process	  [8].	  Elimination	  of	  unreacted	  reagents,	  liberated	  protecting	  groups	  and	  by-­‐
products	   is	   easy	   with	   SPPS,	   because	   these	   compounds	   are	   dissolved	   in	   the	   reaction	  
solvent,	   and	   can	   be	   filtered	   readily	   without	   affecting	   the	   peptide,	   which	   remains	  
attached	  to	  the	  solid	  support	  [8].	  The	  final	  step	  of	  the	  synthesis	  is	  the	  removal	  of	  all	  the	  
remaining	  protecting	  groups	  and	  the	  cleavage	  of	  the	  covalent	  bond	  between	  peptide	  and	  
resin.	   Boc	   (tert-­‐butoxycarbonyl)	   and	   Fmoc	   (9-­‐fluorenylmethyloxycarbonyl)	   are	   the	  
protecting	   groups	   mainly	   used	   for	   derivatization	   of	   the	   amino	   group	   and	   are	  
characterized	  by	  the	  requirement	  of	  different	  reagents	  for	  deprotection:	  Boc	  chemistry	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typically	   uses	   trifluoroacetic	   acid	   (TFA),	   whereas	   the	   base	   labile	   Fmoc	   groups	   are	  
liberated	  by	  piperidine.	  For	  detaching	  the	  peptide	  from	  the	  resin	  hydrofluroric	  acid	  and	  












Figure	  1:	  Principles	  of	  standard	  Fmoc-­‐SPPS:	  The	  first	  amino	  acid	  is	  coupled	  to	  the	  resin	  and	  deprotected	  
before	  the	  next	  amino	  acid	  is	  coupled.	  Repetition	  of	  this	  procedure	  elongates	  the	  peptide,	  which	  is	  cleaved	  
from	  the	  resin	  when	  elongation	  is	  complete.	  
	  
1.3	  Autoimmune	  diseases	  
The	  human	  body	  fights	  infectious	  organisms	  by	  sending	  a	  great	  number	  of	  different	  cells	  
and	  molecules	   into	   the	  battle,	  and	  responses	  can	  be	  described	  as	   innate,	  which	  means	  
that	  every	  healthy	  person	  possesses	  them,	  or	  adaptive	  when	  the	  host	  defence	  adapts	  to	  
the	   presence	   of	   certain	   microbes.	   The	   innate	   immune	   system	   includes	   cells	   that	   can	  
ingest	   and	  kill	  microorganisms	   (macrophages	  and	  neutrophils),	   cells	   that	   can	  kill	  host	  
cells	   infected	   by	   viruses	   (natural	   killer	   cells),	   protein	   mediators	   that	   regulate	   and	  
coordinate	  immunologic	  activities	  (cytokines)	  and	  protein	  systems	  that,	  when	  activated,	  
can	   lead	   to	   recognition	   and	   destruction	   of	   foreign	   organisms	   (complement	   system).	  
These	   mechanisms	   elicit	   very	   fast	   responses	   but	   they	   are	   not	   pathogen-­‐specific.	   In	  
contrast,	   the	   adaptive	   immune	   response,	   constituted	   of	   T	   cells	   and	   B	   cells	   (both	   are	  
lymphocytes),	   elicits	   powerful	   and	   specific	   responses	   to	   any	   pathogens	   encountered	  
because	   of	   highly	   specialized	   antigen	   receptors.	   T	   cells	   are	   further	   divided	   into	   CD4+	  
helper	  T	  cells,	  which	  interact	  with	  macrophages	  and	  B	  cells;	  and	  CD8+	  cytotoxic	  T	  cells,	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bind	   to	   antigens,	   activate	   the	   complement	   system	   or	   promote	   phagocytosis	   by	  
macrophages.	  T	  cells	  and	  B	  cells	  can	  also	  form	  memory	  cells	  that	  can	  mediate	  rapid	  and	  
enhanced	  responses	  to	  second	  and	  subsequent	  exposures	  to	  antigens	  [9,	  10].	  	  
	  
T	  and	  B	  cells	  can	  be	  activated	  without	  the	  presence	  of	  an	  infection-­‐causing	  microbe,	  and	  
when	  these	  responses	  harm	  the	  body	  chronically,	  one	  speaks	  of	  an	  autoimmune	  disease	  
[11,	  12].	  These	  diseases	  contribute	  a	  significant	  portion	  to	  morbidity	  and	  mortality	  and	  
considering	   that	   autoimmune	   diseases	   predominantly	   affect	   younger	   people,	   it	   is	   not	  
surprising	  that	  they	  are	  associated	  with	  major	  health	  expenses	  and	  loss	  of	  productivity	  
for	  the	  society	  [12].	  Studies	  have	  shown	  that	  microorganisms	  can	  trigger	  autoreactivity,	  
because	  microbial	  proteins	  resemble	  host	  proteins	  and	  the	  immune	  cells	  are	  not	  able	  to	  
distinguish	   between	   them.	   Environmental	   and	   so-­‐called	   non-­‐infectious	   triggers	   (e.g.	  
penicillin)	   can	   also	   initiate	   autoreactivity	   [11].	   The	   pathogenesis	   of	   the	   different	  
autoimmune	  diseases	  is	  very	  diverse,	  and	  a	  simple	  classification	  divides	  the	  pathogenic	  
mechanisms	  into	  two	  groups:	  (1)	  there	  is	  an	  error	  in	  the	  process	  that	  decides	  which	  B	  
and	  T	  cells	  are	  allowed	  to	  mature	  or	  how	  long	  these	  cells	  should	  live;	  or,	  (2)	  a	  specific	  
antigen	   (foreign	   or	   self)	   is	   responsible	   for	   an	   inappropriate	   immune	   response	   that	  
results	   in	   an	   autoimmune	   disease	   [11].	   An	   example	   of	   an	   autoimmune	   disease	   is	  
systemic	   lupus	   erythemasus	   (SLE)	   where	   both	   of	   these	   elements	   come	   into	   play,	  
because	   self-­‐reactive	  B	   lymphocytes	  escape	   the	  mechanisms	   that	   should	  prevent	   their	  
formation,	  and	  they	  produce	  antibodies	  that	  form	  complexes	  with	  nuclear	  self-­‐antigens	  
that	  are	  exposed	  on	  dead	  and	  dying	  cells	  [13-­‐15].	  Chronic	  inflammation	  and	  damage	  to	  
organs	  characteristic	  of	  SLE	   is	  a	  consequence	  of	   the	  body’s	   inability	   to	  eliminate	  these	  
complexes	  [16].	  Other	  autoimmune	  diseases	  exhibit	  other	  pathogenic	  mechanisms.	  One	  
purpose	   of	   the	   epithelial	   barrier	   in	   the	   intestines	   is	   to	   keep	   the	   bacterial	   flora	   in	   the	  
intestinal	   lumen,	  but	  when	  bacteria	  are	  able	  to	  cross	  that	  barrier	  they	  come	  in	  contact	  
with	   the	   mucosal	   immune	   system	   [17].	   In	   Crohn’s	   disease,	   abnormalities	   in	   certain	  
subsets	  of	  CD4+	  helper	  T	  cells,	  namely	  TH1	  cells	  and	  TH17	  cells,	  are	  suspected	  to	  cause	  
vigorous	   inflammation	   of	   the	   mucosa	   and	   submucosa	   of	   the	   intestine,	   but	   the	   entire	  
alimentary	   tract	   can	   be	   affected	   [9,	   17].	   Other	   examples	   of	   autoimmune	   diseases	   are	  
ulcerative	   colitis,	   rheumatoid	   arthritis,	  multiple	   sclerosis	   and	   type	   1	   diabetes	  mellitus	  
[11].	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1.4	  Hookworms	  
1.4.1	  Hookworm	  infection	  
Hookworms	  are	  parasitic	  nematodes	  that	  reside	   in	  the	   intestines	  of	  humans	  and	  other	  
mammals	   like	   cats	   and	   dogs.	   Hookworm	   infection	   is	   considered	   one	   of	   the	   most	  
important	   tropical	   diseases	   and	   estimates	   speak	   of	   more	   than	   700	   million	   affected	  
individuals,	   most	   of	   them	   in	   Asia,	   sub-­‐Saharan	   Africa	   and	   South	   America	   [18-­‐20].	  
Complications	   associated	   with	   hookworm	   infections	   include	   iron-­‐defiency	   anaemia,	  
growth	  retardation	  in	  children	  and	  a	  low	  birth	  weight	  of	  infants;	  the	  mortality,	  however,	  
is	  rather	  low	  [19,	  20].	  The	  soil-­‐living	  hookworms	  Necator	  americanus	  and	  Ancylostoma	  
duodenale	  are	  responsible	  for	  the	  majority	  of	  human	  cases	  and	  both	  are	  able	  to	  burrow	  
through	  the	  skin	  when	  a	  person	  is	  in	  contact	  with	  contaminated	  soil	  [20].	  Penetration	  of	  
the	  skin	  results	  in	  an	  itching	  rash	  accompanied	  by	  erythema	  and	  papules	  (“ground	  itch”)	  
[20].	   Infectious	   larvae	  of	   the	   zoonotic	  hookworm	  A.	  braziliense	  cause	   a	  particular	   skin	  
condition	  known	  as	   “larvae	  migrans”,	  where	   the	   larvae	  move	  around	   in	   the	  epidermis	  
[20].	   A.	   duodenale	   can	   also	   gain	   access	   via	   the	   oral	   route	   [20].	   Other	   hookworms	  
primarily	  infect	  animals,	  but	  can	  cause	  zoonosis	  in	  humans;	  examples	  are	  A.	  ceylanicum,	  
which	  infects	  dogs	  and	  cats,	  and	  the	  canine	  hookworm	  A.	  caninum	  [20].	  
	  
Overcoming	   the	   skin	  barrier	  gives	   the	   larvae	  access	   to	   the	   systemic	   circulation,	  which	  
transports	  them	  to	  the	  cardiac	  and	  pulmonary	  system	  [20].	  Arrival	  in	  the	  latter,	  results	  
in	  migration	  to	  parenchymal	  tissue	  and	  ascent	  to	  the	  trachea,	  causing	  a	  sore	  throat	  and	  
cough	  [20].	  Next,	  swallowing	  enables	  the	   larvae	  to	  descend	  the	  alimentary	  tract	   to	  the	  
intestine,	  where	  they	  mature	  to	  the	  adult	  worm	  stage	  and	  attach	  to	  the	  gut	  wall	  [20].	  In	  
the	   intestine	   the	   worm	   feeds	   on	   blood	   by	   biting	   into	   mucosa	   and	   submucosa,	   and	  
releases	  compounds	  with	  anticoagulant	  activity	  so	  that	  the	  blood	  flows	  sufficiently	  from	  
the	  damaged	  vasculature	   [20].	  Finally,	   the	  hookworm	  life	  cycle	   is	  completed	  when	  the	  
females	  start	   to	  produce	  eggs,	  which	  are	  excreted	   from	  the	  host	   [20].	  Persistent	  blood	  
loss	  accompanied	  by	   low	  iron	  intake	  or	  high	  physiological	  demands	  can	  result	   in	   iron-­‐
deficiency	  anaemia	  [20].	  Anaemia	  during	  pregnancy	  is	  particularly	  problematic	  because	  
it	  affects	  the	  mother	  as	  well	  as	  the	  child	  thereby	  increasing	  the	  risk	  for	  low	  birth	  weight	  
and	  growth	  retardation	  [20,	  21].	  Among	  non-­‐anaemic	  manifestations	  are	  hypothermia,	  
epigastric	   pain,	   nausea,	   impotence	   and	   anasarca,	   a	   condition	   caused	   by	   extreme	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hypoproteinaemia	   and	   characterized	   by	   oedema	   of	   the	   face	   and	   lower	   limbs	   and	  
potbelly	  [20].	  	  
	  
1.4.2	  Immunologic	  aspects	  to	  hookworm	  infections	  
Antibodies	   of	   all	   five	   immunoglobulin	   classes	   have	   been	   reported	   to	   recognize	  
hookworm	  antigens,	  and	  a	  successful	  skin	  penetration	  by	  infectious	  larvae	  results	  in	  the	  
earliest	  immune	  responses	  because	  antibodies	  are	  able	  to	  target	  antigens	  on	  the	  surface	  
of	   the	   sheath	   that	   covers	   the	   larvae	   [19,	   22].	   Burrowing	   through	   the	   skin	   causes	   the	  
majority	   of	   the	   larvae	   to	   loose	   the	   sheath,	   and	   because	   most	   of	   the	   immunogenicity	  
relies	   on	   the	   sheath,	   this	  may	   serve	   as	   a	   distraction	  manoeuvre	   to	   lead	   the	   attention	  
away	   from	  the	   larvae,	  which	  would	  render	   the	  antibody	  response	  rather	   ineffective	  at	  
this	   infection	   stage	   [22].	   The	   larvae	   are	   too	   large	   to	   be	   ingested	   by	  macrophages	   and	  
neutrophils,	  therefore	  cellular	  immune	  responses	  against	  larvae	  predominantly	  involve	  
eosinophils,	  which	  attach	   to	  parasitic	  organisms	  and,	  on	  activation,	   release	  substances	  
toxic	  to	  the	  larvae	  [22].	  However,	  it	  is	  not	  clear	  how	  efficient	  eosinophilic	  responses	  are	  
at	  killing	  the	  larvae	  and	  adult	  worms	  [22].	  	  
	  
In	  order	   to	  combat	   the	  adult	  worm	  stages	   in	   the	  small	   intestine,	  TH2	  cells,	   a	   subset	  of	  
CD4+	  helper	  cells,	  are	  activated	  and	  start	  to	  secrete	  the	  cytokines	  Interleukin	  (IL)-­‐4,	  IL-­‐5	  
and	  IL-­‐13	  [9,	  19].	  IL-­‐4	  stimulates	  B-­‐lymphocytes	  to	  proliferate	  and	  mature	  into	  antibody	  
secreting	  plasma	  cells	   [9].	   Immunoglobulin	  G1	  (IgG1),	   IgG4	  and	   IgE	  are	   the	  antibodies	  
that	   make	   up	   the	   most	   important	   parts	   of	   the	   humoral	   response	   against	   intestinal	  
hookworm	  infection,	  but	  in	  what	  degree	  they	  contribute	  to	  fight	  and	  protection	  against	  
hookworms	   requires	   more	   research	   [19,	   22].	   Particularly,	   IgE	   may	   be	   attributed	  
beneficial	   properties,	  whereas	   it	   seems	   that	   an	   ongoing	   infection	   correlates	   best	  with	  
hookworm-­‐specific	  IgG4	  levels	  [19].	  IgD,	  IgE	  and	  IgG	  are	  able	  to	  bind	  to	  basophils,	  which	  
are	   a	   member	   of	   the	   innate	   immune	   system.	   The	   binding	   leads	   to	   the	   liberation	   of	  
inflammatory	  mediators	  and	  IL-­‐4,	  which,	  together	  with	  IL-­‐5	  and	  IL-­‐13,	  are	  crucial	  for	  the	  
immune	  response	  driven	  mainly	  by	  TH2	  cells	  [19].	  It	  is	  proposed	  that	  the	  hookworm	  can	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1.4.3	  Excretory/secretory	  products	  (ES)	  
Suspected	  to	  be	  responsible	  for	  the	  immunomodulatory	  effects,	  and	  thereby	  enabling	  an	  
infection,	   are	   the	   so-­‐called	   excretory/secretory	   products	   (ES),	   which	   are	  
macromolecules	   that	   are	   excreted	  or	   secreted	  by	  hookworms	   [23].	   It	   has	  been	   shown	  
that	   ES	   products	   from	   different	   parasitic	   worms	   are	   able	   to	   affect	   the	   production	   of	  
cytokines,	   chemokines,	   and	   the	   expression	   of	   important	   co-­‐stimulatory	  molecules	   for	  
signal	  transduction	  [24];	   inactivate	  chemokines	  [25];	  and	  modulation	  of	  dendritic	  cells	  
[26].	   The	   neutrophil	   inhibitory	   factor	   (NIF)	   is	   a	   glycoprotein	   found	   in	   the	   ES	   of	   A.	  
caninum	   that	   exhibits	   immunomodulatory	   effects	   by	   binding	   to	   the	   integrin	  
CD11b/CD18	  located	  on	  activated	  neutrophils	  [27,	  28].	  Normally,	  neutrophils	  arrive	  at	  
the	   location	   of	   inflammation	   via	   the	   blood	   stream,	   and	   to	   gain	   access	   to	   the	   inflamed	  
tissue,	   they	   have	   to	   migrate	   through	   the	   endothelium	   [9].	   Before	   the	   migration	   can	  
happen,	  the	  neutrophils	  have	  to	  adhere	  to	  intercellular	  adhesion	  molecules	  (ICAMs)	  via	  
integrins	   [9].	   NIF	   inhibits	   this	   binding,	   as	   well	   as	   the	   release	   of	   hydrogen	   peroxide	  
(H2O2),	  which	   is	   important	   in	   the	  killing	  of	  microorganisms	  [27,	  28].	  Therefore,	   the	  ES	  
products	  could	  serve	  as	  a	  starting	  point	  for	  the	  development	  of	  drugs	  against	  allergies,	  
autoimmune	  disease	  or	  other	  immunity-­‐related	  disorders.	  	  
	  
1.5	  Prelimenary	  data	  
Investigation	  of	  the	  ES	  products	  of	  the	  dog	  hookworm	  A.	  caninum	  exposed	  a	  mixture	  of	  
over	   100	   different	   proteins	   [29].	   Among	   the	   proteins	   were	   ion	   channel	   blockers,	  
carbohydrate-­‐binding	   proteins	   (so-­‐called	   lectins),	   metallo-­‐proteases,	   hyaluronidases,	  
lysozyme-­‐like	  proteins,	   and	   transthyretin-­‐like	  proteins	   (transthyretin	   is	   a	  protein	   that	  
transports	   thyroxine	   and	   retinol	   in	   the	   blood	   and	   cerebrospinal	   fluid)	   [29].	   But	   all	  
preceding	   studies	   of	   the	   ES	   products	   of	   hookworms	   have	   characterized	   protein	  
components	  of	  higher	  molecular	  masses	  (>	  5	  kDa),	  and	  little	  focus	  has	  been	  on	  the	  low	  
molecular	  weight	  ES	  products	   (1	  –	  5	  kDa).	  Therefore,	   the	  hypothesis	  of	   this	  project	   is	  
that	  there	  are	  peptide	  components	  within	  the	  low	  molecular	  weight	  ES	  products	  of	  the	  
canine	  hookworm	  A.	  caninum	  that	  possess	  activity	  as	  immunomodulators.	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1.6	  ShK-­‐like	  peptide	  sequences	  
ShK	  is	  a	  35-­‐residue	  toxin	  isolated	  from	  the	  sea	  anemone	  Stichodactyla	  helianthus	  that	  is	  
able	   to	   block	   voltage-­‐gated	   potassium	   channels	   [30].	   	   Of	   particular	   interest	   is	   the	  
blockage	  of	  the	  Kv1.3	  potassium	  channel	  because	  it	  is	  involved	  in	  T	  cell	  proliferation	  and	  
may	  therefore	  be	   involved	   in	   the	  pathologic	  mechanisms	  of	  autoimmune	  diseases	  [31-­‐
34].	  Dr	   Jason	  Mulvenna	  performed	  an	   in	  silico	   search	  of	  hookworm	  transcriptomes	   for	  
peptide	  sequences	  that	  possess	  the	  same	  cysteine	   framework	  as	  ShK	  and	  discovered	  a	  
number	  of	  sequences.	  Two	  of	  these	  putative	  peptides,	  Name2	  and	  Acan1,	  were	  chosen	  
for	  synthesis	   in	  this	  project	  (figure	  2).	  The	  hypothesis	   is	  that	  these	  peptides	  will	  have	  
the	  same	  tertiary	  structure	  as	  ShK	  and	  may	  also	  be	  able	  to	  block	  potassium	  channels	  and	  
thus	  have	  an	  effect	  on	  the	  immune	  response.	  
	  
	  
Figure	  2:	  Peptide	  sequences	  of	  ShK,	  Name2	  and	  Acan1.	  Name2	  was	  identified	  in	  the	  transcriptome	  of	  N.	  
americanus,	  whereas	   Acan1	  was	   identified	   in	   the	   transcriptome	   of	  A.	  caninum.	   The	   conserved	   cysteine	  
framework	  is	  shown	  by	  the	  solid	  lines	  as	  a	  CysI–VI,	  CysII–IV	  and	  CysIII–V.	  
	  
1.7	  Experimental	  TNBS	  colitis	  in	  mice	  
1.7.1	  Immunology	  of	  TNBS	  coltitis	  
TNBS	   colitis	   is	   an	   experimental	   model	   where	   mice	   are	   treated	   rectally	   with	   2,4,6-­‐
trinitrobenzenesulfonic	   acid	   (TNBS)	   as	   an	   ethanolic	   solution	   in	   order	   to	   cause	   an	  
intestinal	  inflammation	  [35].	  The	  mucous	  membrane	  in	  the	  colon	  is	  damaged	  by	  ethanol	  
(EtOH),	   so	   that	   TNBS	   can	   react	   with	   mouse	   proteins	   leaving	   these	   macromolecules	  
conjugated	  with	   a	   trinitrobenzene	   (TNP)	   group	   (figure	   3)	   [35,	   36].	   The	  TNP-­‐proteins	  
are	  now	  targeted	  by	  the	  immune	  system	  in	  the	  form	  of	  antigen-­‐presenting	  cells	  (APCs),	  
which	  are	  able	  to	  process	  these	  proteins	  and	  present	  the	  antigens	  to	  CD4+	  T	  cells	  [37].	  
The	   activated	   T	   cells	   communicate	   to	   the	   APCs	   to	   secrete	   IL-­‐12,	   which	   promotes	   the	  
differentiation	  of	  immature	  T	  cells	  to	  TH1	  effector	  cells	  that	  produce	  Interferon	  (IFN)-­‐γ	  
and	  tumour	  necrosis	  factor	  (TNF)-­‐α	  [37].	  IFN-­‐γ	  and	  TNF-­‐α	  are	  then	  responsible	  for	  the	  
secretion	   of	   even	   more	   IL-­‐12	   (by	   APCs)	   and	   TNF-­‐α,	   as	   well	   as	   the	   inflammatory	  
ShK R S C I D T I P K S R C T A F Q -­ -­ -­ -­ C K H S M K Y R L S F -­ -­ C R K T C G T C
Name2 Q E C R D R I P Q N V C E Q M K K N G K C D D P R M S T I T E L Q C P K T C G K C
Acan1 Q D I R T A A M E H C A D E K -­ N F D C R R S L R N G D C D N D D K L L E M G Y Y C P V T C G F C E P
I II III IV V VI
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cytokines	  IL-­‐1β	  and	  IL-­‐6	  (by	  macrophages),	  which	  cause	  the	  inflammation	  in	  the	  colon	  




Figure	   3:	   TNBS	   colitis	   works	   by	   conjugating	   proteins	   with	   a	   TNP-­‐moiety,	   which	   activates	   T	   cells	   via	  
antigen	  presentation.	  The	  T	  cells	  secrete	  IFN-­‐γ	  that	  acts	  on	  macrophages	  to	  produce	  cytokines	  that	  cause	  
the	  inflammation.	  	  
	  
1.7.2	  The	  Relation	  between	  the	  TNBS	  model	  and	  Crohn’s	  disease	  
Crohn’s	   disease	   is	   characterized	   by	   inflammation	   of	   predominantly	   gastrointestinal	  
mucous	  membranes	  and	  investigations	  have	  revealed	  that	  TH1	  and	  TH17	  cells,	  as	  well	  as	  
the	   cytokines	   they	  produce	  are	   involved	   in	   the	  pathogenesis	   [38].	  When	  macrophages	  
and	   other	   APCs	   come	   in	   contact	   with	   microorganisms,	   they	   secrete	   IL-­‐12,	   which	  
activates	  TH1	  cells,	  and	  in	  the	  case	  of	  Crohn’s	  disease,	  IL-­‐12	  production	  is	  increased	  [38,	  
39].	   Similar	   to	   the	  TNBS	  mouse	  model,	   the	  TH1	   cells	   then	  produce	   the	   cytokine	   IFN-­‐γ,	  
which	   has	   pro-­‐inflammatory	   properties	   by	   activating	   additional	   macrophages.	   Also,	  
cytokines	   (IL-­‐1,	   IL-­‐6	   and	   IL-­‐23)	   produced	   by	   APCs	   promote	   the	   differentiation	   and	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proliferation	  of	  TH17	  cells,	  but	  their	  role	  in	  connection	  with	  Crohn’s	  disease	  is	  still	  under	  
investigation	   [38,	   40].	   To	   conclude,	   Crohn’s	   disease	   and	   the	  TNBS	   colitis	  model	   share	  
common	  immunologic	  features,	  inter	  alia	  the	  IL-­‐12	  driven	  TH1	  pathway	  with	  increased	  
production	  of	  IFN-­‐γ	  and	  subsequent	  secretion	  of	  inflammatory	  mediators	  (TNF-­‐α,	  IL-­‐1β	  
and	  IL-­‐6).	  	  
	  
1.8	  Aims	  
As	  stated	  earlier,	  the	  hypotheses	  of	  this	  project	  are:	  	  	  
-­‐ The	   low	   molecular	   weight	   ES	   products	   of	   A.	   caninum	   posses	   contains	   peptide	  
components	  that	  posses	  activity	  as	  immunomodulators.	  
-­‐ The	  peptides	  identified	  in	  the	  hookworm	  transcriptome	  have	  a	  tertiary	  structure	  
that	  resembles	  ShK.	  
	  
This	  will	  be	  investigated	  via	  three	  specific	  aims:	  
§ Fractionation	  of	  the	  low	  molecular	  weight	  ES	  products	  of	  A.	  caninum	  
§ Activity	  testing	  of	  the	  fractions	  in	  the	  TNBS	  mouse	  model	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2.	  Results	  
2.1	  Fractionation	  of	   low	  molecular	  weight	  components	  of	  A.	  caninum	  ES	  products	  
(LMW	  AcES)	  	  
The	  low	  molecular	  weight	  components	  of	  the	  hookworm	  A.	  caninum	  ES	  products	  (LMW	  
AcES)	   were	   fractionated	   by	   reverse-­‐phase	   high-­‐pressure	   liquid	   chromatography	   (RP-­‐
HPLC)	   using	   a	   preparative	   column,	   a	   2	   %	   gradient	   of	   buffer	   B	   and	   the	   eluate	   was	  
collected	   in	   intervals	   of	   10	  minutes.	   The	   RP-­‐HPLC	   system	   used	   in	   this	   thesis	   detects	  
absorbance	  at	  215	  nm,	  where	  the	  peptide	  bond	  absorbs	  ultraviolet	  (UV)	  light,	  and	  at	  280	  
nm,	  where	  the	  aromatic	  residues	  Trp	  and	  Tyr	  have	  an	  absorbance	  maximum.	  In	  figures	  
4	   and	  5,	   the	   chromatograms	   of	   the	   fractionation	   of	   the	   first	   batch	   of	   LMW	   AcES	   are	  
shown	   with	   absorbance	   detection	   at	   215	   and	   280	   nm,	   respectively.	   Based	   on	   the	  
chromatograms,	   the	   fractions	  containing	   the	   largest	  amounts	  of	  peptides	  are	  probably	  
fractions	  B	  (10	  –	  20	  minutes),	  C	  (20	  –	  30	  minutes)	  and	  D	  (30	  –	  40	  minutes).	  The	  culture	  
media	  for	  the	  hookworms	  also	  contained	  phenol	  red,	  which	  eluted	  after	  approximately	  
22	  minutes,	  giving	  fraction	  C	  a	  yellow	  colour.	  	  
	  
	  
Figure	  4:	  RP-­‐HPLC	  chromatogram	  of	  the	  first	  batch	  of	  LMW	  AcES	  with	  absorbance	  detection	  at	  215	  nm	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Figure	  5:	  RP-­‐HPLC	  chromatogram	  of	  the	  first	  batch	  of	  LMW	  AcES	  with	  absorbance	  detection	  at	  280	  nm	  
	  
Analytical	  RP-­‐HPLC	  runs	  of	  the	  individual	  fractions	  were	  conducted	  (figures	  A1	  –	  A5)	  
and	  the	  fractions	  were	  tested	  for	  bioactivity	  (section	  2.2).	  
	  
A	   second,	  bigger	  batch	  of	   LMW	  AcES	  was	   fractionated	  exactly	   in	   the	   same	  way	  as	   the	  
first	   one,	   giving	   similar	  RP-­‐HPLC	   chromatograms.	   Fractions	   from	   this	  batch	  were	   also	  
tested	  for	  bioactivity.	  	  
	  
2.2	  Bioactivity	  testing	  of	  fractionated	  LMW	  AcES	  in	  mice	  with	  experimental	  colitis	  
The	   animals	   used	   in	   this	   experiment	   were	   mice	   of	   the	   C57Bl/6-­‐strain.	   In	   order	   to	  
investigate	   the	   potential	   of	   LMW	   AcES	   to	   affect	   the	   course	   of	   experimental	   colitis	   in	  
these	  animals,	  fractions	  obtained	  by	  RP-­‐HPLC,	  as	  well	  as	  unfractionated	  LMW	  AcES	  were	  
injected	  into	  different	  mice	  prior	  to	  colitis	  induction	  by	  TNBS-­‐injection.	  The	  mice	  were	  
organised	   into	  groups,	  where	  one	  group	  served	  as	  a	  positive	  control	   (healthy	  control)	  
that	   had	   access	   to	   food	   and	  water,	   but	   did	   not	   receive	   a	   TNBS-­‐injection,	   injections	   of	  
unfractionated	  or	  fractionated	  LMW	  AcES.	  Additionally,	  a	  negative	  control	  group	  existed	  
(TNBS	   only)	  with	  mice	   that	   received	   only	   a	   TNBS-­‐injection.	   The	   animals	   of	   the	   other	  
groups	  received	  injections	  of	  unfractionated	  LMW	  AcES	  or	  fractions	  before	  the	  induction	  
of	  colitis.	  The	  weight	  was	  monitored	  daily	  and	  after	  three	  days	  the	  mice	  were	  sacrificed	  
and	  dissected	  to	  establish	  the	  severity	  of	  inflammation.	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2.2.1	  First	  batch	  of	  LMW	  AcES	  fractions	  
Compared	  to	  the	  starting	  point	  on	  day	  0,	  only	  the	  animals	  in	  the	  healthy	  control	  group	  
gained	  weight	  as	  depicted	  in	  figure	  6.	  The	  mice	  in	  all	  the	  other	  treatments	  lost	  weight	  
during	   the	   first	   three	  days	  of	   the	   experiment;	  but	   the	  negative	   controls,	   the	  mice	   that	  
received	  unfractionated	  LMW	  AcES,	  fraction	  A,	  fraction	  C	  and	  fraction	  E	  had,	  on	  average,	  
gained	   weight	   between	   the	   measurements	   on	   days	   2	   and	   3.	   Compared	   to	   day	   0,	   the	  
animals	  that	  were	  injected	  with	  fraction	  E	  seemed	  to	  have	  lost	   less	  weight	  than	  all	  the	  
other	  groups,	  except	  the	  healthy	  control	  group.	  Mice	  that	  were	  treated	  with	  any	  of	  the	  
other	  fractions	  (A,	  B,	  C	  or	  D)	  or	  unfractionated	  LMW	  AcES	  seemed	  to	  have	  suffered	  from	  
greater	  weight	  loss	  than	  the	  negative	  control	  group.	  The	  differences	  between	  the	  treated	  
groups	  were	  not	  statistical	  significant	  (one	  way	  ANOVA,	  F	  =	  1.67,	  p	  =	  0.18).	  	  
	  
This	  parallel	  was	  possibly	  biased	  by	  the	  different	  sex	  of	  the	  mice	  in	  the	  different	  groups.	  
The	   groups	   of	   the	   healthy	   control,	   negative	   control	   and	   fraction	   E	   consisted	   of	   male	  




Figure	  6:	  Average	  percentage	  weight	  of	  each	  group	  compared	  to	  day	  0	  	  
	  
Because	   the	   mouse	   colon	   tends	   to	   shrink	   when	   it	   is	   inflamed,	   the	   colon	   length	   was	  
measured.	   The	   colons	   of	   the	   healthy	   control	   animals	  were	   not	   inflamed	   so	   they	  were	  
significantly	   longer	   than	   the	   colons	   of	   the	   other	  mice	   (one	  way	  ANOVA,	   F	   =	   3.70,	   p	   <	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test,	   t	  =	  2.59,	  p	  =	  0.06)	   (figure	   7).	  But	  when	  all	   the	  colitis	  groups	  were	  compared,	  no	  
statistical	  difference	  could	  be	  found	  (one	  way	  ANOVA,	  F	  =	  0.32,	  p	  =0.92).	  	  	  
	  
	  
Figure	  7:	  Comparison	  of	  the	  colon	  length	  of	  the	  different	  groups	  	  
	  
Ulcerations,	   oedema,	   thickening	   of	   the	   colon	   wall,	   impaired	   intestinal	   motility	   and	  
adhesions	  are	  considered	  signs	  of	  colon	  inflammation.	  A	  scoring	  system	  was	  applied	  to	  
assess	   the	  severity	  of	  each	  sign	  of	   inflammation	  (0	  =	  normal	   to	  4	  =	  most	  severe)	   [41].	  
The	   scores	   for	   the	   individual	  mouse	  were	   summed	   up	   and	   the	  mean	   values	   for	   each	  
group	   are	   shown	   in	   figure	   8	   (maximum	   possible	   score	   =	   20).	   Not	   surprisingly,	   the	  
healthy	  controls	  did	  not	  show	  any	  sign	  of	   inflammation,	  whereas	  the	  negative	  controls	  
(x =  9.5	  ±	  2.4)	  and	  the	  fraction	  A-­‐group	  (x =	  9.25	  ±	  2.6)	  had	  the	  highest	  scores.	  Animals	  
that	  received	   fraction	  E	  had	  a	  score	  of	  1	  ±	  0.8	  and	  thus	   the	   lowest	  score	  of	  all	  groups,	  
except	  the	  healthy	  controls.	  The	  fraction	  C	  treated	  group	  had	  only	  a	  medium	  degree	  of	  
inflammation	  (x  =	  2.25	  ±	  2.2).	  Comparison	  of	  the	  negative	  controls	  and	  the	  all	  the	  other	  
colitis	  groups	  did	  not	  reveal	  statistical	  significant	  differences	  (one	  way	  ANOVA,	  F	  =	  1.67,	  
p	  =	  0.18),	  but	  a	  two	  sample	  t-­‐test	  between	  the	  negative	  control	  and	  LMW	  AcES	  (t	  =	  3.04,	  
p	  =	  0.02),	  fraction	  C	  (t	  =	  4.46,	  p	  <	  0.01)	  and	  fraction	  E	  (t	  =	  6.76,	  p	  <	  0.01),	  respectively,	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Figure	  8:	  Macroscopic	  scores	  of	  the	  different	  groups	  	  
	  
2.2.2	  Second	  batch	  of	  LMW	  AcES	  fractions	  
The	  TNBS	  mouse	  model	  was	  also	  used	  to	   test	   the	  second	  batch	  of	  LMW	  AcES	  and	  this	  
time,	  five	  animals	  were	  in	  each	  group.	  If	  one	  disregards	  the	  positive	  control	  group,	  then	  
the	  mice	  treated	  with	  fractions	  C	  and	  E	  had	  the	  highest	  and	  second	  highest	  mean	  weight,	  
respectively,	  compared	  to	  the	  baseline	  weight	  on	  day	  0.	  However,	  the	  differences	  were	  
not	  significant	  when	  compared	  to	  the	  negative	  control	  group	  (one	  way	  ANOVA,	  F	  =	  0.38,	  
p	  =	  0.69)	  (figure	  9).	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The	   animals	   that	   received	   an	   injection	   of	   fraction	   C	   (x	  =	   7.04	   ±	   0.21	   cm)	   had	   longer	  
colons	  than	  those	  with	  fraction	  A	  (x	  =	  5.98	  ±	  0.86	  cm)	  (two	  sample	  t-­‐test,	   t	  =	  2.68,	  p	  =	  
0.049).	  And	  this	  significance	  means	  also	  that	  the	  fraction	  C	  group	  had	  the	  longest	  colons	  
of	  all	   the	  groups	   treated	  with	  TNBS	  (figure	   10).	  The	   fraction	  B	  group	  seemed	  to	  have	  
the	  shortest	  colons.	  	  
	  
	  
Figure	  10:	  Comparison	  of	  the	  colon	  length	  of	  the	  different	  groups	  	  
	  
The	   mice	   that	   were	   injected	   fraction	   C	   were	   the	   only	   colitis	   group	   that	   had	   a	   lower	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2.3	  LC/MS	  analysis	  of	  fractions	  C	  and	  E	  
2.3.1	  Fraction	  C	  	  
	  
	  
Figure	  12:	  RP-­‐HPLC	  chromatogram	  from	  the	  LC/MS	  analysis	  of	  fraction	  C	  
	  
Fraction	  C	  was	  analysed	  by	  LC/MS	  and	   the	  chromatogram	   is	   shown	   in	   figure	   12.	  The	  
software	  was	  able	   to	  automatically	  determine	  the	  original	  molecular	  weight	  of	  species	  
bearing	  several	  charges	  by	  performing	  a	  reconstruction.	  The	  highest	  mass	  that	  could	  be	  
reconstructed	  was	  3759.98	  and	  several	  other	  masses	  between	  this	  and	  2000	  Da	  could	  
be	  detected.	  But	  the	  most	  abundant	  masses	  all	  had	  a	  molecular	  weight	  of	  below	  2000	  Da	  
(figure	  13).	  	  
	  
	  
Figure	  13:	  Reconstruction	  ESI-­‐MS	  the	  masses	  present	  in	  fraction	  C	  
	  
2.3.2	  LC/MS	  of	  fraction	  E	  
The	   chromatogram	   of	   the	   LC/MS-­‐analysis	   of	   fraction	   E	   is	   shown	   in	   figure	   A6.	   The	  
highest	   masses	   reconstructed	   were	   4688.56	   and	   3306.74.	   The	   most	   abundant	   mass	  
	   18	  
found	   during	   the	   reconstruction	   was	   1952.88,	   which	   is	   detected	   as	   several	   different	  
masses	   489.23	   ([M+4H]4+),	   651.97	   ([M+3H]3+)	   and	   977.45	   ([M+2H]2+).	   Figure	   14-­‐A	  
depicts	  the	  mass	  spectrum	  of	  the	  biggest	  peak	  in	  the	  chromatogram	  and	  all	  three	  masses	  
can	  be	  found.	  The	  other	  peaks	  in	  the	  chromatogram	  were	  smaller	  and	  the	  intensity	  on	  






Figure	  14	  A	  -­‐	  G:	  ESI-­‐MS	  of	  the	  major	  peaks	  in	  the	  RP-­‐HPLC	  chromatogram	  (figure	  A7)	  
	  
	  
A	  	   B	  	  
C	   D	  	  
E	   F	  
G	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2.4	  1D	  1H	  NMR	  spectroscopy	  of	  fraction	  C	  
A	  1D	  1H	  nuclear	  magnetic	  resonance	  (NMR)	  spectrum	  was	  recorded	  of	  fraction	  C	  (figure	  
15).	   The	   spectrum	   showed	   peaks	   in	   the	   amide	   bond	   region	   (7.5	   –	   9.5	   ppm)	   and	  
therefore	  it	  is	  possible	  that	  the	  constituents	  of	  the	  fraction	  might	  be	  peptides.	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2.5	  Peptide	  synthesis	  
2.5.1	  Synthesis	  of	  Name2	  
The	   sequence	   of	   Name2	   (figure	   16)	   was	   discovered	   in	   the	   transcriptome	   of	   the	  
hookworm	   N.	   americanus.	   It	   consists	   of	   41	   residues	   and	   has	   a	   molecular	   weight	   of	  
4716.5	  Da.	  Because	  of	  its	  size	  it	  was	  decided	  to	  divide	  the	  sequence	  into	  approximately	  
equal	   sized	  halves	   and	   to	   synthesise	   them	  separately.	  The	  half	  with	   the	  N-­‐terminus	   is	  
from	  now	  on	  called	  Name2	  N-­‐terminus,	  whereas	  the	  part	  with	  the	  C-­‐terminus	  is	  named	  
Name2	  C-­‐terminus.	  After	  the	  successful	  synthesis	  of	  both	  halves	  they	  have	  to	  be	  ligated	  
together	   by	   native	   chemical	   ligation	   (NCL).	   	   NCL	   requires	   that	   the	  Name2	  C-­‐terminus	  
fragment	  has	  a	  N-­‐terminal	  Cys-­‐residue,	  because	  the	  thiol	  group	  is	  crucial	  for	  the	  reaction	  








Figure	  16:	  Amino	  acid	  sequence	  of	  Name2	  
	  
Figure	   17	   summarizes	   the	   synthetic	   scheme	   used	   for	   the	   production	   of	   the	   two	  
fragments.	  Name2	  N-­‐terminus	  was	  synthesised	  with	  a	  diaminobenzoic	  acid	  (Dbz)	  group	  
attached	  to	  the	  C-­‐terminal	  residue.	  When	  the	  chain	  elongation	  was	  complete,	  this	  Dbz-­‐
group	  was	   then	   converted	   to	   a	  N-­‐acylurea	  moiety,	   a	  N-­‐acyl-­‐benzimidazolinone	   (Nbz),	  
which	   is	   readily	   exchanged	  with	   an	   arylthiol	   to	   form	   a	   thioester	   [42].	   The	  N-­‐terminal	  
Gln-­‐residue	   was	   protected	   by	   a	   base-­‐stable	   Boc-­‐group,	   which	   was	   removed	   together	  
with	   the	   other	   protecting	   groups	   in	   the	   cleaving	   process.	   The	   synthesis	   of	   Name2	   C-­‐
































Figure	  17:	  Name2	  N-­‐terminus	  with	  a	  Dbz-­‐group	  attached	  to	  the	  C-­‐terminal	  residue	  (1)	  was	  converted	  to	  
yield	  the	  peptide-­‐Nbz	  (2).	  The	  subsequent	  cleavage	  liberated	  the	  unprotected	  peptide-­‐Nbz	  (3).	  Name2	  C-­‐
terminus	  was	  synthesised	  by	  standard	  Fmoc-­‐SPPS	  and	  then	  cleaved	  (4,	  5).	  3	  and	  5	  were	  ligated	  to	  Name2	  
(6).	  Only	  the	  Boc-­‐group	  protecting	  the	  N-­‐terminal	  Gln-­‐residue	  of	  1	  and	  2	   is	  shown,	  the	  other	  protecting	  
groups	  are	  omitted.	  
	  
2.5.1.1	  Synthesis	  of	  Name2	  N-­‐terminus	  
Name2	  N-­‐terminus	  was	   synthesised	  manually	  on	  a	  0.25	  mmol	   scale	  using	  Fmoc-­‐SPPS.	  
Because	   the	   synthesis	   proceeds	   from	   the	   C-­‐	   to	   the	  N-­‐terminal	   end	   of	   the	   peptide,	   the	  
Rink	  Amide	  4-­‐methylbenzhydrylamine	  (MBHA)	  resin	  was	  initially	  loaded	  with	  3-­‐Fmoc-­‐
4-­‐diaminobenzoic	   acid	   (Fmoc-­‐Dbz).	   The	   loading	   had	   to	   be	   repeated	   twice	   over	   the	  
course	   of	   three	   days	   and	   the	   coupling	   yield	  was	   checked	   by	   ninhydrin	   test.	   After	   the	  
successful	  loading,	  the	  peptide	  chain	  was	  elongated	  as	  determined	  by	  the	  sequence,	  but	  
every	   residue	   had	   to	   be	   coupled	   several	   times	   in	   order	   to	   achieve	   satisfactory	   yields,	  
with	  Arg15	  and	  Arg17	  being	   the	  residues	  hardest	   to	  couple.	  After	  chain	  assembly	  was	  
complete,	   Name2	   N-­‐terminus	  was	   activated	   by	   4-­‐nitrophenyl	   chloroformate	   and	  N,N-­‐
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was	   obtained	   of	   which	   400	   mg	   was	   taken	   out	   for	   cleaving	   using	   a	   mixture	   of	   TFA,	  
triisopropylsilane	   (TIPS),	   3,6-­‐dioxa-­‐1,8-­‐octanedithiol	   (DODT)	   and	   water,	   yielding	   114	  
mg	  of	  peptide	  crude.	  An	  electrospray	  ionization	  mass	  spectrum	  (ESI-­‐MS)	  was	  recorded	  
of	  the	  peptide	  crude	  that	  showed	  two	  major	  products:	  the	  activated	  peptide-­‐Nbz	  and	  a	  
by-­‐product	   with	   masses	   of	   1193.4	   ([M+2]2+)	   and	   796.1	   ([M+3]3+)	   (figure	   A7).	   The	  
calculated	   and	   observed	   ions	   of	   the	   correct	   peptide-­‐Nbz	   in	   the	   crude	   are	   depicted	   in	  
table	   1.	   The	   analytical	   RP-­‐HPLC	   carried	   out	   to	   investigate	   the	   composition	   of	   the	  
peptide	  crude	  is	  shown	  in	  figure	  18	  and	  the	  peaks	  at	  20.4	  and	  21.9	  minutes	  belong	  to	  
the	  by-­‐product	  and	  Name2	  N-­‐terminus	  peptide-­‐Nbz,	  respectively.	  
	  
	  
Figure	  18:	  Analytical	  RP-­‐HPLC	  of	  Name2	  N-­‐terminus	  peptide	  crude	  
	  
74	  mg	   of	   the	   peptide	   crude	  was	   purified	   by	   RP-­‐HPLC	  where	   the	   peptide	   eluted	   after	  
approximately	   29.5	  minutes	   and	   three	   fractions	   could	   be	   obtained	   that	   contained	   the	  
activated	   peptide-­‐Nbz,	   which	   was	   confirmed	   by	   ESI-­‐MS	   (Figure	   A8	   and	   table	   1).	  
Unfortunately,	  the	  same	  major	  by-­‐product	  present	  in	  the	  crude	  eluted	  together	  with	  the	  
correct	  peptide-­‐Nbz	  during	  the	  purification.	  	  
	  
Table	   1:	   Calculated	   and	   observed	   masses	   of	   Name2	   N-­‐terminus	   peptide	   crude	   and	  
purified	  fraction	  
	   [M+2]2+	   [M+3]3+	  
Calculated:	   1282.9	   855.6	  
Observed:	  
Crude	   1282.6	   –	  
Purified	   1282.5	   855.2	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The	   fractions	   were	   analysed	   by	   RP-­‐HPLC	   and	   figure	   19	   shows	   the	   RP-­‐HPLC	  
chromatogram	  of	  the	  fraction	  that	  generated	  the	  highest	  peaks	  at	  retention	  times	  similar	  
to	  the	  peptide	  crude,	  as	  well	  as	  the	  highest	  intensity	  on	  the	  mass	  spectrum.	  That	  fraction	  
contained	   probably	   the	   highest	   amount	   of	   correct	   peptide-­‐Nbz	   but	   also	   considerable	  
amounts	  of	  the	  by-­‐product.	  The	  fractions	  were	  then	  lyophilized	  overnight	  and	  19.67	  mg	  
of	  fractions	  containing	  the	  correct	  peptide-­‐Nbz	  were	  saved	  for	  the	  ligation.	  
	  
	  
Figure	  19:	  Analytical	  RP-­‐HPLC	  of	  purified	  Name2	  N-­‐terminus	  
	  
2.5.1.2	  Synthesis	  of	  Name2	  C-­‐terminus	  
2-­‐Chlorotrityl	  chloride	  resin	  was	  used	  for	  the	  manual	  synthesis	  of	  Name2	  C-­‐terminus	  on	  
a	  0.25	  mmol	   scale.	   Every	   residue	  had	   to	  be	   coupled	   several	   times	   in	   order	   to	   achieve	  
satisfactory	  coupling	  yields,	  which	  were	  determined	  by	  ninhydrin	   test.	  Again,	  arginine	  
was	  the	  residue	  hardest	  to	  couple,	  with	  Arg	  17	  giving	  a	  coupling	  yield	  below	  92	  %	  after	  
the	  fourth	  coupling.	  521	  mg	  of	  peptidyl	  resin	  was	  obtained	  during	  the	  synthesis	  of	  which	  
half	  was	  taken	  out	  for	  cleavage	  using	  a	  mixture	  of	  TFA/TIPS/DODT/H2O.	  ESI-­‐MS	  of	  the	  
peptide	  crude	  confirmed	  the	  presence	  of	  the	  correct	  Name2	  C-­‐terminus	  (figure	  A9	  and	  
table	   2).	  The	  mass	  of	   the	  dry	  peptide	   crude	  was	  78	  mg	  and	  purification	  by	  RP-­‐HPLC,	  
where	   the	  peptide	  eluted	  after	  approximately	  34	  minutes	   resulted	   in	  several	   fractions	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Table	   2:	   Calculated	   and	   observed	   masses	   of	   Name2	   C-­‐terminus	   peptide	   crude	   and	  
purified	  fraction	  
	   [M+2]2+	   [M+3]3+	  
Calculated:	   1165.9	   777.6	  
Observed:	  
Crude	   1165.2	   776.8	  
Purified	   1165.4	   777.4	  
	  
Analytical	  RP-­‐HPLC	  chromatograms	  of	  the	  peptide	  crude	  and	  the	  most	  pure	  fraction	  are	  
depicted	  in	  figures	  20	  and	  21,	  respectively.	  Name2	  C-­‐terminus	  has	  a	  retention	  time	  of	  
approximately	  29	  minutes.	  The	  fractions	  were	  lyophilized.	  	  
	  
	  
Figure	  20:	  Analytical	  RP-­‐HPLC	  chromatogram	  of	  Name	  2	  C-­‐terminus	  peptide	  crude	  
	  
	  
Figure	  21:	  Analytical	  RP-­‐HPLC	  of	  purified	  Name	  2	  C-­‐terminus	  
	  
The	   rest	   of	   the	   peptidyl	   resin	   was	   also	   cleaved	   and	   all	   peptide	   crude	   obtained	   was	  
purified,	  which	  resulted	  in	  14.66	  mg	  of	  fractions	  containing	  Name2	  C-­‐terminus	  saved	  for	  
ligation.	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2.5.1.3	  Native	  chemical	  ligation	  of	  Name2	  N-­‐terminus	  and	  C-­‐terminus	  
1.	  Ligation	  attempt:	  
Because	  a	  by-­‐product	  eluted	  together	  with	  Name2	  N-­‐terminus	  during	  purification,	  this	  
starting	  material	  for	  the	  ligation	  was	  not	  pure	  and	  the	  decision	  was	  made	  to	  use	  twice	  
the	   amount	   of	   Name2	   N-­‐terminus	   compared	   to	   the	   C-­‐terminus,	   which	   was	   relatively	  
pure	   for	   this	   reaction.	   Name2	   N-­‐terminus	   (3.98	  mg)	   and	   C-­‐terminus	   (1.98	  mg)	   were	  
ligated	  using	  a	  ligation	  buffer	  made	  of	  guanidine	  hydrochloride	  (Gn	  ⋅	  HCl)	  and	  disodium	  
hydrogen	   phosphate	   (Na2HPO4)	   at	   pH	   7.91.	   Mercaptophenylacetic	   acid	   (MPAA)	   in	   a	  
concentration	  of	  0.202	  M	  accounted	  for	  the	   formation	  of	   the	  thioester	  that	  reacts	  with	  
the	  Cys-­‐residue	  of	  Name2	  C-­‐terminus	  and	  0.0206	  M	  of	  Tris(2-­‐carboxyethyl)phosphine	  
hydrochloride	   (TCEP	  ⋅	  HCl)	   kept	   the	  Cys-­‐residues	   reduced.	   Success	   of	   the	   ligation	  was	  
examined	   by	   LC/MS	   and	   the	   ESI-­‐MS	   is	   shown	   in	   figure	   A11.	   The	   calculated	   and	  
observed	  ion	  masses	  of	  the	  correct	  ligation	  product	  are	  depicted	  in	  table	  3.	  	  
	  
Table	  3:	  Calculated	  and	  observed	  masses	  of	  Name2	  after	  the	  first	  ligation	  attempt	  
	   [M+3]3+	   [M+4]4+	   [M+5]5+	   [M+6]6+	   [M+7]7+	  
Calculated:	   1573.2	   1180.1	   944.3	   787.1	   674.8	  
Observed:	   1572.9	   1179.9	   943.1	   787.1	   674.8	  
	  
Subsequent	   to	   the	   LC/MS,	   purification	   by	   RP-­‐HPLC	  was	   carried	   out	   and	   the	   fractions	  
were	   analysed	   by	   ESI-­‐MS.	   Unfortunately	   no	   masses	   belonging	   to	   the	   correct	   ligation	  
product	  could	  be	  identified.	  
	  
2.	  Ligation	  attempt	  
MPAA,	  TCEP	  ⋅	  HCl	   and	   a	   buffer	  made	  of	  Gn	  ⋅	  HCl	   and	  Na2HPO4	  were	   also	  used	   for	   this	  
ligation	  attempt,	  but	  the	  reaction	  was	  carried	  out	  at	  a	  pH	  of	  6.98	  and	  larger	  amounts	  of	  
starting	   material	   were	   used	   (15.33	   mg	   N-­‐terminus	   and	   9.30	   mg	   C-­‐terminus).	  
Additionally,	   the	   reaction	   mixture	   was	   degassed	   under	   nitrogen.	   After	   24	   hours,	   the	  
mixture	   was	   loaded	   onto	   a	   preparative	   column	   and	   purified	   by	   RP-­‐HPLC,	   where	   the	  
correct	  ligation	  product	  eluted	  after	  approximately	  34	  minutes	  (figure	  22).	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Figure	  22:	  RP-­‐HPLC	  chromatogram	  of	  the	  purification	  of	  the	  Name2	  ligation	  mixture	  
	  
The	  presence	  of	  the	  ligation	  product	  was	  determined	  by	  ESI-­‐MS	  and	  the	  calculated	  and	  
observed	  masses	  are	  depicted	  in	  table	  4.	  Because	  the	  ESI-­‐MS	  (figure	  A12)	  also	  showed	  
peaks	  of	  unrelated	  masses,	  an	  analytical	  RP-­‐HPLC	  (figure	  23)	  was	  performed	  to	  check	  
the	  purity,	  which	  showed	  several	  other	  peaks,	  but	   the	  dominant	  peak	  belonged	   to	   the	  
correct	  ligation	  product.	  The	  mass	  of	  dry	  product	  obtained	  during	  the	  ligation	  was	  4.55	  
mg.	  
	  
Table	  4:	  Calculated	  and	  observed	  masses	  of	  Name2	  after	  the	  second	  attempt	  of	  ligation	  
	   [M+3]3+	   [M+4]4+	   [M+5]5+	   [M+6]6+	   [M+8]8+	   [M+11]11+	  
Calculated:	   1573.2	   1180.1	   944.3	   787.1	   590.6	   429.8	  
Observed:	   1572.6	   1179.6	   943.8	   786.9	   590.1	   430.0	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2.5.1.4	  Folding	  of	  Name2	  
In	   the	   folding	  process,	   the	   thiol	  groups	  of	   two	  Cys-­‐residues	  are	  oxidised	   to	  a	  disulfide	  
bond.	  Name2	  has	  six	  Cys-­‐residues,	  so	  three	  disulfide	  bonds	  are	  established	  and	  because	  
one	  Cys-­‐residue	  can	  form	  a	  bond	  with	  any	  of	  the	  other	  ones,	  15	  isomers	  are	  possible.	  A	  
trial	  oxidation	   is	   therefore	  performed	  to	   find	  the	  optimal	  buffer	  conditions	  that	   favour	  
the	   correctly	   folded	   peptide.	   The	   analytical	   RP-­‐HPLC	   chromatograms	   of	   oxidations	  









Figure	  24:	  Analytical	  RP-­‐HPLC	  chromatograms	  of	  the	  Name2	  trial	  oxidation	  under	  different	  conditions	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<Peak Table>
Detector A Channel 1 215nm
<Sample Information>
1.	  PBS	  	   2.	  0.1	  M	  NH4HCO3	  
3.	  PBS/propan-­‐2-­‐ol	   4.	  0.1	  M	  NH4HCO3/propan-­‐2-­‐ol	  
5.	  PBS,	  2	  mM	  GSH,	  0.2	  mM	  GSSG	   6.	  0.1	  M	  NH4HCO3,	  2	  mM	  GSH,	  0.2	  mM	  GSSG	  
7.	  PBS/propan-­‐2-­‐ol,	  2	  mM	  GSH,	  0.2	  mM	  GSSG	   8.	  0.1	  M	  NH4HCO3/propan-­‐2-­‐ol,	  2	  mM	  GSH,	  0.2	  mM	  GSSG	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Condition	  5	  was	  found	  not	  only	  to	  result	   in	  the	  highest	  peak,	  but	  also	   in	  the	  best	  peak	  
height	  ratio	  between	  the	  major	  product	  and	  other	  constituents	  of	  the	  mixture.	  Oxidation	  
conditions	   that	   included	   the	   use	   of	   propan-­‐2-­‐ol	   resulted	   in	   no	   clear	   peak.	   1.91	  mg	   of	  
reduced	  Name2	  was	   then	  oxidised	   in	  phosphate	  buffered	   saline	   (PBS),	   2	  mM	  reduced	  
glutathione	  (GSH)	  and	  0.2	  mM	  oxidised	  glutathione	  (GSSG)	  overnight	  at	  23	  °C,	  before	  the	  
oxidation	  mixture	  was	  purified	  by	  RP-­‐HPLC	  (figure	  25).	  	  
	  
	  
Figure	   25:	   RP-­‐HPLC	   chromatogram	  of	   the	  Name2	  oxidation	  mixture;	   oxidised	  Name2	  eluted	   after	  30.8	  
minutes	  	  
	  
ESI-­‐MS	  was	  used	  to	  analyse	  the	  eluate	  the	  ESI-­‐MS	  of	  oxidised	  Name2	  is	  shown	  in	  figure	  
A13,	  whereas	  the	  calculated	  and	  observed	  masses	  of	  oxidised	  Name2	  are	  summarized	  in	  
table	  5.	  The	  oxidation	  of	  the	  Cys-­‐residues	  formed	  three	  disulfide	  bonds	  and	  caused	  the	  
peptide	   to	   loose	   six	   masses.	   1.27	   mg	   of	   oxidised	   Name2	   was	   obtained	   and	   the	  
chromatogram	  of	  the	  analytical	  RP-­‐HPLC	  performed	  to	  check	  the	  purity	  of	  the	  product	  is	  
shown	  in	  figure	  26.	  
	  
Table	  5:	  Calculated	  and	  observed	  masses	  of	  oxidised	  Name2	  
	   [M+3]3+	   [M+4]4+	   [M+5]5+	   [M+6]6+	   [M+11]11+	  
Calculated:	   1571.2	   1178.6	   943.1	   786.1	   429.2	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 22.333 
 22.786  23.134 
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Figure	  26:	  Analytical	  RP-­‐HPLC	  of	  oxidised	  Name2	  
	  
2.5.1.5	  NMR	  of	  Name2	  
A	  1D	  1H	  NMR	  spectrum	  of	  oxidised	  Name2	  was	  recorded	  and	  it	  showed	  well	  dispersed	  
peaks,	   which	   indicates	   that	   the	   peptide	   is	   folded	   properly	   and	   adopts	   an	   ordered	  
structure	  in	  solution.	  Next,	  2D	  NMR	  spectroscopy	  was	  used	  to	  determine	  the	  structure.	  
The	  1H	  chemical	  shifts	  were	  assigned	  as	  described	  before	  [43].	  Briefly,	  total	  correlation	  
spectroscopy	  (TOCSY)	  spectra	  were	  recorded	  and	  used	  to	  identify	  the	  1H	  spin	  system	  of	  
each	  residue	  and	  the	  connectivities	  between	  the	  amino	  acids,	  determined	  by	  assigning	  
the	  peaks	  for	  NH-­‐NHi+1,	  Hα-­‐NHi+1	  and	  Hβ-­‐NHi+1	  in	  the	  nuclear	  Overhauser	  enhancement	  
spectroscopy	  (NOESY)	  spectrum,	  were	  used	  to	  assign	  each	  residue	  to	  a	  specific	  position	  
in	  the	  sequence	  (figure	  27).	  Proline,	  which	  Name2	  has	  three	  of	  in	  its	  sequence,	  does	  not	  
have	  a	  proton	  attached	  to	   the	  nitrogen	  when	   it	   is	  part	  of	  a	  peptide	  bond,	   therefore	  no	  
Hα-­‐NHi+1	   connectivities	   could	   be	   assigned	   for	   these	   residues.	   Instead,	   sequential	  
connections	  to	  the	  proline	  Hδ	  protons	  were	  used	  to	  confirm	  assignments	  and	  to	  confirm	  
that	  all	  three	  Pro-­‐residues	  are	  in	  a	  trans	  conformation.	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Figure	  27:	  1H	  NOESY	  spectrum	  showing	  the	  sequential	  assignment	  of	  Name2	  by	  connecting	  the	  Hα-­‐NHi+1	  
cross	  peaks.	  The	  cross	  peak	  of	  Hα33-­‐NH34	  was	  not	  observed	  in	  this	  spectrum.	  
	  
Figure	  28	  shows	  the	  Hα	  secondary	  chemical	  shifts	  for	  Name2,	  which	  were	  calculated	  by	  
taking	   the	  difference	  of	   the	  observed	  Hα	  chemical	   shifts	  and	  Hα	  random	  coil	   chemical	  
shifts	  of	  the	  same	  residue	  [44].	  Cα	  and	  Cβ	  secondary	  chemical	  shifts	  are	  shown	  in	  figure	  
29.	   The	   secondary	   chemical	   shifts	   can	   provide	   important	   data	   about	   the	   secondary	  
structure	  of	  the	  peptide.	  Hα	  secondary	  chemical	  shifts	  below	  –0.1	  ppm	  of	  four	  or	  more	  
residues	   is	   indicative	   of	   a	   helix,	   whereas	   β-­‐strand	   like	   structures	   have	   Hα	   secondary	  
chemical	  shifts	  greater	  than	  +0.1	  ppm	  of	  at	  least	  three	  residues	  [45].	  Between	  Pro8	  and	  
Lys17,	  as	  well	  as	  between	  Ser27	  and	  Leu32	  Hα	  secondary	  chemical	  shift	  values	  are	  all	  
more	   negative	   than	   –0.1	   ppm,	   which	   suggests	   that	   Name2	   has	   two	   regions	   of	   helical	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Figure	  28:	  Hα	  secondary	  chemical	  shifts	  of	  Name2	  	  
	  
Similarly,	  secondary	  structure	  can	  be	  inferred	  by	  using	  the	  secondary	  chemical	  shift	  of	  
the	   carbon	   atoms	   [46].	   For	   this	   purpose	   a	   2D	   1H	   –	   13C	   heteronuclear	   single	   quantum	  
coherence	  (HSQC)	  spectrum	  was	  recorded	  at	  natural	  abundance	  and	  analysed.	  The	  Cα	  
secondary	  chemical	  shifts	  of	  Pro8	  to	  Lys17	  and	  Ser27	  to	  Gln33	  exceed	  +0.7	  ppm,	  which	  
is	  also	  indicative	  of	  a	  helical	  structure.	  The	  secondary	  chemical	  shift	  of	  the	  β-­‐carbons	  can	  
only	  be	  used	  for	  the	  identification	  of	  β-­‐strands,	  and	  the	  Cβ	  of	  at	  least	  three	  consecutive	  
residues	  should	  have	  secondary	  chemical	  shifts	  that	  exceed	  +0.7	  ppm	  (4.0	  ppm	  for	  Pro)	  
to	  indicate	  a	  β-­‐strand,	  which	  is	  not	  the	  case	  for	  Name2.	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Determination	   of	   the	   three	   dimensional	   structure	   of	   Name2	   was	   based	   on	   distance	  
restraints	   from	   NOESY	   cross	   peaks,	   dihedral	   angle	   restraints	   derived	   from	   coupling	  
constants	  and	  on	  patterns	  of	  chemical	  shifts.	  Table	  6	  lists	  the	  statistics	  for	  the	  ensemble	  
of	   the	  15	   lowest	   energy	   structures	  of	  Name2.	  409	  distance	   restraints	   and	  73	  dihedral	  
angle	   restraints	   were	   included	   in	   structure	   calculations	   performed	  with	   the	   program	  
CYANA	   and	   the	   ensemble	   of	   the	   15	   lowest	   energy	   structures	   chosen	   to	   represent	   the	  
solution	  structure	  of	  Name2	  is	  shown	  in	  figure	  30.	  The	  structures	  did	  not	  have	  nuclear	  
Overhauser	  effect	  (NOE)	  violations	  exceeding	  0.2	  Å	  or	  dihedral	  violations	  exceeding	  2.0	  
Å	   and	   have	   good	   covalent	   geometry	   as	   evident	   from	   low	   target	   functions	   and	   good	  
Ramachandran	  statistics.	  	  	  
	  
	  
Figure	  30:	  Ensemble	  of	  the	  15	  lowest	  energy	  structures	  of	  Name2.	  The	  backbone	  of	  the	  peptide	  is	  shown	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Table	  6:	  Statistics	  for	  the	  ensemble	  of	  the	  15	  lowest	  energy	  structures	  of	  Name2	  
Distance	  restraints	   	  
Intraresidue	  (i-­‐j	  =	  0)	   197	  
Sequential	  (/i-­‐j/	  =	  1)	   140	  
Medium	  range	  (/i-­‐j/	  <5)	   51	  
Long	  range	  (/i-­‐j/	  ≥5)	   21	  
Hydrogen	  bonds	   28	  (for	  14	  hydrogen	  bonds)	  
Total	   409	  
Dihedral	  angle	  restraints	   	  
Φ	   29	  
Χ1	   12	  
Ψ	   32	  
Total	   73	  
CYANA	  score	  (kcal/mol)	   	  
Target	  function	   7.49	  	  10-­‐2	  ±	  2.19	  	  10-­‐2  
Violations	  from	  experimental	  restraints	   	  
NOE	  violations	  exceeding	  0.2	  Å	   0	  
Dihedral	  violations	  exceeding	  2.0	  °	   0	  
Ramachandran	  statistics	   	  
Most	  favoured	   84.5	  %	  
Additionally	  allowed	   12.3	  %	  
Generously	  allowed	   0	  %	  
Disallowed	   0	  %	  
Atomic	  RMSD	  (Å)	   	  
Backbone	  atoms	   0.95	  ±	  0.28	  
Heavy	  atoms	   1.79	  ±	  0.43	  
	  
The	  calculated	  structure	  has	  a	  root	  mean	  square	  deviation	  (RMSD)	  of	  0.95	  ±	  0.28	  Å	  for	  
the	  backbone	  atoms	  and	  1.79±0.49	  Å	  for	  the	  heavy	  atoms.	  The	  ribbon	  depictions	  of	  the	  
mean	   structure	  of	  Name2	  and	  ShK	  are	   shown	   in	   figure	   31.	  Name2	  has	   two	  α-­‐helices,	  
one	  between	  Pro8	  –	  Lys17	  and	   the	  other	  between	  Ser27	  –	  Leu32.	  The	   fold	   resembles	  
ShK,	  which	  has	  two	  helical	  structures	  between	  Ala14	  –	  His19	  and	  Met21	  –	  Arg24,	  but	  the	  
length	  and	  positioning	  of	  the	  helices	  differ,	  presumably	  due	  to	  differences	  in	  the	  number	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of	   residues	   between	   CysII	   –	   CysIII	   (9	   residues	   in	   Name2	   and	   5	   residues	   in	   ShK)	   and	  
CysIII	   –	   CysIV	   (13	   residues	   in	   Name2	   and	   11	   residues	   in	   ShK)	   [47].	   The	   disulfide	  
connectivity	   in	  Name2	  has	   been	   assumed	   to	   be	   similar	   as	   proposed	   for	   ShK,	  which	   is	  
consistent	  with	  our	  data	  [47].	  	  
	  
	  
Figure	  31:	  Ribbon	  depiction	  of	  the	  mean	  structures	  of	  Name2	  (A)	  and	  ShK	  (B).	  	  
	  
2.5.2	  Synthesis	  of	  Acan1	  
Acan1	   is	   a	   51	   residue	   long	   peptide	   with	   a	   molecular	   weight	   of	   5865.5	   Da.	   It	   was	  
discovered	  in	  the	  transcriptome	  of	  the	  dog	  hookworm	  A.	  caninum	  and	  its	  synthesis	  was	  
attempted	  as	  a	  part	  of	  this	  project.	  Similar	  to	  the	  synthesis	  of	  Name2,	  the	  sequence	  was	  
divided	   into	   two	   halves;	   a	   requirement	   is	   that	   Acan1	   C-­‐terminus	   must	   have	   a	   Cys-­‐
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Two	   different	   strategies	   for	   the	   synthesis	   of	   the	   precursor	   for	   the	   Acan1	   N-­‐terminus	  
thioester	  peptide	  were	  applied	  (figure	  33):	  	  
1)	  Acan1	  N-­‐terminus	  was	  synthesised	  as	  a	  peptide	  hydrazide,	  which	  was	  then	  oxidised	  
to	   the	  peptide	  azide	  after	  cleavage	   from	  the	  resin.	  The	  azide	  group	   is	  displaced	  by	  the	  
arylthiol	  that	  forms	  the	  peptide	  thioester	  required	  for	  the	  ligation.	  	  
2)	  Because	  the	  first	  strategy	  was	  not	  successful,	  Acan1	  N-­‐terminus	  was	  synthesised	  with	  
a	  Dbz	  group	  attached	   to	   the	  C-­‐terminal	   residue,	  which	   is	   then	  converted	   to	  a	  peptide-­‐
Nbz	  before	  exchanged	  with	  an	  arylthiol.	  The	  thioester	   is	  then	  supposed	  to	  take	  part	   in	  
the	   ligation	  with	   Acan1	   C-­‐terminus.	   The	   N-­‐terminal	   Gln-­‐residue	   had	   again	   to	   be	   Boc-­‐
protected.	  	  
	  
The	  synthesis	  of	  Acan1	  C-­‐terminus	  should	  have	  been	  straightforward	  and	  2-­‐chlorotrityl	  
chloride	   resin	   was	   used	   in	   the	   first	   synthesis	   attempt.	   But,	   ESI-­‐MS	   of	   a	   test	   cleavage	  
carried	  out	  after	  attachment	  of	  ten	  residues	  showed	  no	  masses	  belonging	  to	  the	  correct	  
peptide.	  This	  might	  have	  been	  due	  to	  peptide	  aggregation	  caused	  by	  the	  high	  loading	  of	  
the	  resin	  (1.3	  mmol/g).	  Then,	  Wang	  resin	  was	  used	  as	  a	  solid	  support	  for	  the	  synthesis,	  
but	  this	  also	  failed	  because,	  proline,	  which	  is	  the	  C-­‐terminal	  residue,	  may	  have	  formed	  a	  
diketopiperazine	   [48].	   Finally,	   Rink	   Amide	  MBHA	   resin	  was	   tried	   for	   the	   synthesis	   of	  
Acan1	  C-­‐terminus	  using	  an	  automated	  peptide	  synthesiser,	  although	   it	  would	  result	   in	  


































Figure	  33:	  In	  the	  first	  synthesis	  strategy	  applied,	  Acan1	  N-­‐terminus	  peptide	  hydrazide	  bound	  to	  the	  resin	  
(7)	   is	   liberated	   by	   TFA-­‐cleavage	   to	   yield	   the	   unprotected	   peptide	   hyrazide	   (8),	   which	   is	   subsequently	  
oxidised	  to	  the	  peptide	  azide	  (9).	  Acan1	  C-­‐terminus	  (10)	  and	  9	  were	  then	  thought	  to	  ligate,	  giving	  Acan1	  
(11).	   	  Second	  strategy:	  Acan1	  N-­‐terminus	  with	  a	  Dbz-­‐group	  attached	  to	  the	  C-­‐terminal	  residue	  (12)	  was	  
converted	  to	  yield	  the	  peptide-­‐Nbz	  (13).	  A	  cleavage	  liberated	  the	  unprotected	  peptide-­‐Nbz	  (14).	  10	  and	  14	  
were	  supposed	  to	  yield	  Acan1	  by	  ligation.	  Only	  the	  Boc-­‐group	  protecting	  the	  N-­‐terminal	  Gln-­‐residue	  of	  12	  
and	  13	  is	  shown,	  the	  other	  protecting	  groups	  are	  omitted.	  
	  
2.5.2.1	  Synthesis	  of	  the	  Acan1	  N-­‐terminus	  as	  a	  peptide	  hydrazide	  
The	  Acan1	  N-­‐terminus	  was	  synthesised	  manually	  as	  a	  peptide	  hydrazide	  on	  a	  0.25	  mmol	  
scale	  using	  the	  2-­‐chlorotrityl	  chloride	  resin.	  Loading	  of	  hydrazine	  hydrate	  onto	  the	  resin	  
and	   standard	   Fmoc-­‐SPPS	  were	   applied	   to	   assemble	   the	   peptide	   hydrazide.	   Repetitive	  



























































	   37	  
Cleavage	  of	  336	  mg	  peptidyl	  resin	  using	  a	  mixture	  of	  TFA/TIPS/DODT/H2O	  resulted	  in	  
159	  mg	  of	  peptide	  crude,	  which	  was	  analysed	  by	  ESI-­‐MS.	  The	  [M+3]3+	  and	  [M+4]4+	  of	  the	  
peptide	  could	  be	  identified	  (figure	  A14	  and	  table	  7).	  The	  peptide	  crude	  was	  purified	  by	  
RP-­‐HPLC	  where	   the	   peptide	   hydrazide	   eluted	   after	   approximately	   31	  minutes	   (figure	  
34).	  	  
	  
Table	  7:	  Calculated	  and	  observed	  masses	  of	  Acan1	  N-­‐terminus	  peptide	  hydrazide	  crude	  
and	  purified	  fraction	  
	   [M+3]3+	   [M+4]4+	  
Calculated:	   1094.8	   821.4	  
Observed:	  
Crude	   1094.6	   820.8	  
Purified	   1094.4	   821.1	  
	  
	  
Figure	  34:	  RP-­‐HPLC	  chromatogram	  of	  the	  purification	  of	  Acan1	  N-­‐terminus	  peptide	  hydrazide	  
	  
Fractions	  containing	   the	  correct	  product	  were	   identified	  by	  ESI-­‐MS,	  and	  analytical	  RP-­‐
HPLC	  was	  used	  to	  determine	  the	  purity	  of	  the	  fractions.	  The	  ESI-­‐MS	  and	  analytical	  RP-­‐
HPLC	   chromatogram	   for	   the	   most	   pure	   fraction	   that	   will	   be	   used	   for	   the	   ligation	   is	  
shown	  in	  figures	  A15	  and	  35,	  respectively.	  The	  observed	  masses	  are	  depicted	  in	  table	  
7.	  The	  mass	  of	  dry	  product	  at	  the	  end	  was	  17.4	  mg.	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Figure	  35:	  Analytical	  RP-­‐HPLC	  chromatogram	  of	  purified	  Acan1	  N-­‐terminus	  peptide	  hydrazide	  
	  
2.5.2.2	  Synthesis	  of	  Acan1	  C-­‐terminus	  
The	  Acan1	  C-­‐terminus	  was	  synthesised	  on	  a	  0.25	  mmol	  scale	  using	  Rink	  Amide	  MBHA	  
resin	   and	   an	   automated	   synthesiser.	   1.661	   g	   of	   peptidyl	   resin	  was	   obtained,	   of	  which	  
379	  mg	  was	   cleaved	   using	   TFA/TIPS/DODT/H2O,	   resulting	   in	   159	  mg	   of	   dry	   peptide	  
crude.	   In	  order	   to	  confirm	  the	  presence	  of	   the	  correct	  peptide	   in	   the	  crude,	  an	  ESI-­‐MS	  
(figure	  A16)	  was	  recorded	  and	  the	  calculated	  and	  observed	  masses	  are	  summarized	  in	  
table	  8.	  The	  chromatogram	  of	  the	  analytical	  RP-­‐HPLC	  of	  the	  peptide	  crude	  is	  shown	  in	  
figure	  36.	  	  
	  
Table	   8:	   Calculated	   and	   observed	   masses	   of	   Acan1	   C-­‐terminus	   peptide	   crude	   and	  
purified	  fraction	  
	   [M+2]2+	  
Calculated:	   1308.5	  
Observed:	  
Crude	   1307.9	  
Purified	   1307.9	  
	  
	  
Figure	  36:	  Analytical	  RP-­‐HPLC	  chromatogram	  of	  Acan1	  C-­‐terminus	  peptide	  crude	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In	   the	  next	   step,	  73	  mg	  of	  peptide	  crude	  was	  purified	  by	  RP-­‐HPLC,	  where	   the	  peptide	  
eluted	  after	  approximately	  48.5	  minutes.	  A	   total	  of	  six	   fractions	  containing	   the	  correct	  
peptide	   were	   identified	   by	   ESI-­‐MS	   and	   analytical	   RP-­‐HPLC	   was	   used	   to	   evaluate	   the	  
purity	  of	  each	  fraction.	  The	  observed	  mass	  of	   the	  [M+2]2+	   is	  shown	  in	  table	  8	  and	  the	  
ESI-­‐MS	  and	  analytical	  RP-­‐HPLC	  chromatogram	  of	   the	  most	  pure	   fraction	   is	  depicted	   in	  
figures	  A17	  and	  37,	  respectively.	  20.71	  mg	  of	  dry	  product	  was	  saved	  for	  the	  ligation.	  
	  
	  
Figure	  37:	  Analytical	  RP-­‐HPLC	  chromatogram	  of	  purified	  Acan1	  C-­‐terminus	  
	  
2.5.2.3	  Native	  chemical	  ligation	  of	  Acan1	  using	  a	  peptide	  hydrazide	  
Acan1	  N-­‐terminus	  peptide	  hydrazide	  and	  Acan1	  C-­‐terminus	  were	  dissolved	   in	   ligation	  
buffer	  at	  a	   low	  pH	  and	  sodium	  nitrite	   (NaNO2)	  was	   then	  added	   for	   the	  oxidation	  step.	  
MPAA	  was	   introduced	   for	   the	   thioester	   formation	   followed	  by	  a	  pH	  adjustment	   to	  7.6	  
and	  the	  reaction	  mixture	  was	  then	  allowed	  to	  react	  overnight	  at	  23	  °C.	  The	  mixture	  was	  	  
loaded	  onto	  an	  analytical	  column	  and	  purified	  by	  RP-­‐HPLC.	  The	  chromatogram	  is	  shown	  
in	  figure	  38.	  	  
	  
	  
Figure	  38:	  RP-­‐HPLC	  chromatogram	  of	  the	  purification	  of	  the	  Acan1	  ligation	  mixture	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The	  eluate	  was	  analysed	  by	  ESI-­‐MS,	  but	  no	  correct	   ligation	  product	  could	  be	  detected.	  
The	  ESI-­‐MS	  of	  the	  fraction	  collected	  at	  17.5	  minutes	  is	  depicted	  in	  figure	  39	  and	  shows	  
masses	   of	   817.3	   ([M+4]4+)	   and	   1089.1	   ([M+3]3+)	   that	   could	   correspond	   to	   a	  molecule	  
with	  a	  molecular	  weight	  of	  3265	  Da.	  A	  possible	  explanation	  for	  this	  is	  that	  the	  side	  chain	  
of	  the	  C-­‐terminal	  Asp-­‐residue	  reacted	  with	  the	  hydrazide	  group	  and	  formed	  a	  cyclization	  
product	  (figure	  40)	  which	  is	  unable	  to	  take	  part	  in	  the	  ligation	  process	  [49].	  
	  
	  
Figure	  39:	  ESI-­‐MS	  of	  the	  fraction	  that	  presumably	  contains	  the	  cyclization	  product	  of	  Acan1	  N-­‐terminus	  





Figure	   40:	   Aspartic	   acid	   reacts	   with	   the	   hydrazide	   group	   and	   forms	   an	   intra-­‐molecular	   cyclization	  
product	  
	  
2.5.2.4	  Synthesis	  of	  Acan1	  N-­‐terminus	  with	  a	  Dbz-­‐group	  
For	   this	   synthesis,	   Dbz	  was	  manually	   loaded	   onto	   the	   Rink	   Amide	  MBHA	   resin	   using	  
Fmoc-­‐Dbz.	  The	  loaded	  resin	  was	  transferred	  to	  an	  automated	  synthesiser,	  which	  carried	  
out	   the	  chain	  elongation	  of	   the	  peptide.	  A	   test	  cleavage	  was	  carried	  out	  right	  after	   the	  
 +Q1: 12.022 to 12.422 min from Sample 1 (20120327_acan1_hydrazid_ligation_16hours) of 20120327_acan1_hydrazid_ligation_16hours.wiff (Tu... Max. 1.7e5 cps.
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Molecular	  weight:	  3281.5	  
	  
Molecular	  weight:	  3263.5	  
Calculated	  [M+3]3+	  =	  1088.9	  
Calculated	  [M+4]4+	  =	  816.9	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synthesis	  and	  the	  ESI-­‐MS	  (figure	  A18)	  showed	  the	  presence	  of	  the	  desired	  product	  and	  
a	  by-­‐product	  having	  a	  calculated	  molecular	  weight	  of	  approximately	  116.5	  Da	  less	  than	  
the	  correct	  product	  (table	  9).	  	  
	  
Table	  9:	  Overview	  of	  the	  calculated	  and	  observed	  masses	  of	  correct	  Acan1	  N-­‐terminus	  




[M+3]3+	   [M+4]4+	  
Calculated	  for	  Acan1	  N-­‐terminus	  with	  Dbz:	   3400.8	   1134.6	   851.2	  
Observed:	  




1095.6	   822.1	  
	  
For	   the	   formation	   of	   the	   peptide-­‐Nbz,	   397	   mg	   of	   peptidyl	   resin	   was	   treated	   with	   4-­‐
nitrophenyl	   chloroformate	   and	   DIPEA.	   The	   subsequent	   cleavage,	   using	   a	   mixture	   of	  
TFA/TIPS/DODT/H2O,	  resulted	  in	  the	  peptide	  crude,	  which	  was	  analysed	  by	  ESI-­‐MS	  and	  
showed	  only	  a	  minor	  peak	  for	  the	  [M+3]3+	  of	  the	  correct	  peptide-­‐Nbz	  (figure	  A19	  and	  
table	   10).	   The	   peaks	   indicating	   masses	   of	   1104.8	   and	   828.5	   correspond	   to	   the	   by-­‐
product	  activated	  to	  a	  peptide-­‐Nbz.	  	  
	  
Table	   10:	   Calculated	   and	  observed	  masses	   of	  Acan1	  N-­‐terminus	  peptide-­‐Nbz	   and	   the	  
observed	  masses	  of	  the	  by-­‐product	  as	  a	  peptide-­‐Nbz	  
	   [M+3]3+	   [M+4]4+	  
Calculated	  for	  Acan1	  N-­‐terminus	  peptide-­‐Nbz:	   1143.2	   857.7	  
	   	   	  
Observed:	  
Acan1	  N-­‐terminus	  peptide-­‐Nbz	   1143.8	   –	  
By-­‐product	  peptide	  Nbz	   1104.8	   828.5	  
	  
65	   mg	   of	   peptide	   crude	   was	   then	   purified	   by	   RP-­‐HPLC	   using	   a	   preparative	   column	  
(figure	  41).	  The	  fractions	  were	  analysed	  by	  ESI-­‐MS	  and	  several	  fractions	  contained	  the	  
peptide-­‐Nbz	   of	   the	   by-­‐product	   (figure	   A20),	   which	   eluted	   after	   approximately	   33	  
minutes,	   but	   only	   one	   fraction	   contained	   the	   correct	   Acan1	   N-­‐terminus	   peptide-­‐Nbz,	  
which	  eluted	  after	  43.5	  minutes	  (figure	  A21).	  Analytical	  RP-­‐HPLC	  chromatograms	  of	  the	  
	   42	  
most	   pure	   by-­‐product	   peptide-­‐Nbz	   and	   fraction	   containing	   the	   correct	   Acan1	   N-­‐
terminus	  peptide-­‐Nbz	  are	  shown	  in	  figures	  42	  and	  43,	  respectively.	  
	  
	  




Figure	  42:	  Analytical	  RP-­‐HPLC	  chromatogram	  of	  purified	  by-­‐product	  peptide-­‐Nbz	  
	  
	  
Figure	   43:	   Analytical	   RP-­‐HPLC	   chromatogram	  of	   the	   fraction	   containing	   the	   correct	   Acan1	  N-­‐terminus	  
peptide-­‐Nbz	  
	  
Another	   batch	   of	   peptidyl	   resin	   (407	   mg)	   was	   activated	   using	   4-­‐nitrophenyl	  
chloroformate	   and	   DIPEA.	   After	   the	   cleavage	   with	   TFA/TIPS/DODT/H2O,	   ESI-­‐MS	  was	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 10.567 
 14.258  14.358  14.650 
 18.073  18.675  19.085 
 21.394  21.936  22.265 
 23.874  24.592  24.816  25.044  25.235  2 . 81 
 27.058  28.059 
 28.586  46.162 
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used	   to	   analyse	   the	   peptide	   crude,	   and	   this	   time	   no	   ions	   of	   the	   Acan1	   N-­‐terminus	  
peptide-­‐Nbz	   could	   be	   detected.	   The	   [M+3]3+	   (1104.5)	   and	   [M+4]4+	   (828.6)	   of	   the	   by-­‐
product	  peptide-­‐Nbz	  can	  be	  seen	  on	  the	  spectrum	  (figure	  A22).	  60	  mg	  of	  peptide	  crude	  
was	   then	   purified	   by	   RP-­‐HPLC	   and	   ESI-­‐mass	   spectra	   of	   the	   fractions	   were	   recorded	  
(figure	   A23).	   The	   by-­‐product	   peptide-­‐Nbz	   eluted	   after	   approximately	   31.5	   minutes	  
(figure	  44).	  To	  determine	  the	  purity	  of	  the	  fraction	  an	  analytical	  RP-­‐HPLC	  was	  carried	  
out,	  which	  is	  shown	  in	  figure	  45.	  	  
	  
	  




Figure	  45:	  Analytical	  RP-­‐HPLC	  chromatogram	  of	  purified	  by-­‐product	  peptide-­‐Nb	  
	  
2.5.2.5	  Native	  chemical	  ligation	  of	  of	  Acan1*	  
It	   was	   decided	   to	   use	   the	   by-­‐product	   peptide-­‐Nbz	   obtained	   during	   the	   synthesis	   of	  
Acan1	  N-­‐terminus,	  from	  now	  on	  called	  Acan1*	  N-­‐terminus,	  for	  a	  ligation	  with	  Acan1	  C-­‐
terminus.	   The	   starting	   material,	   11.37	   mg	   Acan1*	   N-­‐terminus	   and	   9.40	   mg	   Acan1	   C-­‐
terminus,	   was	   dissolved	   in	   pH-­‐adjusted	   ligation	   buffer.	   After	   24	   hours,	   the	   ligation	  
mixture	  was	  purified	  by	  RP-­‐HPLC,	  where	  Acan1*	  eluted	  after	  approximately	  49	  minutes	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30 Detector A Channel 2 280nm
 10.606 
 14.410  14.600 
 18.099  18.724  19.081  19.622  20. 03  20.969 
 23.341  23.871  24.323  24.828  25.035  25.228 
 25.946  26.230  26.511  26.971  27.552  28.075 
 46.123 
<Peak Table>
Detector A Channel 1 215nm
<Sample Information>
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Figure	  46:	  RP-­‐HPLC	  chromatogram	  of	  the	  purification	  of	  the	  Acan1*	  ligation	  mixture	  
	  
Three	  fractions	  containing	  Acan1*	  could	  be	  obtained	  and	  mass	  spectra	  of	  the	  fractions	  
are	  shown	  in	  figures	  A24	  –	  A26.	  The	  observed	  masses	  are	  summarized	  in	  table	  11.	  
	  
Table	   11:	   Overview	   of	   the	   masses	   observed	   on	   the	   ESI-­‐MS	   of	   the	   three	   fractions	  
containing	  Acan1*	  
	   [M+4]4+	   [M+5]5+	  
Observed:	  
Fraction	  37	   1438.0	   1150.6	  
Fraction	  38	   1438.0	   1150.5	  
Fraction	  39	   1437.8	   1150.8	  
	  
Because	  the	  ESI-­‐MS	  of	   the	   fractions	  also	  showed	  other	  major	  peaks,	   they	  were	   further	  
analysed	  by	  RP-­‐HPLC	  (figure	  47)	  and	  the	  chromatograms	  showed	  a	  peak	  at	  a	  retention	  
time	   of	   approximately	   29	  minutes,	   which	   is	   probably	   caused	   by	  MPAA.	   Acan1*	   has	   a	  
retention	  time	  of	  37.4	  minutes	  and	  its	  peak	  can	  be	  seen	  in	  all	  three	  chromatograms.	  But,	  
none	   of	   its	   peaks	   are	   perfect.	   In	   the	   chromatogram	   of	   fraction	   37	   the	   peak	   forms	   a	  
shoulder,	  whereas	  it	  is	  possible	  to	  see	  the	  top	  of	  a	  second	  peak	  immediately	  to	  the	  right	  
of	   the	  Acan1*	  peak	   in	   the	  chromatogram	  of	   fraction	  38.	  The	  chromatogram	  of	   fraction	  
39	   shows	   only	   a	   minor	   peak	   at	   a	   retention	   time	   of	   37.4	   minutes	   and	   a	   major	   peak	  
around	   37.9	  minutes,	  meaning	   that	   this	   fraction	   is	   highly	   impure	   and	   only	   contains	   a	  
little	  amount	  of	  Acan1*.	  The	  best	  candidates	  for	  an	  oxidation	  were	  therefore	  fractions	  37	  
and	  38,	  although	  they	  were	  not	  pure	  as	  well.	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 22.246  22.973 
 23.353 
 24.336  25.936  26.146  26.866  27.189  27.514  27.991  28.529  29.234  29.537  30.079  31.084  32.255  32.755  33.249  33.688  34.263 
 36.722  37.844  38. 99 
 40.703  41.264  42.014  42.750  43.353 




 50.707  51.621  52.074  52.768  53.389  53. 20  54.399  54. 17  55.436  55.787  56.585  57. 00  57.930  58.950  59.451  59.985  60.823  61.440  62.292  63.440  64.347  65.038  66.208  66. 33 
 9.383 
 71.57672 116 73.1 6 73 13 4. 34  4.767  7 . 49  76.075  76.6 7  77.164  77.821  78.408  80.032  80.688  81.375  82.078  82.748  83.136  83.935  84.125 
 86.633  86.758  87.045 
 9.633  90.483  90.569  91.358  92.394  93.3 4 
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E: Right Shimadzu 20120411_acan1_ligation_39.lcd 
Analysis Report
Sample Name : Acan1_ligation
Sample ID : 39
Data Filename : 20120411_acan1_ligation_39.lcd
Method Filename : 1pc1mL.lcm
Batch Filename : 20120411_acan1_ligation.lcb
Vial # : 1-53 Sample Type : Unknown
Injection Volume : 75 uL
Date Acquired : 12/04/2012 2:01:30 AM Acquired by : System Administrator
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2.5.2.6	  Folding	  of	  Acan1*	  
The	   analytical	   RP-­‐HPLC	   chromatograms	   of	   the	   trial	   oxidation	   under	   eight	   different	  









Figure	  48:	  Analytical	  RP-­‐HPLC	  chromatograms	  of	  the	  Name2	  trial	  oxidation	  under	  different	  conditions	  
	  
Comparison	  of	   the	  chromatograms	  shows	  that	   treatment	  with	  condition	  2	   leads	  to	   the	  
highest	  peak	  at	  a	  retention	  time	  of	  33.9	  minutes.	  Three	  chromatograms	  show	  a	  peak	  for	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E: Right Shimadzu 20120418_acan1_oxidation_1.lcd 
Analysis Report
Sample Name : Acan1_oxidation
Sample ID : 1
Data Filename : 20120418_acan1_oxidation_1.lcd
Method Filename : 1pc1mL.lcm
Batch Filename : 20120418_acan1_oxidation.lcb
Vial # : 1-83 Sample Type : Unknown
Injection Volume : 40 uL
Date Acquired : 18/04/2012 5:32:51 PM Acquired by : System Administrator
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E: Right Shimadzu 20120418_acan1_oxidation_2.lcd 
Analysis Report
Sample Name : Acan1_oxidation
Sample ID : 2
Data Filename : 20120418_acan1_oxidation_2.lcd
Method Filename : 1pc1mL.lcm
Batch Filename : 20120418_acan1_oxidation.lcb
Vial # : 1-84 Sample Type : Unknown
Injection Volume : 40 uL
Date Acquired : 18/04/2012 7:10:20 PM Acquired by : System Administrator
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E: Right Shimadzu 20120418_acan1_oxidation_3.lcd 
Analysis Report
Sample Name : Acan1_oxidation
Sample ID : 3
Data Filename : 20120418_acan1_oxidation_3.lcd
Method Filename : 1pc1mL.lcm
Batch Filename : 20120418_acan1_oxidation.lcb
Vial # : 1-85 Sample Type : Unknown
Injection Volume : 40 uL
Date Acquired : 18/04/2012 8:47:49 PM Acquired by : System Administrator










































































Detector A Channel 1 215nm
<Sample Information>
28/04/2012 7:53:09 PM  Page 1 / 5 
E: Right Shimadzu 20120418_acan1_oxidation_4.lcd 
Analysis Report
Sample Name : Acan1_oxidation
Sample ID : 4
Data Filename : 20120418_acan1_oxidation_4.lcd
Method Filename : 1pc1mL.lcm
Batch Filename : 20120418_acan1_oxidation.lcb
Vial # : 1-86 Sample Type : Unknown
Injection Volume : 40 uL
Date Acquired : 18/04/2012 10:25:16 PM Acquired by : System Administrator
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E: Right Shimadzu 20120418_acan1_oxidation_5.lcd 
Analysis Report
Sample Name : Acan1_oxidation
Sample ID : 5
Data Filename : 20120418_acan1_oxidation_5.lcd
Method Filename : 1pc1mL.lcm
Batch Filename : 20120418_acan1_oxidation.lcb
Vial # : 1-87 Sample Type : Unknown
Injection Volume : 40 uL
Date Acquired : 19/04/2012 12:02:44 AM Acquired by : System Administrator
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E: Right Shimadzu 20120418_acan1_oxidation_6.lcd 
Analysis Report
Sample Name : Acan1_oxidation
Sample ID : 6
Data Filename : 20120418_acan1_oxidation_6.lcd
Method Filename : 1pc1mL.lcm
Batch Filename : 0120418_acan1_oxidation.lcb
Vial # : 1-88 Sample Type : Unknown
Injection Volume : 40 uL
Date Acquired : 19/04/2012 1:40:14 AM Acquired by : System Administrator
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E: Right Shimadzu 20120418_acan1_oxidation_7.lcd 
Analysis Report
Sample Name : Acan1_oxidation
Sample ID : 7
Data Filename : 20120418_acan1_oxidation_7.lcd
Method Filen me : 1pc1 L.lcm
Batch Filename : 20120418_acan1_oxidation.lcb
Vial # : 1-89 Sample Type : Unknown
Injection Volume : 40 uL
Date Acquired : 19/04/2012 3:17:42 AM Acquired by : System Administrator
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E: Right Shimadzu 20120418_acan1_oxidation_8.lcd 
Analysis Report
Sample Name : Acan1_oxidation
Sample ID : 8
Data Filename : 20120418_acan1_oxidation_8.lcd
M th d Filen m : 1pc1 L.lcm
Batch Filename : 20120418_acan1_oxidation.lcb
Vial # : 1-90 Sample Type : Unknown
Injection Volume : 40 uL
Date Acquired : 19/04/2012 4:55:11 AM Acquired by : System Administrator











50 Detector A Channel 1 215nm
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0 Detector A Channel 2 280nm
<Peak Table>
Detector A Channel 1 215nm
<Sample Information>
8.	  0.1	  M	  NH4HCO3/propan-­‐2-­‐ol,	  2	  mM	  GSH,	  0.2	  mM	  GSSG	  7.	  PBS/propan-­‐2-­‐ol,	  2	  mM	  GSH,	  0.2	  mM	  GSSG	  
6.	  0.1	  M	  NH4HCO3,	  2	  mM	  GSH,	  0.2	  mM	  GSSG	  
1.	  PBS	  	   2.	  0.1	  M	  NH4HCO3	  
3.	  PBS/propan-­‐2-­‐ol	   4.	  0.1	  M	  NH4HCO3/propan-­‐2-­‐ol	  
5.	  PBS,	  2	  mM	  GSH,	  0.2	  mM	  GSSG	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MPAA	   around	   28.8	   minutes,	   which	   is	   the	   same	   retention	   time	   as	   can	   be	   seen	   in	   the	  
chromatograms	   of	   the	   fractions	  with	   reduced	  Acan1*,	  whereas	   the	   peaks	   presumably	  
belonging	   to	   oxidised	   Acan1*	   all	   have	   a	   shorter	   retention	   time	   compared	   to	   reduced	  
Acan1*.	   Condition	  8	   resulted	   in	   no	   visible	   peak.	   2.00	  mg	  of	   reduced	  Acan1*	  was	   then	  
oxidised	   in	   0.1	   M	   ammonium	   bicarbonate	   (NH4HCO3)	   and	   the	   oxidation	  mixture	   was	  
purified	  by	  RP-­‐HPLC	  (figure	  49).	  	  
	  
	  
Figure	  49:	  RP-­‐HPLC	  chromatogram	  of	  the	  Acan1*	  oxidation	  mixture	  
	  
ESI-­‐MS	  was	  used	  to	  analyse	  the	  eluate	  and	  most	  of	  the	  fractions	  collected	  from	  34	  to	  40	  
minutes	  contained	  oxidised	  Acan1*.	  The	  ESI-­‐MS	  of	  the	  three	  fractions	  that	  generated	  the	  
highest	   intensity	  on	  the	  mass	  spectrometer	  are	  shown	  in	  figures	  A27	  –	  A29,	  whereas	  
the	  observed	  masses	  of	  oxidised	  Acan1*	  are	  summarized	  in	  table	  12.	  
	  
Table	   12:	   Overview	   of	   the	   masses	   observed	   on	   the	   ESI-­‐MS	   of	   the	   three	   fractions	  
containing	  oxidised	  Acan1*	  
	   [M+4]4+	   [M+5]5+	  
Observed:	  
Fraction	  9	   1436.7	   1149.5	  
Fraction	  10	   1436.3	   1149.4	  
Fraction	  11	   1436.4	   1149.5	  
	  
1.84	  mg	  of	  oxidised	  Acan1*	  was	  obtained	  and	  the	  chromatograms	  of	  the	  analytical	  RP-­‐
HPLC	   performed	   to	   check	   the	   purity	   of	   the	   fractions	   containing	   oxidised	   Acan1*	   are	  
shown	  in	  figure	  50.	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E: Right Shimadzu 20120420_acan1_oxidation.lcd 
Analysis Report
Sample Name : 20120420_acan1_oxidation
Sample ID : 20120420_acan1_oxidation
Data Filename : 20120420_acan1_oxidation.lcd
Method Filename : 1pc3mL.lcm
Batch Filename : 
Vial # : -1 Sample Type : Unknown
Injection Volume : 1 uL
Date Acquired : 20/04/2012 3:33:44 PM Acquired by : System Administrator
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28/04/2012 8:29:52 PM  Page 1 / 3 
E: Right Shimadzu 20120420_acan1_oxidation.lcd 
Analysis Report
Sample Name : 20120420_acan1_oxidation
Sample ID : 20120420_acan1_oxidation
Data Filename : 20120420_acan1_oxidation.lcd
Method Filename : 1pc3mL.lcm
Batch Filename : 
Vial # : -1 Sample Type : Unknown
Injection Volume : 1 uL
Date Acquired : 20/04/2012 3:33:44 PM Acquired by : System Administrator
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Figure	  50:	  Analytical	  RP-­‐HPLC	  chromatograms	  of	  the	  fractions	  that	  contained	  oxidised	  Acan1*	  
	  
2.5.2.7	  NMR	  of	  Acan1*	  
A	  1D	  1H	  NMR	  spectrum	  of	  Acan1*	  (figure	  51)	  was	  recorded	  and	  the	  peaks	  in	  the	  amide	  
bond	   region	   (7.8	   –	   8.5	   ppm)	   are	   not	  well	   dispersed,	  which	   indicates	   that	   the	   peptide	  
does	  not	  possess	  a	  well	  defined	  three	  dimensional	  structure.	  
	  
	  
Figure	  51:	  1D	  1H	  NMR	  spectrum	  of	  Acan1*	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E: left shimadzu 20120420_acan1_oxidation_9.lcd 
Analysis Report
Sample Name : Acan1_oxidation
Sample ID : 9
Data Filename : 20120420_acan1_oxidation_9.lcd
Method Filename : 1pc1mL.lcm
Batch Filename : 20120420_acan1_oxidation.lcb
Vial # : 1-10 Sample Type : Unknown
Injection Volume : 75 uL
Date Acquired : 21/04/2012 8:29:25 AM Acquired by : System Administrator
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E: Right Shimadzu 20120420_acan1_oxidation_10.lcd 
Analysis Report
Sample Name : Acan1_oxidation
Sample ID : 10
Data Filename : 20120420_acan1_oxidation_10.lcd
Method Filename : 1pc1mL.lcm
Batch Filename : 20120420_R3 B1-22R MttPhiPr2_LB2 + Acan1_ox_fr10.lcb
Vial # : 1-12 Sample Type : Unknown
Injection Volume : 75 uL
Date Acquired : 21/04/2012 8:37:12 AM Acquired by : System Administrator
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E: left shimadzu 20120420_acan1_oxidation_11.lcd 
Analysis Report
Sample Name : Acan1_oxidation
Sample ID : 11
Data Filename : 20120420_acan1_oxidation_11.lcd
Method Filename : 1pc1mL.lcm
Batch Filename : 20120420_acan1_oxidation.lcb
Vial # : 1-11 Sample Type : Unknown
Injection Volume : 75 uL
Date Acquired : 21/04/2012 10:06:56 AM Acquired by : System Administrator
Date Processed : 21/04/2012 11:43:58 AM Processed by : System Administrator
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2.5.2.8	  Ligation	  of	  Acan1	  
The	  one	  fraction	  that	  contained	  the	  correct	  Acan1	  N-­‐terminus	  peptide-­‐Nbz	  was	  used	  to	  
try	  a	  ligation	  with	  Acan1	  C-­‐terminus	  to	  yield	  Acan1.	  After	  24	  hours,	  the	  ligation	  mixture	  
was	  purified	  by	  RP-­‐HPLC	  and	  the	  eluate	  was	  analysed	  by	  ESI-­‐MS,	  but	  no	  correct	  ligation	  
product	  could	  be	  detected.	  
	  
3.	  Discussion	  
3.1	  Bioactivity	  testing	  of	  fractionated	  LMW	  AcES	  
Autoimmune	   diseases	   are	   a	   major	   health	   burden	   and	   associated	   with	   an	   increasing	  
number	   of	   cases	   in	   the	   developed	  world	   [50].	   Therefore	   it	   is	   pivotal	   to	   have	   effective	  
therapy	  options	  available,	  and	  for	  the	  inflammatory	  bowel	  diseases	  like	  ulcerative	  colitis	  
and	  Crohn’s	  disease	  a	  long	  list	  of	  selectable	  drugs	  exists,	  ranging	  from	  aminosalicylates	  
over	   corticosteroids	   and	   immunosuppressants,	   to	   the	   novel	   biological	   TNF-­‐α	   blockers	  
[50].	  But	  however	  effective	  these	  drugs	  are,	  they	  do	  not	  come	  without	  serious	  adverse	  
effects	   like	   metabolic	   disturbances	   or	   a	   susceptibility	   to	   infections	   [50].	   When	   the	  
diseases	  progresses	  in	  spite	  of	  drug	  treatment	  or	  when	  patients	  are	  not	  able	  to	  take	  the	  
drugs	  because	  the	  adverse	  effects	  are	  too	  severe,	  even	  invasive	  actions	  like	  surgery	  have	  
to	   be	   considered	   [51,	   52].	   Therefore,	   new	   options	   for	   the	   treatment	   of	   autoimmune	  
diseases	  are	  needed	  and	  they	  have	  to	  be	  effective,	  payable,	  convenient	  and	  safe.	  	  
	  
The	   ability	   to	   infect	   a	   great	   number	   of	   individuals	   and	   to	   survive	   inside	   the	   host	   for	  
several	  years	  has	  drawn	  the	  attention	  of	  researchers	  towards	  hookworms	  [18,	  26].	  The	  
ES	   products	   of	   the	   hookworms	   are	   suspected	   to	   contribute	   an	   important	   part	   to	   the	  
modulation	   of	   the	   host	   immune	   system	   and	   one	   aim	   of	   this	   project	   was	   therefore	   to	  
fractionate	  crude	  LMW	  AcES	  and	   investigate	  the	  potential	  of	   the	   fractions	  to	  affect	   the	  
course	   of	   experimental	   colitis	   in	  mice,	   which	   has	   similarities	   with	   Crohn’s	   disease	   in	  
humans	  [35].	  	  
	  
Unfractionated	   LMW	   AcES	   is	   able	   to	   reduce	   the	   inflammatory	   cytokine	   IFN-­‐γ	   and	  
increase	   the	   level	   of	   IL-­‐4,	   which	   shifts	   the	   immune	   response	   to	   the	   TH2	   branch	  
(unpublished	  data).	  The	  first	  LMW	  AcES	  batch	  was	  fractionated	  and	  then	  tested	   in	  the	  
	   50	  
TNBS	  mouse	  model.	  Normally,	  the	  animals	  rapidly	  lose	  weight,	  but	  start	  to	  recover	  after	  
2	   or	   3	   days.	   If	   the	   samples	   tested	  have	   any	  protective	   effect	   against	   the	   experimental	  
colitis,	   the	  weight	   of	   those	   animals	   should	   be	   higher	   than	   the	  weight	   of	   the	   negative	  
controls.	  When	  the	   first	  batch	  was	   tested,	   it	   looked	   like	   fraction	  E	  was	  able	   to	  achieve	  
this,	   but	   this	   result	   was	   not	   significant.	   The	   colons	   of	   the	   healthy	   controls	   are	  
significantly	  longer	  than	  the	  colons	  of	  all	  the	  other	  groups,	  except	  the	  fraction	  C	  group.	  
In	  contrast,	   there	  was	  not	   found	  any	  statistical	  difference	  between	  the	   treated	  groups,	  
including	   fraction	   C.	   Colon	   health	   was	   also	   assessed	   and	   the	   animals	   treated	   with	  
unfractionated	   LMW	   AcES,	   fractions	   C	   and	   E	   had	   lower	   macroscopic	   scores	   than	   the	  
negative	   control	   group.	   A	   probable	   bias	   for	   this	   parallel	   is	   the	   fact	   that	   three	   groups	  
consisted	  of	  male	  animals	   (positive	  and	  negative	  controls,	   fration	  E),	  whereas	   the	  rest	  
consisted	  of	   females.	  A	   second	  batch	  of	  LMW	  AcES	  was	   fractionated	  and	   tested	   in	   the	  
TNBS	  model.	  Again,	   the	  weight	  monitoring	  did	  not	   show	   significant	   improvements	   on	  
animals	   treated	   with	   hookworm	   fractions,	   but	   the	   trend	   was	   that	   fractions	   C	   and	   E	  
caused	  the	  mice	  to	  gain	  more	  weight	  than	  the	  negative	  control	  group.	  The	  mice	  treated	  
with	  fraction	  C	  had	  longer	  colons	  than	  all	  the	  other	  colitis	  groups	  and	  also	  significantly	  
healthier	  colons	  than	  the	  negative	  control.	  	  
	  
The	  results	  of	   these	  two	  test	  runs	  are	  not	  very	  meaningful,	   the	  weight	  monitoring,	   the	  
most	  important	  parameter,	  did	  not	  give	  significant	  results.	  But	  a	  trend	  can	  be	  seen:	  mice	  
treated	   with	   fraction	   E	   from	   both	   batches	   seemed	   to	   weigh	   more	   than	   the	   negative	  
control	  group.	  And	  when	  the	  second	  batch	  was	   tested,	   fraction	  C	  gave	   the	  best	  results	  
with	   longer	  and	  healthier	  colons	   (compared	   to	   the	  negative	  control).	  LC/MS	  and	  NMR	  
spectroscopy	  were	  also	  used	  to	  examine	  fraction	  C	  and	  it	  appears	  that	  it	  might	  contain	  
peptides	  with	  molecular	  weights	  above	  3000	  Da.	  Fraction	  E	  was	  also	  analysed	  by	  LC/MS	  
and	  contained	  masses	  of	  higher	  molecular	  weight.	  	  
	  
For	  the	  future,	  the	  activity	  testing	  should	  be	  scaled	  up	  with	  more	  animals	  in	  each	  group	  
to	  see	  if	  any	  of	  the	  fractions	  significantly	  can	  protect	  against	  weight	  loss.	  Injecting	  larger	  
amounts	   to	   see	   if	   the	   effect	   increases,	   can	   also	   be	   tried.	   The	   results	   of	   this	   project	  
suggest	  that	  the	  activity	  may	  reside	  in	  fractions	  C	  and	  E.	  These	  fractions	  should	  also	  be	  
further	  investigated	  to	  characterise	  what	  kind	  of	  molecules	  that	  might	  be	  responsible	  for	  
the	  protective	  effects.	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3.2	  Synthesis	  of	  Name2	  
Name2	   was	   identified	   from	   the	   transcriptome	   of	   the	   hookworm	   N.	   americanus	   and	  
possesses	  the	  cysteine	  framework	  of	  ShK.	  Name2	  has	  41	  residues	  in	  its	  sequence,	  thus	  it	  
is	   six	  amino	  acids	   longer	   than	  Shk,	   and	   therefore	   it	  was	   interesting	   to	   see	   if	   the	   three	  
dimensional	  structure	  of	  Name2	  resembled	  the	  structure	  of	  ShK.	  Because	  Name2	  has	  a	  
considerable	  length,	  its	  sequence	  was	  divided	  into	  two	  halves	  and	  ligated	  via	  NCL.	  The	  
synthesis	   of	   both	   fragments	  was	   challenging	   and	   even	   after	   purifying	   both	   fragments,	  
they	  contained	  by-­‐products.	  This	  might	  also	  be	   the	   reason	   for	  why	  no	  correct	   ligation	  
product	   could	   be	   obtained	   after	   the	   first	   ligation	   reaction.	   Due	   to	   the	   impurities,	   the	  
amounts	   of	   product	   formed	   were	   not	   large	   enough	   to	   be	   isolated	   by	   RP-­‐HPLC	   and	  
confirmed	  by	  ESI-­‐MS.	  That	   the	   ligation	  method	  did	  work	  was	  confirmed	  by	  the	  LC/MS	  
run.	  The	  second	  ligation	  attempt	  was	  successful	  and	  4.55	  mg	  of	  ligated	  product	  could	  be	  
obtained,	  but	  over	  24	  mg	  of	  starting	  material	  had	  to	  be	  used	  as	  input.	  After	  assembly	  of	  
the	   peptide	   chain,	   formation	   of	   the	   disulfide	   bonds	   was	   required.	   Name2	   has	   six	  
cysteines	  and	  therefore	  there	  are	  15	  different	  isormers	  that	  can	  theoretically	  be	  formed.	  
Eight	  oxidation	  conditions	  were	  trialed	  for	  the	  oxidative	  folding	  of	  Name2.	  The	  condition	  
that	   resulted	   in	   one	  major	   oxidised	   product,	   based	   on	  RP-­‐HPLC	   and	  MS	   analysis,	  was	  
then	  used	   for	   the	   large-­‐scale	  oxidation	  of	  Name2.	   Subsequent	  purification	  and	  ESI-­‐MS	  
analysis,	   revealed	   a	   major	   peptide	   product	   with	   a	   mass	   corresponding	   to	   oxidised	  
Name2.	  This	  peptide	  was	   analysed	  by	  RP-­‐HPLC	  and	  was	   found	   to	  be	  pure	   enough	   for	  
NMR	  analysis.	  The	  NMR	  spectroscopy	  revealed	  that	   the	   fold	  of	  Name2	  resembled	  ShK,	  
both	  having	   two	  helical	   structures.	  However,	   the	  number	   of	   residues	   between	  CysII	   –	  
CysIII	  and	  CysIII	  –	  CysIV	  differs	  and	  therefore,	  the	  length	  and	  positioning	  of	  the	  helices	  is	  
different	  in	  the	  two	  peptides.	  
	  
It	  should	  be	   investigated	   if	  Name2	  has	  any	  bioactivity,	   for	  example	  the	  ability	   to	  block	  
potassium	  channels	  like	  ShK.	  And	  if	  it	  does,	  the	  important	  residues	  for	  the	  binding	  to	  its	  
target	  should	  be	  elaborated	  by	  doing	  alanine	  scans,	  where	  the	  residues	  in	  the	  sequence	  
are	  replaced	  by	  alanine	  one	  by	  one.	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3.3	  Synthesis	  of	  Acan1	  	  
Acan1	  was	  another	  sequence	  that	  has	  the	  ShK	  cysteine	  framework	  and	  was	  found	  in	  the	  
transcriptome	   of	   the	   hookworm	  A.	   caninum.	   As	   a	   part	   of	   this	   project	   the	   synthesis	   of	  
Acan1	   was	   tried	   using	   Fmoc-­‐SPPS,	   which	   posed	   several	   difficulties.	   The	   peptide	   was	  
divided	  into	  two	  halves	  because	  it	  has	  a	  length	  of	  51	  residues,	  which	  means	  it	  is	  longer	  
than	  Name2.	  In	  order	  to	  ligate	  the	  halves,	  two	  different	  NCL	  strategies	  were	  tried.	  First,	  
NCL	  via	  the	   formation	  of	  peptide	  hydrazide	  was	  attempted,	  and	  when	  this	  method	  did	  
not	  work,	  the	  same	  NCL	  strategy,	  using	  the	  Dbz	  group,	  as	  for	  the	  synthesis	  of	  Name2	  was	  
applied.	  Both	  ligation	  strategies	  function	  via	  the	  formation	  of	  peptide	  thioesters.	  
NCL	   via	   the	   formation	   of	   a	   peptide	   hydrazide	   proved	   unsuccessful	   because	   the	   C-­‐
terminal	   Asp-­‐residue	   of	   Acan1	   N-­‐terminus	   formed	   a	   cyclization	   product	   with	   the	  
hydrazide	  group	  that	  is	  unable	  to	  be	  ligated.	  Because	  the	  cyclization	  will	  happen	  when	  
the	   C-­‐terminal	   residue	   is	   Asp,	   Asn	   or	   Gln,	   this	   NCL	   strategy	   cannot	   be	   used	   for	   the	  
synthesis	  of	  Acan1	  if	  the	  peptide	  is	  not	  divided	  at	  a	  different	  place	  in	  its	  sequence	  [49].	  
Since	  a	  Cys-­‐residue	   is	   required	  at	   the	  N-­‐terminal	   residue	  of	  one	  peptide	   fragment	  and	  
Acan1	   has	   six	   Cys-­‐residues,	   there	   are	   six	   potential	   places	   where	   the	   peptide	   can	   be	  
divided.	  To	  divide	  it	  between	  Asp28	  and	  Cys29,	  which	  was	  tried	  in	  the	  synthesis,	  turned	  
out	   not	   to	   work.	   The	   same	   residue	   combination	   appears	   earlier	   in	   the	   sequence	  
(Asp19/Cys20).	   Therefore,	   the	   only	   real	   options	   with	   this	   method	   are	   His11/Cys12,	  
Tyr41/Cys42	  and	  Thr45/Cys46.	  But	   then	  will	  one	   fragment	  be	  very	  much	   longer	   than	  
the	  other	  one	  and	  one	  can	  assume	  that	   the	  synthesis	  yield	  of	   the	   longer	   fragment	  will	  
probably	   be	   quite	   low.	   Another	   possibility	   would	   be	   to	   divide	   the	   peptide	   into	   three	  
parts.	   Work	   on	   the	   rate	   of	   ligation	   reactions	   have	   shown	   that	   His	   and	   Tyr	   at	   the	   C-­‐
terminus	  favour	  fast	  reactions,	  whereas	  Thr	  is	  among	  the	  slowest	  reacting	  residues	  [53].	  
	  
Because	   the	   NCL	   using	   a	   peptide	   hydrazide	   did	   not	  work,	   the	   Acan1	  N-­‐terminus	  was	  
synthesised	  as	  a	  peptide-­‐Dbz	  on	  an	  automated	  synthesiser.	  A	  50:50	  mixture	  of	  correct	  
product	   and	   by-­‐product	   was	   obtained,	   but	   conversion	   to	   the	   peptide-­‐Nbz	   gave	   bad	  
results	   and	   only	   one	   fraction	  with	   the	   correct	   peptide-­‐Nbz	   could	   be	   obtained.	   On	   the	  
other	   hand,	   quite	   a	   lot	   peptide-­‐Nbz	   could	   be	   produced	   of	   the	   by-­‐product,	   which	  was	  
used	  to	  ligate	  with	  Acan1	  C-­‐terminus	  to	  yield	  Acan1*.	  It	  seemed	  that	  the	  conversion	  step	  
from	   Dbz	   to	   Nbz	  was	   the	  most	   difficult	   one	   in	   the	   synthesis.	   The	   synthesis	   of	   the	   C-­‐
terminus	  was	  also	  challenging	  in	  that	  different	  resins	  had	  to	  be	  tried,	  and	  at	  the	  end	  the	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Rink	  Amide	  MBHA	  resin	  was	  used,	  which	  resulted	  in	  an	  amide	  at	  the	  C-­‐terminal	  residue,	  
where	   the	   native	   peptide	   has	   a	   free	   carboxylic	   acid.	   But	   compared	   to	   the	   N-­‐terminal	  
part,	  this	  synthesis	  was	  considerable	  easier	  and	  resulted	  in	  a	  crude	  peptide	  product	  with	  
the	  fewest	  by-­‐products	  and	  pure	  peptide	  in	  large	  quantities.	  Oxidative	  folding	  of	  Acan1*	  
was	   attempted,	   but	   the	   1D	   1H	   NMR	   spectrum	   of	   the	  main	   product	   revealed	   that	   this	  
peptide	  had	  a	  poorly	  defined	  3D	  structure.	  
	  
Regarding	  these	  ligation	  methods,	  the	  purity	  of	  the	  fragment	  to	  be	  ligated	  is	  important.	  
Because	   it	   is	   a	   low	   yielding	   procedure,	   the	   ligation	  might	   fail	   if	   the	   starting	  material	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4.	  Conclusion	  
In	  this	  project,	   low	  molecular	  weight	  excretory/secretory	  products	  (LMW	  AcES)	  of	  the	  
dog	  hookworm	  A.	  caninum	  was	   fractionated	  by	  RP-­‐HPLC	  and	   tested	   for	  activity	   in	   the	  
TNBS	   colitis	   model.	   The	   bioactivity	   tests	   were	   inconclusive,	   but	   trends	   could	   be	  
identified	   and	   it	   seems	   that	   the	   activity	   resides	   in	   two	   of	   the	   fractions.	   These	   two	  
fractions	   have	   been	   further	   investigated	   by	   LC/MS	   to	   characterise	   their	   content	   and	  
compounds	  of	  molecular	  weights	  above	  3000	  Da	  have	  been	  found	  in	  both	  of	  them,	  but	  
this	  needs	   further	  elaboration.	  The	   fractions	   should	  also	  be	   retested	   in	   larger	   trials	   to	  
see	   if	   significance	   in	   the	   weight	   monitoring	   can	   be	   achieved.	   The	   weight	   monitoring	  
gives,	   in	  my	  opinion,	   the	  most	  objective	   impression	  of	  potential	  protection	  against	   the	  
detrimental	  colitis.	  	  
	  
In	  the	  second	  part	  of	  this	  project,	  the	  synthesis	  of	  two	  peptides,	  Name2	  and	  Acan1,	  that	  
have	  the	  characteristic	  cysteine	  framework	  of	  the	  ShK	  toxin	  was	  tried.	  Because	  of	  its	  size	  
(41	  residues)	  the	  synthesis	  of	  Name2	  was	  accomplished	  by	  dividing	  the	  peptide	  into	  two	  
fragments	  that	  were	  synthesised	  separately	  using	  Fmoc-­‐SPPS	  and	  then	  ligated	  together	  
by	   native	   chemical	   ligation	   (NCL).	   The	   successful	   folding	   of	  Name2	  was	   confirmed	  by	  
NMR	   spectroscopy,	   which	   was	   also	   used	   to	   determine	   the	   structure	   of	   the	   peptide.	  
Name2	  has	   two	  helical	   structures	  between	  Pro8	  –	  Lys17	  and	  Ser27	  –	  Leu32.	  ShK	  also	  
has	  two	  helices,	  but	  they	  are	  shorter	  with	  only	  two	  residues	  between	  the	  helices.	  
	  
The	  synthesis	  of	  Acan1	  was	  more	  challenging	  and	  unfortunately	  unsuccessful.	  NCL	  via	  
the	  formation	  of	  a	  peptide	  hydrazide	  is	  not	  applicable	  for	  this	  peptide	  and	  NCL	  with	  a	  C-­‐
terminal	   acylurea	   moiety	   involves	   a	   conversion	   step	   that	   did	   not	   result	   in	   the	  
intermediate	  of	  the	  N-­‐terminus	  fragment	  needed	  for	  the	  ligation.	  A	  substantial	  amount	  
of	   a	   converted	   by-­‐product	   could	   be	   obtained,	   which	   was	   successfully	   ligated	   to	   the	  
correct	   C-­‐terminus	   fragment	   of	   Acan1	   but	   NMR	   spectroscopy	   after	   oxidative	   folding	  
revealed	  that	  it	  did	  not	  possess	  a	  well	  defined	  three	  dimensional	  structure.	  
	  
This	   project	   is	   part	   of	   the	   exciting	   research	   that	   happens	   on	   the	   immunomodulatory	  
effects	  of	  hookworms.	  Hopefully,	  the	  LMW	  AcES	  and	  ShK-­‐like	  peptides	  can	  in	  the	  future	  
contribute	  to	  the	  treatment	  of	  autoimmune	  diseases.	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5.	  Materials	  and	  Methods	  
5.1	  Fractionation	  of	   low	  molecular	  weight	  components	  of	  A.	  caninum	  ES	  products	  
(LMW	  AcES)	  
5.1.1	  Origin	  of	  LMW	  AcES	  material	  analysed	  in	  this	  project	  
Stray	  dogs	  were	  euthanized	  at	  The	  University	  of	  Queensland	  Veterinary	  School	  and	  A.	  
caninum	  was	  obtained	  from	  their	  small	  intestines.	  The	  worms	  were	  washed	  in	  PBS	  and	  
cultured	   for	   3	   hours	   at	   37	   °C	   with	   5	   %	   CO2	   in	   RPMI	   1640	   medium,	   100	   units/ml	  
penicillin	  G	  sodium,	  100	  μg/ml	  streptomycin	  sulfate,	  and	  0.25	  μg/ml	  amphotericin	  B.	  A	  
10	  kDa	  cutoff	  membrane	  was	  used	  to	  isolate	  the	  low	  molecular	  weight	  fraction	  of	  the	  ES	  
products.	  
	  
5.1.2	  Fractionation	  of	  LMW	  AcES	  	  
After	  thawing	  the	  samples	  slowly	  at	  23	  °C,	  a	  disposable	  syringe	  and	  a	  syringe	  filter	  (pore	  
size:	  0.45	  μm)	  were	  used	  to	  filter	  the	  sample.	  The	  filtered	  sample	  was	  manually	  loaded	  
onto	  a	  C18	  protein	  and	  peptide	   column	   from	  GRACE	  VYDAC	   (250	  mm	  x	  22	  mm,	  300	  Å	  
pore	   size,	   10	  μm	  particle	   size)	  using	  a	   Shimadzu	  Prominence	  HPLC	   system:	  Shimadzu	  
Prominence	   DGU-­‐20A5	   (degasser),	   Shimadzu	   Prominence	   LC-­‐20AT	   (solvent	   delivery	  
unit),	  Shimadzu	  Prominence	  CBM-­‐20A	  (system	  controller),	  Shimadzu	  Prominence	  SPD-­‐
20A	  (UV/VIS	  detector)	  and	  Lab	  solutions	  software.	  The	  mobile	  phase	  was	  constituted	  of	  
two	  different	  buffers,	  buffer	  A	  and	  buffer	  B	  (table	  13).	  UV	  absorbance	  was	  monitored	  at	  
215	  nm	  and	  280	  nm.	  	  
	  
Table	  13:	  RP-­‐HPLC	  mobile	  phase	  buffers	  	  
	   Constituents	  
Buffer	  A	   0.05	  %	  TFA	  in	  H2O	  
Buffer	  B	   0.045	  %	  TFA	  in	  acetonitrile/H2O	  (90:10	  v/v)	  
	  
For	   the	   sample	   elution	   a	   gradient	   program	   that	   consisted	   of	   a	   2	  %	   linear	   gradient	   of	  
buffer	  B	  (0	  –	  40	  minutes),	  then	  ramping	  to	  100	  %	  buffer	  B	  over	  1	  minute,	  holding	  at	  100	  
%	  buffer	  B	  for	  4	  minutes,	  ramping	  back	  to	  0	  %	  buffer	  B	  over	  1	  minute	  and	  holding	  at	  0	  
%	  buffer	  B	  for	  11	  minutes.	  The	  flow	  rate	  was	  set	  to	  8	  ml/minute.	  Samples	  were	  collected	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according	   to	   the	   scheme	  shown	   in	   table	   14.	  The	   fractions	  were	  shock	   frozen	   in	  a	  dry	  
ice/acetone	  bath	  and	  lyophilized.	  
	  
Table	  14:	  Fraction	  collection	  scheme	  	  
Time	  of	  elution	  (minutes)	   Fraction	  
0	  –	  10	   A	  
10	  –	  20	   B	  
20	  –	  30	   C	  
30	  –	  40	   D	  
40	  –	  50	   E	  
	  
The	   trifluoroacetate	   ion	   forms	   hydrogen	   bonds	   with	   peptides,	   thereby	   potentially	  
disturbing	   the	   analysis	   of	   the	   fractions,	   but	   also	   affecting	   biological	   assays	   [54].	   The	  
fractions	  B,	  C	  and	  D	  were	  therefore	  re-­‐dissolved	  in	  10	  mM	  hydrochloric	  acid	  (HCl	  (aq))	  
and	  some	  acetonitrile	   in	  order	   to	  remove	   the	   trifluoroacetate	   [54].	  The	   fractions	  were	  
then	  lyophilized.	  
	  
5.2	  Bioactivity	  testing	  of	  fractionated	  LMW	  AcES	  in	  mice	  with	  experimental	  colitis	  
5.2.1	  Endotoxin	  removal	  with	  Endo	  Trap®	  	  
Endotoxins	   are	   components	   of	   the	   outer	   cell	   membrane	   of	   Gram-­‐negative	   bacteria,	  
normally	   called	   lipopolysaccharide.	   As	   a	   result	   of	   cell	   lysis,	   these	   components	   are	  
released	  and	  can	   trigger	   the	  release	  of	   cytokines	  by	  phagocytes,	  which	  can	  potentially	  
affect	   the	   results	   of	   the	   bioassay	   [55].	   	   Because	   the	   LMW	   AcES	   was	   obtained	   from	  
hookworms	  that	  previously	  lived	  in	  the	  small	  intestines	  of	  dogs,	  it	  was	  possible	  that	  the	  
sample	  was	  contaminated	  by	  endotoxins.	  Therefore	  an	  Endo	  Trap®	  endotoxin	  removal	  
system	  was	  used	  to	  clear	  all	  samples	  before	  biological	  testing.	  Because	  this	  system	  is	  an	  
affinity	   matrix	   it	   selectively	   binds	   the	   toxins.	   Aliquots	   from	   each	   sample	   were	   taken	  
before	  (40	  μl)	  and	  after	  (50	  μl)	  endotoxin	  removal	  to	  determine	  peptide	  concentrations.	  	  
An	   endotoxin	   quantification	   using	   Limulus	   Amebocyte	   Lysate	  was	   performed	   and	   the	  
amount	  of	  endotoxin	  was	  below	  detection	  levels.	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5.2.2	  Peptide	  quantification	  with	  Micro	  BCA™	  Protein	  Assay	  Kit	  
At	  alkaline	  pH,	  peptides/proteins	  can	  reduce	  cupric	   ions	  (Cu2+)	  to	  cuprous	  ions	  (Cu1+).	  
The	  Micro	  BCA™	  Protein	  Assay	  Kit	  utilizes	  bicinchonic	  acid	  (BCA)	  to	  detect	  cuprious	  ions	  
in	  solution	  by	  chelation	  because	  two	  BCA	  molecules	  chelate	  one	  Cu1+,	  and	  the	  product	  of	  
this	   reaction	   strongly	   absorbs	   light	   at	   562	   nm.	   Absorbance	   increases	   linearly	   with	  
increasing	   peptide	   concentration	   [56].	   Peptide	   concentrations	   of	   the	   samples	   taken	  
before,	  and	  after	  endotoxin	  removal	  were	  measured	  according	  to	  the	  assay	  kit	  manual.	  
Bovine	   serum	   albumin	   was	   used	   as	   a	   standard.	   After	   incubating	   for	   2	   hours	   the	  
absorbance	  was	  measured	  with	  a	  POLARstar	  Omega	  (BMG	  LABTECH)	  microplate	  reader	  
with	  MARS	  Data	   Analysis	   Software.	   The	   analysis	   software	   also	   calculated	   the	   peptide	  
concentrations	  (table	  15).	  
	  
Table	  15:	  Peptide	  concentrations	  before	  and	  after	  endotoxin	  removal	  
Fraction:	  
Peptide	  concentration	  before	  
endotoxin	  removal	  
Peptide	  concentration	  after	  endotoxin	  
removal	  
A	   865.4	  µg/ml	   1032.6	  µg/ml	  
B	   4213.3	  µg/ml	   9070.7	  µg/ml	  
C	   4728	  µg/ml	   8040	  µg/ml	  
D	   6096	  µg/ml	   8373.3	  µg/ml	  
E	   208	  µg/ml	   234.5	  µg/ml	  
	  
Because	  the	  peptide	  concentration	  appears	  to	  be	  higher	  after	  the	  removal	  of	  endotoxin	  
than	   before,	   the	   concentration	   values	   for	   the	   aliquots	   that	   did	   not	   underwent	   the	  
removal	  procedure	  were	  used	  for	  further	  experiments.	  
	  
5.2.3	  Mouse	  experiment	  
The	   C57Bl/6	   mouse	   strain	   was	   used	   for	   the	   experiment,	   and	   the	   animals	   were	  
purchased	   from	   the	   Animal	   Resource	   Centre	   (Canning	   Vale,	   Western	   Australia,	  
Australia).	  The	  mice	  had	  access	   to	   food	  and	  water	  ad	  libitum.	  The	  experiment	   lasted	  4	  
days	   and	   was	   performed	   twice.	  Tables	   16	   and	   17	   list	   the	   animal	   characteristics	   for	  
testing	  of	  batch	  1	  and	  2,	  respectively.	  For	  batch	  1,	  three	  groups	  consisted	  of	  only	  male,	  
and	  the	  remaining	  groups	  of	  female	  animals.	  Only	  male	  animals	  were	  used	  for	  batch	  2.	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Table	  16:	  Characteristics	  of	  the	  experimental	  animals	  –	  batch	  1	  
Species	   Mouse	  
Strain	   C57Bl/6	  
Sex	  
Groups	  1,	  2	  &	  8:	  male	  
Groups	  3	  –	  7:	  female	  
Age:	   6	  weeks	  
Weight	  (g)	  
Males:	  23.96	  –	  26.88	  
Females:	  18.56	  –	  21.66	  
	  
Table	  17:	  Characteristics	  of	  the	  experimental	  animals	  –	  batch	  2	  
Species	   Mouse	  
Strain:	   C57Bl/6	  
Sex:	   Male	  
Weight	  (g)	   19.24	  –	  24.10	  
	  
5.2.4	  Experimental	  design	  
The	  mouse	  experiment	  included	  8	  groups	  with	  4	  animals	  in	  each	  group	  for	  testing	  of	  the	  
fractions	   from	   the	   first	  LMW	  AcES	  batch	   (table	   18).	   Five	  animals	  were	   in	   each	  of	   the	  
seven	  groups	  when	  the	  second	  batch	  was	  tested	  (table	  19).	  The	  mice	  in	  group	  1	  served	  
as	  positive	  controls	  and	  were	  untreated.	  The	  animals	   in	  the	  second	  group	  represented	  
the	  negative	  control,	  and	  underwent	  only	  TNBS	  administration.	  All	  animals	  in	  the	  other	  
groups	   were	   administered	   TNBS	   for	   colitis	   induction.	   In	   addition,	   they	   were	   injected	  
with	  500	  μl	  of	  unfractionated	  LMW	  AcES	  (group	  3	  –	  first	  LMW	  AcES	  batch)	  or	  20	  μg	  of	  









	   59	  
Table	  18:	  Overview	  of	  the	  groups	  for	  testing	  of	  the	  first	  batch	  of	  LMW	  AcES	  
No.	   Group	  name	   TNBS	  administration	   Amount	  of	  sample	  to	  inject	  
1	   Healthy	  control	   ✗	   ✗	  
2	   TNBS	  only	   ✓	   ✗	  
3	   LMW	  AcES	   ✓	   500	  µl	  of	  LMW	  AcES	  	  
4	   Fraction	  A	   ✓	   20	  µg	  of	  LMW	  AcES	  fraction	  A	  in	  PBS	  
5	   Fraction	  B	   ✓	   20	  µg	  of	  LMW	  AcES	  fraction	  B	  in	  PBS	  
6	   Fraction	  C	   ✓	   20	  µg	  of	  LMW	  AcES	  fraction	  C	  in	  PBS	  
7	   Fraction	  D	   ✓	   20	  µg	  of	  LMW	  AcES	  fraction	  D	  in	  PBS	  
8	   Fraction	  E	   ✓	   20	  µg	  of	  LMW	  AcES	  fraction	  E	  in	  PBS	  
	  
Table	  19:	  Overview	  of	  the	  groups	  for	  testing	  of	  the	  second	  batch	  of	  LMW	  AcES	  
No.	   Group	  name	   TNBS	  administration	   Amount	  of	  sample	  to	  inject	  
1	   Healthy	  control	   ✗	   ✗	  
2	   TNBS	  only	   ✓	   ✗	  
3	   Fraction	  A	   ✓	   20	  µg	  of	  LMW	  AcES	  fraction	  A	  in	  PBS	  
4	   Fraction	  B	   ✓	   20	  µg	  of	  LMW	  AcES	  fraction	  B	  in	  PBS	  
5	   Fraction	  C	   ✓	   20	  µg	  of	  LMW	  AcES	  fraction	  C	  in	  PBS	  
6	   Fraction	  D	   ✓	   20	  µg	  of	  LMW	  AcES	  fraction	  D	  in	  PBS	  
7	   Fraction	  E	   ✓	   20	  µg	  of	  LMW	  AcES	  fraction	  E	  in	  PBS	  
	  
5.2.5	  Material	  used	  for	  mice	  anaesthesia	  
The	  mice	  were	  fully	  anesthetized	  with	  a	  solution	  mixture	  of	  Ilium	  Ketamil®	  (Ketamine	  
100	   mg/ml,	   Troy	   Laboratories	   Australia	   Pty	   Ltd)	   and	   Ilium	   Xilazil®	   (Xylazine	   100	  
mg/ml,	  Troy	  Laboratories	  Australia	  Pty	  Ltd)	   in	  PBS	  (table	   20).	  200	  µl	  of	   this	  solution	  
mixture	  was	  injected	  intraperitoneally	  in	  every	  mouse	  that	  underwent	  colitis	  induction	  
with	  TNBS.	  	  
	  
Table	  20:	  Anaesthetics	  used	  for	  anaesthesia	  and	  its	  duration	  
Ketamine	  100	  mg/ml	   0.05	  ml	  injection	  solution/100	  g	  body	  weight	  
Xylazine	  100	  mg/ml	   0.005	  ml	  injection	  solution/100	  g	  body	  weight	  
Duration	  of	  anaesthesia	   Approximately	  30	  minutes	  
	   60	  
5.2.6	  Sample	  injection	  
20	  µg	  of	  fraction	  sample	  was	  to	  be	  injected	  intraperitoneally	  per	  mouse.	  Because	  of	  the	  
needle	  dead	  volume,	  100	  µg	  was	  regarded	  the	  minimum	  amount	  of	  sample	  that	  had	  to	  
be	  prepared	  per	  group	  with	  four	  mice.	  The	  volume	  that	  was	  injected	  per	  mouse	  was	  200	  
µl.	  This	  means	  that	  the	  fraction	  volume	  containing	  100	  µg	  of	  peptide	  had	  to	  be	  diluted	  
with	  a	  specific	  volume	  of	  high	  grade	  PBS	  to	  make	  up	  a	  final	  volume	  of	  1000	  µl.	  500	  µl	  of	  
unfractionated	  LMW	  AcES	  was	  injected	  in	  each	  mouse	  of	  group	  3	  when	  the	  first	  batch	  of	  
LMW	  AcES	  was	  tested.	  
	  
5.2.7	  Colitis	  induction	  
TNBS	  for	  colitis	  induction	  was	  purchased	  from	  Sigma	  Aldrich	  and	  for	  the	  administration,	  
a	   25	   mg/ml	   TNBS	   solution	   in	   45	  %	   EtOH/water	   (v/v)	   was	   prepared	   by	   Dr	   Severine	  
Navarro.	   Colitis	   was	   then	   induced	   by	   TNBS	   as	   previously	   described	   [35].	   For	   the	  
intrarectal	   injection	   of	   the	   TNBS/EtOH	   mixture,	   a	   3,5-­‐French,	   38-­‐cm,	   polyurethane	  
catheter	   and	   a	   1	   ml	   disposable	   syringe	   was	   used.	   After	   filling	   the	   syringe	   with	   the	  
TNBS/EtOH	   mixture,	   the	   catheter	   tip	   was	   lubricated	   with	   Viscotears®	   eye	   gel.	   The	  
catheter	  was	  then	  inserted	  into	  the	  rectum	  of	  the	  mouse,	  which	  was	  hold	  by	  its	  tail,	  and	  
100	  µl	  of	  the	  TNBS/EtOH	  mixture	  was	  administered	  to	  the	  colon.	  Ultimately,	  the	  mouse	  
was	  held	  by	  its	  tail	  for	  30	  seconds,	  enabling	  the	  mixture	  to	  distribute	  evenly	  in	  the	  colon.	  
	  
5.2.8	  Sacrifice	  and	  dissection	  
On	  day	  3	  after	  the	  colitis	  induction	  with	  the	  TNBS/EtOH	  enema,	  the	  mice	  were	  sacrificed	  
using	  carbon	  dioxide	  in	  a	  closed	  system,	  and	  then	  dissected.	  The	  abdomen	  was	  sprayed	  
with	   EtOH/H2O	   (70:30	   v/v)	   and	   a	   laparotomy	   was	   performed	   with	   a	   longitudinal	  
incision	  to	  open	  the	  abdominal	  cavity	  [35].	  Fat	  and	  cecum	  ware	  placed	  to	  the	  side	  and	  
the	  colon	  was	  removed	  entirely.	  After	  measuring	  the	  colon’s	  length	  with	  a	  ruler,	  it	  was	  
opened	  longitudinally	  and	  washed	  in	  PBS	  to	  remove	  the	  stool.	  	  	  	  	  
	  
5.2.9	  Macroscopic	  Evaluation	  
The	  normal	  mouse	  colon	  is	  divided	  into	  three	  sections,	  an	  ascending,	  a	  transverse	  and	  a	  
descending	  colon	  [57].	  Mucosal	  folds	  are	  transverse	  in	  the	  upper	  parts	  of	  the	  colon	  and	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longitudinal	  in	  the	  descending	  colon	  [57].	   	  A	  light	  microscope	  was	  used	  to	  examine	  the	  
cleaned	  colons	  for	  signs	  of	  inflammation	  and	  formation	  of	  connective	  tissue	  between	  the	  
colon	   and	   adjacent	   visceral	   organs	   (adhesions),	   degree	   of	   ulcerations,	   wall	   thickness,	  
oedema	   and	   impaired	   intestinal	   motility	   were	   considered	   signs	   of	   inflammation.	   The	  
severity	  was	  determined	  by	  a	  macroscopic	  scoring	  system	  where	  the	  parameters	  were	  
graded	  (0	  =	  normal	  to	  4	  =	  most	  severe)	  as	  described	  before	  [41].	  	  
	  
5.3	  LC/MS	  of	  fractions	  C	  and	  E	  
The	  LC/MS	  system	  consisted	  of:	  
-­‐ Shimadzu	  CBM20A	  system	  controller	  
-­‐ Shimadzu	  Pump	  LC20AD	  solvent	  delivery	  unit	  
-­‐ Shimadzu	  SIL20AC	  Autosampler	  
-­‐ Shimadzu	  CTO20A	  Column	  oven	  
-­‐ Shimadzu	  SUBCvp	  Subcontroller	  
-­‐ C18	  HPLC	  column	  
-­‐ AB	  Sciex	  Triple	  TOF	  5600	  System	  mass	  spectrometer	  with	  Analyst	  software	  
	  
3.00	  μl	  of	  sample	  was	  injected	  and	  the	  flow	  rate	  was	  set	  to	  0.0008	  ml/minute.	  
	  
Liquid	   chromatography	  method:	   1	  %	   buffer	   B	   for	   5	  minutes,	   linear	   ramping	   to	   40	  %	  
buffer	  B	  over	  25	  minutes,	  linear	  ramping	  to	  80	  %	  buffer	  B	  over	  5	  minutes,	  holding	  at	  80	  
%	  buffer	  B	  for	  5	  minutes,	  ramping	  back	  to	  1	  %	  buffer	  B	  over	  0.1	  minute	  and	  holding	  at	  1	  
%	  buffer	  B	  for	  10	  minutes.	  
	  
5.4	  NMR	  spectroscopy	  of	  fraction	  C	  
1D	  1H	  NMR	  spectrum	  of	  fraction	  C	  was	  recorded	  on	  a	  Bruker	  600	  Mhz	  spectrometer	  at	  
298	  K.	  The	  sample	  was	  dissolved	  in	  450	  μl	  H2O	  and	  50	  μl	  D2O.	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5.5	  Peptide	  synthesis	  
5.5.1	  Deprotection	  for	  Fmoc	  chemistry	  	  
The	   ring	   system	   of	   the	   Fmoc-­‐group	   of	   a	   protected	   amino	   acid	   (Fmoc-­‐Xaa,	   15)	   has	  
electron	  withdrawing	  properties,	  which	  means	  that	  the	  hydrogen	  on	  carbon-­‐9	  is	  acidic	  
and	  can	  be	   removed	  via	  β-­‐elimination	  by	  a	  weak	  base	   (figure	   52)	   [8].	  The	   secondary	  
amine	  piperidine	  (16)	  is	  commonly	  used	  for	  this	  deprotonation	  and	  induces	  an	  electron	  
shift	  that	  ruptures	  the	  molecule	  [8].	  The	  result	  of	  this	  reaction	  is	  the	  deprotected	  amino	  
acid	   (Xaa,	   18),	   carbon	   dioxide	   (CO2)	   and	   a	   dibenzofulvene	   (17)	   intermediate	   [8].	  
Piperidine	   reacts	   further	   with	   the	   dibenzofulvene	   intermediate	   to	   form	   the	   fulvene-­‐





















Figure	   52:	   Deprotection	   step	   by	   step;	   (15)	   Fmoc-­‐Xaa,	   (16)	   piperidine,	   (17)	   Dibenzofulvene,	   (18)	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5.5.2	  Peptide	  bond	  formation	  from	  HBTU-­‐	  and	  HCTU-­‐mediated	  reactions	  
In	   this	   thesis,	   either	   O-­‐(6-­‐benzotriazol-­‐1-­‐yl)-­‐N,N,N’,N’-­‐tetramethyluronium	  
hexafluorophosphate	   (HBTU)	   or	   O-­‐(6-­‐chlorobenzotriazol-­‐1-­‐yl)-­‐N,N,N’,N’-­‐
tetramethyluronium	  hexafluorophosphate	  (HCTU)	  was	  used	  as	  coupling	  reagent.	  	  
Deprotonation	   by	   DIPEA	   (20)	   generates	   the	   carboxylate	   anion	   (22)	   of	   the	   Fmoc-­‐
protected	  amino	  acid	  (21)	  (figure	  53).	  The	  carboxylate	  anion	  is	  now	  able	  to	  attack	  the	  
coupling	  reagent	  (23),	  resulting	  in	  the	  formation	  of	  the	  O-­‐acyl-­‐uronium	  cation	  (24).	  Two	  
different	   pathways	   for	   the	   formation	  of	   a	   new	  peptide	  bond	   that	   yields	   the	   elongated	  
peptide	  (27)	  are	  now	  possible.	  Either,	   the	  O-­‐acyl-­‐uronium	  cation	   is	  attacked	  by	   the	  N-­‐
terminal	   amino	   group	   of	   the	   resin-­‐bound	   peptide	   (25)	   and	   forms	   the	   peptide	   bond	  
directly,	  or,	  it	  reacts	  with	  the	  benzotriazolyloxy	  anion	  (26)	  to	  construct	  a	  benzotriazolyl	  
ester	  (28),	  which	  has	  to	  be	  aminolyzed	  in	  a	  second	  step	  in	  order	  to	  elongate	  the	  peptide.	  
Additionally	  to	  tetramethyl	  urea	  (29),	  that	  is	  released	  in	  both	  pathways	  of	  the	  reaction	  
with	   the	   O-­‐acyl-­‐uronium	   cation,	   pathway	   B	   also	   leads	   to	   the	   release	   of	  















































Figure	   53:	   Formation	   of	   a	   new	   peptide	   bond;	   (20)	   DIPEA,	   (21)	   Fmoc-­‐Xaa,	   (22)	   carboxylate	   anion	   of	  
Fmoc-­‐Xaa,	   (23)	   coupling	   reagent,	   (24)	   O-­‐acyl-­‐uronium	   cation,	   (25)	   resin-­‐bound	   peptide,	   (26)	  









































































































X = H  HBTU
X = Cl HCTU
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5.5.3	  The	  ninhydrin	  test	  
The	   purpose	   of	   the	   ninhydrin	   test	   is	   to	   determine	   the	   yield	   of	   a	   coupling	   reaction	   by	  
quantifying	  unreacted	  primary	  amines	   in	   the	  sample	   [58].	  A	  small	   resin	  aliquot	   (3	  –	  5	  
mg)	   is	   taken	   out	   of	   the	   reaction	   vessel,	   washed	   with	   50/50	   methanol	  
(MeOH)/dichloromethane	   (DCM),	   dried	   until	   the	   resin	   has	   a	   sandy	   appearance,	  
transferred	  to	  a	  test	  tube	  and	  weighed.	  Then,	  2	  drops	  of	  76	  %	  w/w	  phenol,	  4	  drops	  of	  
0.2	  mM	  potassium	   cyanide	   in	   pyridine,	   and	   2	   drops	   of	   0.28	  M	   ninhydrin	   in	   EtOH	   are	  
added	  to	  the	  resin.	  As	  a	  control,	   the	  reagents	   in	  the	  same	  amounts	  are	  also	  added	  to	  a	  
test	  tube	  containing	  no	  resin.	  After	  incubating	  both	  tubes	  at	  100	  °C	  for	  5	  minutes,	  2.8	  ml	  
of	  EtOH/H2O	  (60:40	  v/v)	  is	  added.	  The	  resin	  is	  allowed	  to	  settle	  and	  the	  control	  solution	  
is	   used	   to	   zero	   the	   spectrophotometer.	   Finally,	   the	   absorbance	   of	   the	   sample	   is	  
measured.	  Usually,	  the	  absorbance	  is	  measured	  at	  570	  nm,	  but	  in	  this	  thesis	  λ	  =	  580	  nm	  
was	   used.	   Ninhydrin	   (31)	   reacts	   with	   the	   amino	   group	   of	   a	   bound	   residue	   (32),	  
generating	   the	   Schiff’s	   base	   (33)	   (figure	   54).	   Shift	   of	   the	   double	   bond	   (34)	   and	  
subsequent	  hydrolysis	  yields	  the	  aldehyde	  (35)	  and	  another	  amine	  (36)	  that	  reacts	  with	  
a	  second	  molecule	  of	  ninhydrin	  to	  finally	  give	  an	  anion,	  Ruhemann’s	  purple	  (38)	  which	  
is	  in	  equilibrium	  with	  its	  tetraoxo	  form	  (37)	  [8].	  Ruhemann’s	  purple	  is	  the	  chromophore	  
with	   absorbance	  maxima	   at	   410	   and	   570	   nm	   [58].	   The	   percentage	   coupling	   yield	   can	  
then	  be	  calculated	  using	  following	  formula:	  
%  !"#$%&'(  !"#$% = 100  %   ⋅    1−
200   ⋅   !!"#
!"   ⋅!"##  !"  !"#$% 	  
where	  A580	  is	  the	  absorbance	  measured	  at	  580	  nm	  and	  SV	  is	  the	  substitution	  value	  of	  the	  
















































Figure	  54:	  Reactions	  of	  the	  ninhydrin	  test;	  (31)	  ninhydrin,	  (32)	  peptide	  bound	  residue,	  (33)	  Schiff’s	  base,	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5.5.4	  Native	  chemical	  ligation	  via	  the	  formation	  of	  a	  C-­‐terminal	  acylurea	  moiety	  	  
Initially,	   the	   Fmoc	   group	   on	   the	   Rink	   Amide	   MBHA	   resin	   (39)	   is	   removed	   with	  
piperidine	   yielding	   the	   deprotected	   resin	   (40)	   (figure	   55).	   Fmoc-­‐Dbz	   is	   then	   loaded	  
onto	  the	  resin	  (41)	  using	  HBTU	  and	  DIPEA,	  before	  it	  is	  deprotected	  with	  piperidine	  and	  
standard	  Fmoc	  SPPS	  is	  applied	  to	  elongate	  the	  peptide	  chain	  (42).	  The	  last	  residue	  has	  to	  
be	  protected	  by	  base	  stable,	  but	  acid	  labile,	  protecting	  groups;	  the	  α-­‐amino	  group	  of	  the	  
last	   residue	   is	   therefore	   derivatized	   with	   a	   Boc	   group	   [42].	   When	   chain	   assembly	   is	  
complete,	   acylation	   by	   4-­‐nitrophenyl	   chloroformate	   (43)	   and	   treatment	   with	   DIPEA	  
results	   in	   the	   formation	   of	   the	   resin	   bound	  peptide-­‐Nbz	   (44)	   [42].	   Cleavage	  with	  TFA	  
yields	  the	  free	  peptide-­‐Nbz	  (45),	  which	  forms	  a	  thioester	  (47)	  when	  reacting	  with	  MPAA	  
(46)	   at	   pH	   7	   [42].	   Finally,	   the	   thiol	   group	   of	   a	   Cys	   residue	   at	   the	   N-­‐terminus	   of	   the	  
peptide	  (48)	   to	  be	   ligated	  to	  the	  thioester	  peptide	  attacks	  the	  α-­‐carbonyl	  giving	  a	  new	  
thioester	   (49)	   [59].	   A	   spontaneous	   rearrangement	   leads	   to	   the	   formation	   of	   the	   final	  



















































Figure	   55:	   Native	   chemical	   ligation	   via	   the	   formation	   of	   a	   C-­‐terminal	   acylurea	   functionality;	   (39)	   Rink	  
Amide	  MBHA	  resin,	   (40)	  deprotected	  resin,	   (41)	  Fmoc-­‐Dbz	   loaded	  resin,	   (42)	  peptide	  with	  Dbz,	   (43)	  4-­‐
nitrophenyl	   chloroformate,	   (44)	   resin-­‐bound	  peptide-­‐Nbz,	   (45)	  peptide-­‐Nbz,	   (46)	  MPAA,	   (47)	   thioester,	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5.5.5	  Native	  chemical	  ligation	  via	  the	  formation	  of	  a	  peptide	  hydrazide	  	  
In	   this	   thesis,	   2-­‐chlorotrityl	   chloride	   resin	   (51)	   was	   used	   as	   a	   solid	   support	   for	   the	  
peptide	  hydrazide	  (53)	  (figure	  56).	  Loading	  of	  the	  hydrazide	  group	  onto	  the	  resin	  (52)	  
is	   achieved	   by	   treating	   it	   with	   a	   mixture	   of	   hydrazine	   hydrate,	   DIPEA	   and	   N,N-­‐
Dimethylformamide	  (DMF).	  Standard	  Fmoc-­‐SPPS	  and	  a	  subsequent	  cleavage	  provide	  the	  
final	  peptide	  hydrazide	  (53)	  [49].	  Oxidation	  with	  NaNO2	  at	  a	  low	  pH	  results	  first	  in	  the	  
formation	  of	  the	  peptide	  azide	  (54),	  which	  is	  then	  transformed	  to	  a	  thioester	  (47)	  when	  
MPAA	  (46)	  is	  introduced	  in	  the	  next	  step	  [49].	  Finally,	  the	  thiol	  group	  of	  a	  Cys-­‐residue	  at	  
the	  N-­‐terminus	  of	  the	  peptide	  (48)	  to	  be	  ligated	  to	  the	  thioester	  peptide	  attacks	  the	  α-­‐
carbonyl	   giving	   a	   new	   thioester	   (49)	   [59].	   A	   spontaneous	   rearrangement	   leads	   to	   the	  


















Figure	   56:	   Native	   chemical	   ligation	   via	   the	   formation	   of	   the	   a	   peptide	   hydrazide;	   (51)	   2-­‐chlorotrityl	  
chloride	  resin,	  (52)	  resin	  loaded	  with	  a	  hydrazide	  group,	  (53)	  peptide	  hydrazide,	  (54)	  peptide	  azide,	  (46)	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5.5.6	  Synthesis	  of	  Name	  2	  
5.5.6.1	  Synthesis	  of	  Name2	  N-­‐terminus	  
482	   mg	   (0.25	   mmol	   scale)	   of	   Rink	   Amide	   MBHA	   resin	   (GL	   Biochem	   (Shanghai)	   Ltd,	  
China)	  was	  transferred	  to	  a	  reaction	  vessel	  and	  swollen	  in	  DMF	  for	  0.5	  hour.	  The	  resin	  
was	   deprotected	   with	   piperidine/DMF	   (50:50	   v/v)	   twice	   for	   1	   minute	   and	   washed	  
thoroughly	  with	  DMF	  to	  remove	  piperidine	  and	  the	  liberated	  Fmoc	  group.	  4	  equivalents	  
of	   Fmoc-­‐Dbz,	   2	  ml	   of	   0.5	  M	  HBTU	   in	  DMF	   and	   0.174	  ml	   of	   DIPEA	  were	   added	   to	   the	  
reaction	  vessel,	  mixed	  thoroughly	  and	  allowed	  to	  react	  for	  19	  hours	  and	  45	  minutes	  in	  
order	  to	  load	  the	  resin.	  Ninhydrin	  test	  revealed	  a	  poor	  coupling	  yield	  (86.4	  %),	  therefore	  
the	   loading	  was	   repeated	   twice	   the	   two	   subsequent	  days.	  After	   the	   successful	   loading	  
(coupling	  yield:	  99.6	  %),	  the	  remaining	  residues	  were	  coupled	  using	  4	  equivalents	  of	  the	  
respective	   amino	   acid,	   2	  ml	   of	   0.5	  M	   HBTU	   in	   DMF	   and	   0.174	  ml	   of	   DIPEA.	   The	   last	  
residue	   was	   glutamine	   with	   a	   Boc	   group	   for	   protection	   of	   the	   α-­‐amino	   group	   and	   a	  
xanthenyl	  (Xan)	  group	  for	  side	  chain	  protection.	  Couplings	  were	  checked	  by	  ninhydrin	  
test	   and	   test	   cleavages	   were	   conducted	   to	   monitor	   the	   synthesis.	   After	   complete	  
assembly	  of	   the	   linear	  peptide	  chain,	   the	  resin	  was	  washed	  with	  DCM	  and	  10	  ml	  of	  4-­‐
nitrophenyl	   chloroformate	   in	   DCM	   (100	  mg	   of	   4-­‐nitrophenyl	   chloroformate	   in	   10	   ml	  
DCM)	  was	   added	   to	   the	   reaction	   vessel	   and	   allowed	   to	   react	   for	   1	   hour	   at	   23	   °C.	   The	  
solution	  was	  then	  removed	  by	  vacuum	  filtration	  and	  the	  resin	  was	  washed	  three	  times	  
with	  DCM	  and	  three	  times	  with	  DMF.	  In	  the	  next	  step	  10	  ml	  of	  DIPEA/DMF	  (10:90	  v/v)	  
was	   added	   to	   the	   reaction	   vessel	   and	   allowed	   to	   stand	   for	   15	  minutes	   before	   it	   was	  
removed	  by	  vacuum	   filtration.	  Finally	   the	   resin	  was	  washed	   five	   times	  with	  DMF,	   five	  
times	   with	   DCM	   and	   dried	   under	   nitrogen.	   A	   total	   of	   1.924	   g	   of	   peptidyl	   resin	   was	  
obtained	  and	  400	  mg	  was	  taken	  out	  for	  cleavage.	  The	  peptide	  was	  cleaved	  from	  the	  resin	  
for	   2	   hours	   at	   23	   °C	   using	   50	  ml	   of	   TFA/TIPS/DODT/H2O	   (90:3:3:3	   v/v/v/v).	   After	   a	  
while,	   the	   cleavage	  mixture	   remained	   slightly	   yellow,	  which	   is	   indicative	   of	   free	   trityl	  
protecting	  groups.	  Therefore,	  an	  additional	  0,5	  ml	  of	  TIPS	  was	  added	  to	  scavenge	  these	  
remaining	   groups.	   Most	   of	   the	   TFA	   was	   removed	   using	   a	   rotary	   evaporator	   and	   the	  
crude	  peptide	  was	  washed	  with	  cold	  diethyl	  ether	  and	  extracted	  with	  buffer	  A/buffer	  B	  
(50:50	   v/v).	   The	   peptide	   crude	   was	   then	   lyophilized	   overnight.	   Crude	   peptide	   was	  
purified	  by	  RP-­‐HPLC	  using	  a	  preparative	  column	  (250	  x	  22	  mm,	  300	  Å	  pore	  size,	  10	  μm	  
	   71	  
particle	  size)	  and	  a	  1	  %	  gradient	  of	  buffer	  B.	  ESI-­‐MS	  was	  used	  to	   identify	  the	  fractions	  
containing	  the	  peptide.	  Analytical	  RP-­‐HPLC	  of	  both	  crude	  and	  fractions	  were	  run.	  
	  
5.5.6.2	  Synthesis	  of	  Name2	  C-­‐terminus	  
2-­‐Chlorotrityl	   chloride	   resin	   (Merck	   Schuchardt	   OHG,	   Germany)	   was	   used	   for	   the	  
manual	   synthesis	   of	   the	   Name2	   C-­‐terminus.	   214	   mg	   of	   resin	   (0.25	   mmol	   scale;	  
substitution	   value:	   1.3	  mmol/g)	  were	   transferred	   to	   a	   reaction	   vessel	   and	   swollen	   in	  
DCM	  for	  0.5	  hour.	  In	  order	  to	  load	  the	  resin	  with	  the	  first	  residue,	  2	  equivalents	  of	  Fmoc-­‐
Cys	  and	  8	  equivalents	  DIPEA	  were	  dissolved	   in	  DCM,	  added	  to	   the	  reaction	  vessel	  and	  
allowed	  to	  react.	  After	  2	  hours	  the	  solution	  was	  removed	  by	  vacuum	  filtration	  and	  the	  
reaction	  vessel	  was	   rinsed	  with	  DCM	  before	  another	  2	  equivalents	  of	  Fmoc-­‐Cys	  and	  8	  
equivalents	   of	   DIPEA	   in	   DCM	   were	   added	   and	   allowed	   to	   react	   for	   2	   hours.	   To	   cap	  
unreactive	   sites	   the	   resin	   was	   treated	   with	   DCM/MeOH/DIPEA	   (17:2:1	   v/v/v),	   then	  
washed	  with	  DCM	  and	  DMF	  [8].	  Removal	  of	  the	  Fmoc	  group	  was	  achieved	  by	  treatment	  
with	   piperidine/DMF	   (50:50	   v/v)	   twice	   for	   1	   minute	   and	   washing	   with	   DMF.	   4	  
equivalents	   of	   the	   respective	   Fmoc	   protected	   amino	   acid	   were	   dissolved	   in	   2	   ml	   of	  
coupling	  reagent	  and	  0.174	  ml	  of	  DIPEA	  before	  the	  mixture	  was	  added	  to	  the	  reaction	  
vessel.	   For	   this	   synthesis,	   0.5	  M	  HCTU	   in	   DMF	  was	   used	   for	   the	   first	   coupling,	   and	   if	  
additional	   couplings	  of	   that	   residue	  were	  necessary,	  0.5	  M	  HBTU	   in	  DMF	  was	  used	  as	  
coupling	   reagent.	   Couplings	   were	   checked	   by	   ninhydrin	   test	   and	   test	   cleavages	   were	  
conducted	   to	   monitor	   the	   synthesis.	   After	   complete	   chain	   assembly,	   the	   N-­‐terminal	  
Fmoc	   group	  was	   removed	  with	   piperidine/DMF	   (50:50	   v/v)	   (2	   x	   1	  minute);	   the	   resin	  
was	  washed	  with	  DMF	  and	  DCM	  and	  then	  dried	  under	  nitrogen.	  The	  peptide	  was	  cleaved	  
from	  the	  resin	  for	  2	  hours	  at	  23	  °C	  using	  50	  ml	  of	  TFA/TIPS/DODT/H2O	  (90:3:3:3).	  Most	  
of	  the	  TFA	  was	  removed	  using	  a	  rotary	  evaporator	  and	  the	  crude	  peptide	  was	  washed	  
with	   cold	  diethyl	   ether	   and	  extracted	  with	  buffer	  A/buffer	  B	   (50:50	  v/v).	  The	  peptide	  
crude	   was	   lyophilized	   overnight.	   Crude	   peptide	   was	   purified	   by	   RP-­‐HPLC	   using	   a	  
preparative	   column	   (250	   x	   22	  mm,	   300	   Å	   pore	   size,	   10	   μm	   particle	   size)	   and	   a	   1	  %	  
gradient	  of	  buffer	  B.	  ESI-­‐MS	  was	  used	   to	   identify	   the	   fractions	   containing	   the	  peptide.	  
Analytical	  RP-­‐HPLC	  of	  both	  crude	  and	  fractions	  were	  run.	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5.5.6.3	  Native	  chemical	  ligation	  of	  Name2	  
The	  ligation	  between	  the	  N-­‐terminus	  and	  the	  C-­‐terminus	  part	  of	  Name	  2	  was	  attempted	  




MPAA	   (169.52	  mg)	   and	   TCEP	  ⋅	  HCl	   (29.52	  mg)	  were	   transferred	   to	   a	   scintillation	   vial	  
containing	  5	  ml	  of	  ligation	  buffer,	  giving	  a	  MPAA	  concentration	  of	  0.202	  M	  and	  a	  TCEP	  ⋅	  
HCl	  concentration	  of	  0.0206	  M.	  The	  pH	  was	  adjusted	  to	  7.0	  with	  2	  M	  sodium	  hydroxide	  
(NaOH),	  but	  the	  amount	  NaOH	  added	  was	  too	  much,	  so	  the	  pH	  ended	  up	  at	  7.91.	  Name2	  
N-­‐terminus	   (3.98	   mg)	   and	   Name2	   C-­‐terminus	   (1.98)	   mg	   were	   transferred	   to	   an	  
eppendorf	   tube,	   and	   0.5	   ml	   of	   ligation	   buffer	   was	   added	   to	   the	   tube	   to	   dissolve	   the	  
peptides.	  The	  mixture	  was	  allowed	  to	  react	  for	  21	  hours	  at	  23	  °C.	  0.1	  ml	  was	  taken	  out	  of	  
the	  reaction	  mixture	  to	  run	  a	  LC/MS.	  The	  remaining	  reaction	  mixture	  was	  diluted	  with	  
1.5	  ml	  of	  buffer	  A	  before	  it	  was	  loaded	  onto	  a	  preparative	  column	  (250	  x	  22	  mm,	  300	  Å	  
pore	  size,	  10	  μm	  particle	  size)	  to	  be	  purified	  by	  RP-­‐HPLC	  using	  a	  1	  %	  gradient	  of	  buffer	  
B.	  The	  fractions	  were	  analysed	  by	  ESI-­‐MS.	  
	  
2. Attempt:	  
MPAA	  (33.87	  mg,	  0.201	  M)	  and	  TCEP	  ⋅	  HCl	  (5.80	  mg,	  0.0202	  M)	  were	  transferred	  to	  a	  3	  
ml	   HPLC	   vial.	   1	   ml	   of	   ligation	   buffer	   was	   added	   and	   the	   pH	  was	   raised	   to	   6.98	   with	  
concentrated	  NaOH.	  The	  mixture	  was	  degassed	  by	  bubbling	  nitrogen	   into	   the	  mixture	  
through	  a	  long	  needle	  while	  the	  vial	  was	  sealed	  with	  a	  septum.	  Then,	  15.33	  mg	  of	  Name2	  
N-­‐terminus	   and	   9.30	   mg	   of	   Name2	   C-­‐terminus	   were	   dissolved	   in	   the	   ligation	   buffer	  
before	  the	  reaction	  mixture	  was	  degassed	  one	  more	  time	  under	  nitrogen	  and	  allowed	  to	  
react	  for	  approximately	  24	  hours.	  The	  next	  day,	  1	  ml	  of	  4	  %	  TFA	  was	  added	  in	  order	  to	  
precipitate	  some	  of	  the	  MPAA	  and	  the	  mixture	  was	  transferred	  to	  a	  scintillation	  vial	  and	  
filled	  up	  with	  buffer	  A	  (ca.	  20	  ml),	  filtered	  and	  loaded	  onto	  a	  preparative	  column	  (250	  x	  
21,20	  mm,	  300	  Å	  pore	  size,	  10	  μm	  particle	  size)	  to	  be	  purified	  by	  RP-­‐HPLC	  using	  a	  1	  %	  
gradient	  of	  buffer	  B.	  The	  fractions	  were	  analysed	  by	  ESI-­‐MS	  and	  the	  fraction	  containing	  
the	  ligation	  product	  was	  analysed	  by	  RP-­‐HPLC	  and	  lyophilized.	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5.5.6.4	  Folding	  of	  Name2	  
For	   the	   folding	   of	   Name	   2,	   a	   trial	   oxidation	   with	   eight	   different	   conditions	   was	  
conducted	  with	  a	  peptide	  concentration	  of	  0.5	  mg/ml	  in	  eppendorf	  tubes	  at	  23	  °C:	  
	  
1. 0.1	  ml	  PBS	  
2. 0.1	  ml	  0.1	  M	  NH4HCO3	  
3. 0.1	  ml	  PBS/propan-­‐2-­‐ol	  (50:50)	  
4. 0.1	  ml	  NH4HCO3/propan-­‐2-­‐ol	  (50:50)	  
5. 0.1	  ml	  PBS,	  2	  mM	  GSH	  and	  0.2	  mM	  GSSG	  
6. 0.1	  ml	  0.1	  M	  NH4HCO3,	  2	  mM	  GSH	  and	  0.2	  mM	  GSSG	  
7. 0.1	  ml	  PBS/propan-­‐2-­‐ol	  (50:50),	  2	  mM	  GSH	  and	  0.2	  mM	  GSSG	  
8. 0.1	  ml	  NH4HCO3/propan-­‐2-­‐ol	  (50:50),	  2	  mM	  GSH	  and	  0.2	  mM	  GSSG	  
	  
After	   24	   hours,	   the	   folding	   mixtures	   were	   analysed	   by	   RP-­‐HPLC	   using	   an	   analytical	  
column	  (250	  x	  4.6	  mm,	  300	  Å	  pore	  size,	  5	  μm	  particle	  size)	  and	  a	  1	  %	  gradient	  of	  buffer	  
B.	  Condition	  5	  was	  found	  not	  only	  to	  give	  the	  highest	  peak	  of	  the	  major	  product	  but	  also	  
the	   best	   peak	   height	   ratio	   between	   the	  major	   product	   and	   the	   other	   products	   in	   the	  
mixture.	  1.91	  mg	  of	  reduced	  Name	  2	  was	  then	  oxidised	  in	  10	  ml	  of	  PBS	  containing	  2	  mM	  
GSH	  and	  0.2	  mM	  GSSG	  for	  24	  hours	  at	  23	  °C.	  The	  oxidation	  mixture	  was	  purified	  by	  RP-­‐
HPLC	  using	   a	   semi-­‐preparative	   column	   (250	  x	  10	  mm,	  300	  Å	  pore	   size,	   5	  μm	  particle	  
size)	  and	  a	  1	  %	  gradient	  of	  buffer	  B.	  ESI-­‐MS	  was	  used	  to	   identify	  the	  fraction	  with	  the	  
correct	   mass	   and	   that	   fraction	   was	   lyophilized	   overnight.	   The	   oxidised	   peptide	   was	  
analysed	  by	  1D	  1H	  NMR	  on	  a	  Bruker	  600	  Mhz	  spectrometer.	  	  
	  
5.5.6.5	  NMR	  spectroscopy	  of	  Name2	  
The	  peptide	  was	  dissolved	  in	  450	  μl	  H2O	  and	  50	  μl	  D2O.	  1D,	  TOCSY	  and	  NOESY	  proton	  
spectra	  were	  recorded	  on	  a	  BRUKER	  600	  Mhz	  spectrometer	  at	  298	  K	  with	  a	  mixing	  time	  
of	  150	  ms.	  To	  characterise	  slowly	  exchanging	  protons,	  the	  peptide	  was	  dissolved	  in	  D2O	  
and	  1D	  1H,	  TOCSY,	  NOESY	  and	  1H	  –	  13C	  HSQC	  spectra	  were	  recorded	  on	  a	  BRUKER	  900	  
Mhz	  spectrometer.	  The	  HSQC	  was	  run	  at	  natural	  abundance.	  The	  sequential	  assignment	  
was	  performed	  as	  previously	  described	  [43].	  NOE	  peak	  volumes	   in	   the	  NOESY	  spectra	  
were	   translated	   into	   distance	   restraints	  with	   the	   appropriate	   pseudoatom	   corrections	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using	  the	  program	  CYANA.	  Backbone	  dihedral	  angle	  restraints	  were	  derived	  from	  3JHα,HN	  
coupling	  constants	  measured	  directly	   from	  1D	  spectra.	  Additional	  backbone	  restraints	  
including	  Ψ	  angles	  were	  derived	  from	  Talos+,	  which	  compares	  observed	  chemical	  shifts	  
with	   reported	   chemical	   shifts	   from	  known	   structures	   in	   the	   protein	   data	   bank	   (PDB).	  
Intraresidue	   NOE	   and	   3JHα-­‐Hβ	   coupling	   patterns	   derived	   from	   ECOSY	   were	   used	   in	  
assigning	   Χ1	   angle	   conformation	   of	   the	   side	   chains.	   The	   structure	   was	   calculated	   by	  
using	   torsion	   angle	   dynamics	   within	   the	   CYANA	   software.	   Fifty	   structures	   were	  
calculated	   and	   the	   15	   lowest	   energy	   structures	  were	   retained	   for	   analysis.	   Structures	  
were	  visualised	  with	  MOLMOL.	  
	  
5.5.7	  Synthesis	  of	  Acan1	  
5.5.7.1	  Synthesis	  of	  Acan1	  N-­‐terminus	  as	  a	  peptide	  hydrazide	  
192	   mg	   (0.25	   mmol	   scale,	   substitution	   value:	   1,3	   mmol/g)	   of	   2-­‐chlorotrityl	   chloride	  
resin	  (Merck	  Schuchardt	  OHG,	  Germany)	  was	  swollen	   for	  30	  minutes	   in	  25	  ml	  of	  DMF	  
and	   cooled	   at	   0	   °C	   in	   a	   round	   bottom	   flask	   [60].	   A	  mixture	   of	   DIPEA	   (0.131	  ml,	   0.75	  
mmol),	   hydrazine	   hydrate	   (0.121	  ml,	   2.5	  mmol)	   and	   DMF	   (1	  ml)	  was	   added	   drop	   by	  
drop	  and	  the	  suspension	  was	  stirred	  for	  30	  minutes	  at	  23	  °C.	  This	  step	  was	  repeated	  for	  
another	  30	  minutes.	  The	  resin	  was	  then	  filtered	  in	  a	  reaction	  vessel,	  washed	  with	  DMF,	  
water,	  DMF,	  MeOH	  and	  diethyl	  ether.	  Standard	  manual	  Fmoc-­‐SPPS	  was	  applied	  for	  chain	  
elongation.	  Amino	  acids	  were	  coupled	  using	  2	  ml	  of	  0.5	  M	  HBTU	  in	  DMF	  or	  0.5	  M	  HCTU	  
in	  DMF	  and	  0.174	  ml	  of	  DIPEA.	  For	  deprotection	  piperidine/DMF	  (50:50)	  was	  used	  and	  
couplings	  were	   checked	  by	  ninhydrin	   test.	  After	   chain	   assembly	  was	   complete,	   a	   final	  
deprotection	  with	   piperidine/DMF	   (50:50	   v/v)	  (1	   x	   1	  minute	   and	  1	   x	   5	  minutes)	  was	  
carried	   out	   and	   the	   resin	  was	  washed	  with	   DMF	   and	  DCM	   before	   it	  was	   dried	   under	  
nitrogen.	   The	   peptidyl	   resin	   (336	  mg)	  was	   cleaved	  with	   50	  ml	   TFA/TIPS/DODT/H2O	  
(90:3:3:3	  v/v/v/v)	  for	  2	  hours	  at	  23	  °C.	  Most	  of	  the	  TFA	  was	  evaporated	  and	  the	  solution	  
was	   washed	   with	   diethyl	   ether	   and	   extracted	   with	   buffer	   A/buffer	   B	   (50:50).	   The	  
peptide	  crude	  was	  lyophilized	  and	  purified	  by	  RP-­‐HPLC	  using	  a	  preparative	  column	  (250	  
x	  22	  mm,	  300	  Å	  pore	  size,	  10	  μm	  particle	  size)	  and	  a	  1	  %	  gradient	  of	  buffer.	  Fractions	  
were	  analysed	  by	  ESI-­‐MS.	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5.5.7.2	  Synthesis	  of	  Acan	  1	  C-­‐terminus	  
480	   mg	   (0.25	   mmol	   scale)	   of	   Rink	   Amide	   MBHA	   resin	   (GL	   Biochem	   (Shanghai)	   Ltd,	  
China)	   was	   swollen	   in	   DMF	   for	   0.5	   hour	   in	   a	   reaction	   vessel.	   The	   resin	   was	   then	  
transferred	  to	  a	  CS	  336X	  automated	  synthesiser	  (C	  S	  Bio	  Co.,	  USA)	  that	  carried	  out	  the	  
deprotection	  of	  the	  resin	  (with	  piperidine/DMF	  (20:80	  v/v)	  and	  the	  peptide	  elongation	  
using	   Fmoc	   protected	   amino	   acids,	   0.5	  M	  HBTU	   in	   DMF	   and	   1	  M	  DIPEA	   in	   DMF.	   The	  
synthesiser	   also	   accomplished	   the	   final	   deprotection	   of	   the	  N-­‐terminal	   residue.	   Every	  
residue	  was	   coupled	   once	   and	  when	   chain	   assembly	  was	   complete,	   the	   peptidyl	   resin	  
was	  washed	  with	  DMF	  by	   the	   synthesiser,	   then	   transferred	   to	   a	   reaction	   vessel	   to	   be	  
washed	  with	  DCM	  and	  dried	  under	  nitrogen.	  379	  mg	  of	  peptidyl	  resin	  was	  cleaved	  at	  23	  
°C	  for	  2	  hours	  using	  50	  ml	  of	  TFA/TIPS/DODT/H2O	  (90:3:3:3	  v/v/v/v).	  The	  majority	  of	  
TFA	  was	  evaporated	  under	  pressure;	  peptide	  crude	  was	  precipitated	  with	  diethyl	  ether,	  
extracted	  with	  buffer	  A/buffer	  B	  (50:50	  v/v)	  and	  lyophilized	  overnight.	  73	  mg	  of	  peptide	  
crude	  was	  purified	  by	  RP-­‐HPLC	  with	  a	  preparative	  column	  (250	  x	  22	  mm,	  300	  Å	  pore	  
size,	  10	  μm	  particle	  size)	  using	  a	  1	  %	  gradient	  of	  buffer	  B.	  Fractions	  were	  analysed	  by	  
ESI-­‐MS.	  	  
	  
5.5.7.3	  Ligation	  of	  Acan	  1	  using	  a	  peptide	  hydrazide	  
The	  pH	  of	  1	  ml	  of	  buffer	  containing	  6	  M	  Gn	  ⋅	  HCl	  and	  0.2	  M	  Na2HPO4	  was	  adjusted	  to	  2.83	  
using	  32	  %	  HCl.	  5.11	  mg	  Acan1	  C-­‐terminus	  and	  6.24	  mg	  of	  Acan1	  N-­‐terminus	  peptide	  
hydrazide	   were	   dissolved	   in	   the	   buffer	   and	   held	   at	   –10	   °C,	   0.1	   ml	   of	   0.2	   M	   NaNO2	  
solution	  was	  added	  drop	  by	  drop	  and	  stirred.	  After	  20	  minutes	  0.5	  ml	  of	  0.2	  M	  MPAA	  in	  
neutral	  buffer	  (6	  M	  Gn	  ⋅	  HCl	  and	  0.2	  M	  Na2HPO4)	  was	  added	  to	  the	  ligation	  mixture,	  the	  
pH	  was	  adjusted	  to	  7.60	  using	  concentrated	  NaOH	  and	  stirring	  was	  continued	  overnight.	  
The	   next	   day,	   0.2	  ml	  was	   taken	   out	   of	   the	   ligation	  mixture	   and	   analysed	   by	  RP-­‐HPLC	  
using	   an	   analytical	   column	   (150	   x	  2.1	  mm,	  300	  Å	  pore	   size,	   5	   μm	  particle	   size)	   and	   a	  
method	   that	   started	  with	   5	  %	  buffer	   for	   5	  minutes	   and	   then	   a	   2	  %	   linear	   gradient	   of	  
buffer	  B.	  Fractions	  were	  analysed	  by	  ESI-­‐MS.	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5.5.7.4	  Synthesis	  of	  Acan1	  N-­‐terminus	  with	  a	  Dbz	  group	  
460	  mg	  of	  Rink	  Amide	  MBHA	  (0.25	  mmol	  scale)	  was	  swollen	  for	  30	  minutes	  in	  a	  reaction	  
vessel,	   deprotected	   with	   piperidine/DMF	   (50:50	   v/v)	   twice	   for	   1	   minute,	   and	   loaded	  
with	  Fmoc-­‐Dbz.	  4	  equivalents	  of	  Fmoc-­‐Dbz	  was	  activated	  with	  2	  ml	  of	  0.5	  M	  HBTU	   in	  
DMF	   and	   0.174	   ml	   DIPEA	   and	   transferred	   to	   the	   reaction	   vessel.	   The	   loading	   was	  
repeated	  three	  times	  and	  checked	  by	  ninhydrin	  test.	  The	  resin	  was	  then	  transferred	  to	  a	  
CS	   336X	   automated	   synthesiser	   (C	   S	   Bio	   Co.,	   USA),	   which	   carried	   out	   the	   chain	  
elongation	   using	   piperidine/DMF	   (20:80	   v/v)	   for	   deprotection,	   4	   equivalents	   of	   Fmoc	  
amino	  acids,	  0.5	  M	  HBTU	  in	  DMF	  and	  1	  M	  DIPEA	  in	  DMF	  for	  activation.	  The	  last	  residue	  
was	  glutamine	  with	  a	  Boc	  group	  for	  protection	  of	  the	  α-­‐amino	  group	  and	  a	  Xan	  group	  for	  
side	   chain	   protection.	   Arginines	   were	   coupled	   twice.	   After	   the	   chain	   assembly	   was	  
complete,	  the	  peptidyl	  resin	  was	  washed	  with	  DMF	  and	  DCM	  before	  it	  was	  dried	  under	  
nitrogen.	  A	  test	  cleavage	  was	  performed	  to	  check	  if	  the	  synthesis	  was	  successful.	  397	  mg	  
of	   peptidyl	   resin	  was	   swollen	   in	  DCM	   for	   45	  minutes	   before	   100	  mg	  of	   4-­‐nitrophenyl	  
chloroformate	  in	  10	  ml	  DCM	  was	  added	  and	  allowed	  to	  react	  for	  85	  minutes.	  The	  resin	  
was	   washed	   with	   DCM	   and	   DMF;	   10	   ml	   of	   DIPEA/DMF	   (10:90	   v/v)	   was	   added	   and	  
removed	  by	  vacuum	  filtration	  after	  30	  minutes.	  After	  washing	  the	  resin	  with	  DMF	  and	  
DCM,	  it	  was	  dried	  under	  nitrogen.	  397	  mg	  of	  peptidyl	  resin	  was	  cleaved	  using	  50	  ml	  of	  
TFA/TIPS/DODT/H2O	   (90:3:3:3	   v/v/v/v)	   for	   2	   hours	   at	   23	   °C.	   Most	   of	   the	   TFA	   was	  
removed	  from	  the	  solution	  containing	  the	  peptide	  crude,	  which	  was	  then	  washed	  with	  
diethyl	   ether	   and	   extracted	   with	   buffer	   A/buffer	   B	   (50:50).	   The	   peptide	   crude	   was	  
lyophilized	  and	  purified	  by	  RP-­‐HPLC	  using	  a	  preparative	  column	  (250	  x	  22	  mm,	  300	  Å	  
pore	  size,	  10	  μm	  particle	  size)	  and	  a	  1	  %	  gradient	  of	  buffer	  B.	  Fractions	  were	  analysed	  
by	  ESI-­‐MS.	  
	  
407	   mg	   of	   peptidyl	   resin	   was	   swollen	   in	   DCM	   for	   45	   minutes	   and	   activated	   with	   5	  
equivalents	  of	  4-­‐nitrophenyl	  chloroformate	  (50.39	  mg)	  in	  DCM	  for	  85	  minutes.	  The	  resin	  
was	  washed	  with	  DCM	   and	  DMF	   before	   5	  ml	   of	   0.5	  M	  DIPEA	   in	  DMF	  was	   added	   and	  
allowed	  to	  react	  for	  15	  minutes.	  Washes	  with	  DMF	  and	  DCM	  were	  carried	  out	  before	  the	  
resin	  was	  dried	  under	  nitrogen.	  20	  ml	  of	  TFA/TIPS/DODT/H2O	  (90:3:3:3	  v/v/v/v)	  was	  
used	   to	   cleave	   the	   peptide	   from	   the	   resin	   at	   23	   °C	   (2	   hours).	   Most	   of	   the	   TFA	   was	  
removed	  from	  the	  solution	  containing	  the	  peptide	  crude,	  which	  was	  then	  washed	  with	  
diethyl	   ether	   and	   extracted	   with	   buffer	   A:buffer	   B	   (50:50).	   The	   peptide	   crude	   was	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lyophilized	  and	  purified	  (60	  mg)	  by	  RP-­‐HPLC	  using	  a	  preparative	  column	  (250	  x	  21,20	  
mm,	  300	  Å	  pore	  size,	  10	  μm	  particle	  size)	  and	  a	  1	  %	  gradient	  of	  buffer	  B.	  Fractions	  were	  
analysed	  by	  ESI-­‐MS.	  
	  
5.5.7.5	  Ligation	  of	  Acan1*	  
The	  pH	  of	  1	  ml	  of	  ligation	  buffer	  containing	  6	  M	  Gn	  ⋅	  HCl,	  0.2	  M	  Na2HPO4,	  0.201	  M	  MPAA	  
and	  0.0209	  M	  TCEP	  ⋅	  HCl	  was	  adjusted	  from	  4.31	  to	  6.81	  using	  concentrated	  NaOH.	  The	  
mixture	   was	   degassed	   under	   nitrogen	   for	   10	   minutes	   before	   11.37	   mg	   of	   Acan1*	   N-­‐
terminus	   and	   9.40	   mg	   of	   Acan1	   C-­‐terminus	   were	   added	   and	   the	   degassing	   under	  
nitrogen	  was	  conducted	  for	  another	  10	  minutes.	  The	  ligation	  mixture	  was	  stirred	  at	  23	  
°C	  and	  allowed	  to	  react	  for	  at	  least	  24	  hours.	  1	  ml	  of	  4	  %	  TFA	  was	  added	  to	  the	  mixture,	  
diluted	  with	   buffer	   A	   (final	   volume:	   ca.	   20	  ml)	   and	   loaded	   on	   a	   preparative	   RP-­‐HPLC	  
column	  (250	  x	  22	  mm,	  300	  Å	  pore	  size,	  10	  μm	  particle	  size)	  to	  be	  purified	  using	  a	  1	  %	  
gradient	  of	  buffer	  B.	  The	  fractions	  were	  analysed	  by	  ESI-­‐MS.	  	  	  	  	  
	  
5.5.7.6	  Folding	  of	  Acan1*	  
For	  the	  folding	  of	  Acan1*,	  a	  trial	  oxidation	  with	  eight	  different	  conditions	  was	  conducted	  
with	  a	  peptide	  concentration	  of	  0.5	  mg/ml	  in	  eppendorf-­‐tubes	  at	  23	  °C:	  
	  
1. 0.1	  ml	  PBS	  
2. 0.1	  ml	  0.1	  M	  NH4HCO3	  
3. 0.1	  ml	  PBS/propan-­‐2-­‐ol	  (50:50)	  
4. 0.1	  ml	  NH4HCO3/propan-­‐2-­‐ol	  (50:50)	  
5. 0.1	  ml	  PBS,	  2	  mM	  GSH	  and	  0.2	  mM	  GSSG	  
6. 0.1	  ml	  0.1	  M	  NH4HCO3,	  2	  mM	  GSH	  and	  0.2	  mM	  GSSG	  
7. 0.1	  ml	  PBS/propan-­‐2-­‐ol	  (50:50),	  2	  mM	  GSH	  and	  0.2	  mM	  GSSG	  
8. 0.1	  ml	  NH4HCO3/propan-­‐2-­‐ol	  (50:50),	  2	  mM	  GSH	  and	  0.2	  mM	  GSSG	  
	  
After	   24	   hours,	   the	   folding	   mixtures	   were	   analysed	   by	   RP-­‐HPLC	   using	   an	   analytical	  
column	  (250	  x	  4.6	  mm,	  300	  Å	  pore	  size,	  5	  μm	  particle	  size)	  and	  a	  1	  %	  gradient	  of	  buffer	  
B.	   Condition	   2	   was	   then	   used	   for	   an	   oxidation	   on	   a	   larger	   scale,	   so	   that	   2.00	   mg	   of	  
reduced	  Acan1*	  were	  oxidised	   in	  10	  ml	  of	  0.1	  M	  NH4HCO3	   for	  24	  hours	   at	  23	   °C.	  The	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oxidation	  mixture	  was	  purified	  by	  RP-­‐HPLC	  using	  a	  semi-­‐preparative	  column	  (250	  x	  10	  
mm,	  300	  Å	  pore	  size,	  5	  μm	  particle	  size)	  and	  a	  1	  %	  gradient	  of	  buffer	  B.	  ESI-­‐MS	  was	  used	  
to	   identify	   the	   fraction	   with	   the	   correct	   mass	   and	   that	   fraction	   was	   lyophilized	  
overnight.	  
	  
5.5.7.7	  NMR	  spectroscopy	  of	  Acan1*	  
1D	  1H	  NMR	  spectrum	  of	  fraction	  C	  was	  recorded	  on	  a	  Bruker	  600	  Mhz	  spectrometer	  at	  
298	  K.	  The	  peptide	  was	  dissolved	  in	  450	  μl	  H2O	  and	  50	  μl	  D2O.	  
	  
5.5.7.8	  Ligation	  of	  Acan	  1	  
The	  pH	  of	  1	  ml	  of	  ligation	  buffer	  containing	  6	  M	  Gn	  ⋅	  HCl,	  0.2	  M	  Na2HPO4,	  0.199	  M	  MPAA	  
and	  0.0205	  M	  TCEP	  ⋅	  HCl	  was	  adjusted	  from	  4.48	  to	  7.02	  using	  concentrated	  NaOH.	  After	  
degassing	   for	   10	   minutes,	   1.00	   mg	   of	   Acan	   1	   N-­‐terminus	   and	   1.29	   mg	   of	   Acan	   1	   C-­‐
terminus	   were	   dissolved	   in	   0.2	   ml	   of	   ligation	   buffer	   before	   it	   was	   degassed	   for	   an	  
additional	  10	  minutes.	  The	  ligation	  mixture	  was	  stirred	  at	  23	  °C	  and	  allowed	  to	  react	  for	  
at	   least	   24	  hours.	   0.2	  ml	   of	   4	  %	  TFA	  was	   added	   to	   the	  mixture,	   diluted	  with	  buffer	  A	  
(final	  volume:	  ca.	  20	  ml)	  and	  loaded	  on	  a	  semi-­‐preparative	  RP-­‐HPLC	  column	  (250	  x	  10	  
mm,	  300	  Å	  pore	  size,	  5	  μm	  particle	  size)	  to	  be	  purified	  using	  a	  1	  %	  gradient	  of	  buffer	  B.	  




Preparative,	  semi-­‐preparative	  and	  analytical	  RP-­‐HPLC	  was	  performed	  using	  a	  Shimadzu	  
Prominence	  HPLC	  system	  that	  consisted	  of:	  
-­‐ Shimadzu	  Prominence	  DGU-­‐20A5	  degasser	  
-­‐ Shimadzu	  Prominence	  LC-­‐20AT	  solvent	  delivery	  unit	  
-­‐ Shimadzu	  Prominence	  CBM-­‐20A	  system	  controller	  
-­‐ Shimadzu	  Prominence	  SPD-­‐20A	  UV/VIS	  detector	  
-­‐ Lab	  solutions	  software	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Preparative	  columns:	  
-­‐ GRACE	  VYDAC	  HPLC	  Columns	  C18	  218TP1022	  (250	  x	  22	  mm,	  300	  Å	  pore	  size,	  10	  
μm	  particle	  size)	  
-­‐ Phenomenex	  Jupiter	  C18	  (250	  x	  21.20	  mm,	  300	  Å	  pore	  size,	  10	  μm	  particle	  size)	  
	  
Semi-­‐preparative	  column	  
-­‐ GRACE	  VYDAC	  HPLC	  Columns	  C18	  218TP510	  (250	  x	  10	  mm,	  300	  Å	  pore	  size,	  5	  
μm	  particle	  size)	  
	  
Analytical	  columns:	  
-­‐ GRACE	  VYDAC	  HPLC	  Columns	  C18	  218TP54	  (250	  x	  4.6	  mm,	  300	  Å	  pore	  size,	  5	  μm	  
particle	  size)	  
-­‐ GRACE	   VYDAC	   Everest	   C18	   238EV54	   (250	   x	   4.6	   mm,	   300	   Å	   pore	   size,	   5	   μm	  
particle	  size)	  
-­‐ GRACE	  VYDAC	  HPLC	  Columns	  C18	  218TP5215	  (150	  x	  2.1	  mm,	  300	  Å	  pore	  size,	  5	  
μm	  particle	  size)	  
	  
Mass	  spectrometry:	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7.2	  LC/MS	  of	  fraction	  E	  
	  
	  






Figure	  A7:	  ESI-­‐MS	  of	  Name2	  N-­‐terminus	  peptide	  crude	  
 +Q1: 4.408 to 4.558 min from Sample 1 (20120328_name2_nterm_crude) of 20120328_name2_nterm_crude.wiff (Turbo Spray) Max. 4.6e5 cps.


























D	   E	  
F	  
G	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Figure	  A8:	  ESI-­‐MS	  of	  purified	  Name2	  N-­‐terminus	  
	  
	  
Figure	  A9:	  ESI-­‐MS	  of	  Name2	  C-­‐terminus	  peptide	  crude	  
	  
	  
Figure	  A10:	  ESI-­‐MS	  of	  purified	  Name2	  C-­‐terminus	  
 +Q1: 2.405 to 2.505 min from Sample 1 (20120330_name2_nterm_purification) of 20120330_name2_nterm_purification.wiff (Turbo Sp... Max. 2.7e6 cps.





























226.1 786.5632.2 754.3243.1 411.3 556.2 1185.0
850.5 867.4771.3656.4 980.6499.9 721.9394.4 1030.5212.4 260.1 606.8549.0 1202.5377.2 1223.8442.7 1176.5959.8906.9758.9
 +Q1: 3.857 to 4.107 min from Sample 1 (20120301_name2_cterm_crude) of 20120301_name2_cterm_crude.wiff (Turbo Spray) Max. 1.3e5 cps.


























226.0 882.5 920.3511.4 615.4 762.3 999.1 1087.5633.4 847.6
939.2410.1 1140.4718.4 1116.8570.9 1310.6871.9456.8 1209.5959.4552.6349.3 894.3836.0299.5250.1 663.3 774.6 1089.0468.9 903.9590.0 1114.91042.4 1193.0435.0 811.4373.2 977.6532.1223.0 1313.1 1423.0289.1 629.9 1524.7414.3 696.8 1408.91296.71184.0
 +Q1: 8.665 to 8.966 min from Sample 1 (20120329_name2_cterm_purification) of 20120329_name2_cterm_purification.wiff (Turbo Sp... Max. 9.4e5 cps.


























916.3511.3 718.3 999.9 1107.0231.0 573.2
686.4410.0254.0 545.1 900.8 1249.3658.4 1116.3769.5 1144.5215.1 846.4 1310.2427.1 942.2577.0 1019.2307.3
656.0444.2 598.7302.3 493.2 892.9704.4475.3 1102.3878.4759.3 1362.41260.5384.3 1012.1 1042.2972.6581.2 1490.51159.6 1592.91423.1
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Figure	  A11:	  ESI-­‐MS	  that	  confirmed	  the	  presence	  of	  the	  correct	  ligation	  product	  –	  1.	  ligation	  attempt	  
	  
Figure	  A12:	  ESI-­‐MS	  of	  the	  fraction	  containing	  Name2	  –	  2.	  ligation	  attempt	  
	  
	  
Figure	  A13:	  ESI-­‐MS	  of	  oxidised	  Name2	  
 +Q1: 17.258 to 17.308 min from Sample 2 (name2) of name2name2.wiff (Turbo Spray) Max. 2.3e6 cps.

























639.3621.5 943.1674.8 1276.6851.5827.7749.2545.3 916.1654.0606.9 981.1 1150.8 1572.9736.5459.1 1179.1814.6 869.2 1048.1428.2339.8212.5 1361.8761.3256.9 1533.6
 +Q1: 32.107 to 32.357 min from Sample 1 (20120404_name2_ligation_purification_part3) of 20120404_name2_ligation_purification_part3.wiff (T... Max. 6.8e5 cps.































1151.1839.2 950.0 1175.2 1572.6511.2 1360.5872.2 1126.9632.2 718.2 869.0573.4 938.0784.8231.0
545.3 908.8487.2 980.1430.0254.2 1080.2 1571.6658.4 761.3 841.0316.4 743.2540.9 1302.4201.3 1534.01260.8989.5489.4 863.8 1147.0691.3327.1 361.2 1093.1415.0 806.0284.4 630.3 1343.81304.41062.4725.9537.3222.2 1561.11528.51272.0
 +Q1: 8.966 to 9.216 min from Sample 1 (20120417_name2_oxidation) of 20120417_name2_oxidation.wiff (Turbo Spray) Max. 2.9e5 cps.






























555.1 916.1 1079.4 1169.4
254.1 529.1 1330.0658.2 686.1443.9 1532.51145.8769.3 920.3 1141.11085.9 1226.3203.3 935.9 1336.0786.1666.5527.2 898.3747.4430.3310.0 613.9368.1 477.9 1404.7 1550.41104.2 1473.0921.0733.8
	   92	  
	  
Figure	  A14:	  ESI-­‐MS	  of	  crude	  Acan1	  N-­‐terminus	  hydrazide	  
	  
	  
Figure	  A15:	  ESI-­‐MS	  of	  purified	  Acan1	  N-­‐terminus	  peptide	  hydrazide	  
	  
	  
Figure	  A16:	  ESI-­‐MS	  of	  Acan1	  C-­‐terminus	  peptide	  crude	  
 +Q1: 4.658 to 5.009 min from Sample 1 (20120319_acan1_nterm_hydrazine_crude_2) of 20120319_acan1_nterm_hydrazine_crude_2... Max. 5.7e4 cps.





























675.4 1013.0355.2 651.6591.8207.2 728.5 825.2 990.8 1065.3507.4303.2 845.4437.1 681.8 1131.51019.8803.6341.3
587.8266.8 668.5 1223.8831.4 946.3 1140.1
336.9 863.7499.6 1597.01346.7 1419.1777.4482.8421.5 1136.6 1451.31219.1227.9
 +Q1: 17.681 to 17.982 min from Sample 1 (20120324_acan1_nterm_hydrazine_purification) of 20120324_acan1_nterm_hydrazine_pu... Max. 9.7e5 cps.

























513.0 536.9 657.3241.1 1083.1496.5427.2 667.9 1113.4807.7755.9 887.9253.0 1002.2521.3 634.9573.0226.1 1394.61133.3685.3 998.5498.0364.5 381.0337.4 792.8 938.4843.3 1066.4 1558.31314.31197.0 1502.7
 +Q1: 7.764 to 7.914 min from Sample 1 (20120319_acan1_cterm_crude) of 20120319_acan1_cterm_crude.wiff (Turbo Spray) Max. 2.1e5 cps.



























1177.3 1193.5837.2755.1 917.2 940.1 1046.5209.2 1278.5641.0 1104.3 1192.3 1560.31298.6 1535.3281.2 354.7 1339.3428.9 540.0 1437.2879.4623.5 809.8786.3 1037.4239.4 704.9 994.6 1084.2674.1507.2259.0 446.8 1553.1393.3 1373.7
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Figure	  A17:	  ESI-­‐MS	  of	  purified	  Acan1	  C-­‐terminus	  
	  
	  
Figure	  A18:	  ESI-­‐MS	  of	  a	  test	  cleavage	  of	  Acan1	  N-­‐terminus	  right	  after	  the	  synthesis	  
	  
	  
Figure	  A19:	  ESI-­‐MS	  of	  the	  peptide	  crude	  after	  activation	  and	  cleavage	  of	  the	  first	  batch	  of	  Acan1	  N-­‐
terminus	  peptidyl	  resin	  
	  
 +Q1: 13.975 to 14.125 min from Sample 1 (20120320_acan1_cterm_purification) of 20120320_acan1_cterm_purification.wiff (Turbo S... Max. 2.1e6 cps.





















1054.4951.1 1177.3837.2 1560.41192.9917.2 1437.41397.2551.3 755.1 1298.5804.4 1135.4641.0 1103.4244.4 1028.4690.8436.9 1226.0933.2 1549.31454.0
 +Q1: 7.764 to 8.065 min from Sample 1 (20120331_acan1_nterm_dbz_testcleavage) of 20120331_acan1_nterm_dbz_testcleavage.wiff (Turbo S... Max. 2.8e5 cps.




























1095.6254.2 1134.2818.1249.0 596.8539.2427.3 513.2 846.3709.6679.4 794.0
836.0547.8 605.2
776.1 829.6 1094.9680.5267.2 1114.1588.4 634.9 847.9789.8403.9 514.7 651.2 782.4 1114.9485.0 895.8306.1 1103.4592.3217.2 1009.1232.1 322.2 869.2487.4436.2 697.3 1158.2970.3 1066.8458.3 1033.2279.4 1158.9899.6299.0 1185.3360.0 1256.4 1558.31301.6 1359.4 1464.4
 +Q1: 2.855 to 3.005 min from Sample 1 (20120402_acan1_nterm_nbz_crude_2) of 20120402_acan1_nterm_nbz_crude_2.wiff (Turbo Spray) Max. 9.7e4 cps.


























862.1837.9628.3 1164.6240.8 988.9529.9 746.1 1069.4 1137.7677.6 1008.9943.0486.3472.0281.3 1566.7580.1 757.1 990.5776.4661.4 892.9355.0246.8 564.8 1028.2 1549.9705.6 1141.3 1159.5878.7499.3434.0 1215.1327.1 1275.11325.3 1442.0 1572.7
1464.4382.0229.4
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Figure	  A20:	  ESI-­‐MS	  of	  a	  fraction	  containing	  the	  by-­‐product	  peptide-­‐Nbz	  (1.	  batch)	  
	  
Figure	  A21:	  ESI-­‐MS	  of	  the	  fraction	  containing	  the	  correct	  Acan1	  N-­‐terminus	  peptide-­‐Nbz	  (1.	  batch)	  
	  
	  
Figure	  A22:	  ESI-­‐MS	  of	  the	  peptide	  crude	  after	  activation	  and	  cleavage	  of	  the	  second	  batch	  of	  Acan1	  N-­‐
terminus	  peptidyl	  resin	  
	  
	  
 +Q1: 21.188 to 21.438 min from Sample 1 (20120304_acan1_nterm_crude) of 20120304_acan1_nterm_crude.wiff (Turbo Spray) Max. 7.9e5 cps.






























1131.2817.5 1089.5813.1854.2427.2 472.2 767.6513.2241.2
1114.21098.3663.0 860.3771.5530.2 1002.4 1567.3221.1 243.9 763.4634.8 933.3463.9 552.9
667.2356.9 1078.1837.8 1109.51060.4468.3 747.8850.9 976.6577.3206.4 1314.0383.2320.2 1550.41217.5 1398.7 1446.5
 +Q1: 42.175 to 42.475 min from Sample 1 (20120304_acan1_nterm_crude) of 20120304_acan1_nterm_crude.wiff (Turbo Spray) Max. 1.1e5 cps.




























834.2 1104.2984.2873.7 1131.4792.5530.2267.1 496.0 838.8 978.3 1103.0555.0 668.2427.2 1045.1481.1 877.3759.3253.2 780.1451.0 826.0556.2 596.9 1095.6354.6 1164.8 1460.5698.7 1001.9485.3 990.1774.7 909.1294.5 1118.2213.1 1251.5442.0 843.3561.3 673.2621.9326.9 1372.4 1453.31185.3 1524.51170.6306.0 489.8 1354.01257.8
 +Q1: 5.911 to 6.111 min from Sample 1 (20120403_acan1_nterm_nbz_crude) of 20120403_acan1_nterm_nbz_crude.wiff (Turbo Spray) Max. 1.8e5 cps.
























1039.2628.1 871.2 1002.8 1131.4808.7754.3472.3213.2 1102.4529.8 1003.4824.0 1558.3974.3627.1 643.1459.8 1123.6800.7 873.1685.4514.3245.0 1177.8267.1 538.7385.1 1020.4 1313.9599.2 934.9636.4 886.7 1460.81430.3 1541.31195.9409.2272.2
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Figure	  A23:	  ESI-­‐MS	  of	  a	  fraction	  containing	  the	  by-­‐product	  peptide-­‐Nbz	  (2.	  Batch)	  
	  
	  
Figure	  A24:	  ESI-­‐MS	  of	  fraction	  37	  	  
	  
	  
Figure	  A25:	  ESI-­‐MS	  of	  fraction	  38	  	  
	  
	  
 +Q1: 25.195 to 25.395 min from Sample 1 (20120405_acan1_nterm_2.activation_prurification) of 20120405_acan1_nterm_2.activation_prurificati... Max. 1.1e6 cps.



























663.1556.2 860.4221.1 1002.3 1083.5 1567.3634.9 775.0759.0530.2 1086.5267.0 933.3545.9 642.9485.2 846.8312.3 374.4 994.8916.0219.4 1077.6 1134.0582.1 830.7 1576.2693.2 1314.31190.5 1419.4275.9 1445.6
 +Q1: 43.727 to 43.978 min from Sample 1 (20120411_acan1_ligation) of 20120411_acan1_ligation.wiff (Turbo Spray) Max. 4.9e5 cps.
























871.4 1146.91117.9 1287.2895.7 1348.11233.1628.1209.1 1051.9 1368.4780.1 848.9 1429.21174.1756.8 1154.8951.3251.3 1253.8307.7 939.6539.9 1557.4512.0436.9383.0 708.3267.3 612.1
 +Q1: 45.731 to 45.981 min from Sample 1 (20120411_acan1_ligation) of 20120411_acan1_ligation.wiff (Turbo Spray) Max. 5.8e5 cps.


























1095.9209.1 891.6 1016.6 1131.1 1188.5 1429.31315.1628.3539.7 854.0707.7 770.5 867.6308.0 1343.9999.7383.0 1466.7512.1436.9 1532.5612.9 915.2 993.4262.1247.3
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Figure	  A26:	  ESI-­‐MS	  of	  fraction	  39	  	  
	  
	  
Figure	  A27:	  ESI-­‐MS	  of	  fraction	  9	  from	  the	  oxidation	  of	  Acan1*	  
	  
	  
Figure	  A28:	  ESI-­‐MS	  of	  fraction	  10	  from	  the	  oxidation	  of	  Acan1*	  
	  
 +Q1: 47.484 to 47.785 min from Sample 1 (20120411_acan1_ligation) of 20120411_acan1_ligation.wiff (Turbo Spray) Max. 4.0e5 cps.






















1150.8 1429.0209.4 854.2 1088.9 1376.71127.5953.2 1183.9 1249.1308.3 1310.51112.6 1401.7228.0 1056.3628.0 1372.6871.4 1265.2985.2 1191.4 1541.5837.3686.5 755.8539.9512.1436.8411.3351.8 1273.8617.9246.1
 +Q1: 9.868 to 10.168 min from Sample 1 (20120420_acan1_oxidation) of 20120420_acan1_oxidation.wiff (Turbo Spray) Max. 9.6e4 cps.



























246.8 872.4 1077.9 1399.51346.51100.4 1446.0954.9859.9 1139.5496.4 1287.91026.2221.1 417.5281.3 1310.1668.2326.9 1391.6597.0 739.4 1086.3759.5 1064.2514.8 837.0 1449.3970.9 1467.2 1526.4916.7438.9 1227.9
 +Q1: 10.969 to 11.270 min from Sample 1 (20120420_acan1_oxidation) of 20120420_acan1_oxidation.wiff (Turbo Spray) Max. 1.9e5 cps.
























1431.41346.4 1375.8871.2 1100.8854.1628.4 1123.2
1357.0 1441.81371.11154.3 1342.71096.81026.3 1245.7955.2 1085.5221.1 1537.4351.8 769.9668.3280.9 1499.9496.1419.0 888.3573.2 1395.1756.2597.1 1184.71030.1
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Figure	  A29:	  ESI-­‐MS	  of	  fraction	  11	  from	  the	  oxidation	  of	  Acan1*	  
 +Q1: 12.122 to 12.422 min from Sample 1 (20120420_acan1_oxidation) of 20120420_acan1_oxidation.wiff (Turbo Spray) Max. 8.7e4 cps.
























1375.6 1445.01101.0871.1515.2 854.0 1110.8
1261.7627.9 957.4 1537.9403.1 1441.51374.91078.2854.9 1115.1220.9 342.7 872.3 955.1324.8 1471.71336.0580.7 1218.2667.9 743.4428.7 1575.21022.4496.3 756.5597.3 882.8 1350.01064.4 1476.4566.4378.4269.1
